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ABSTRACT 
Leukemia originates from blood-forming tissue and it occurs in people of all ages. 
Various genetic and epigenetic alterations drive the malignant transformation of 
progenitor cells resulting in aberrant cell proliferation, lack of differentiation and 
extended survival. Acute leukemias can be divided into either myeloid or lymphoid 
diseases, based on the blood cell lineage from where the leukemic cells arise. Based 
on the malignant precursor from where acute lymphoblastic leukemia (ALL) 
originates, ALLs can be further subdivided into B cell precursor ALL (BCP-ALL) or 
T cell ALL (T-ALL) which often carry either chromosomal aberrations or distinct 
gene expression patterns. Unlike in BCP-ALL, distinct T-ALL subtypes do not serve 
as prognostic markers. ALL is more common in pediatric patients, with the peak 
incidence at 2-5 years of age. ALL survival in pediatric patients has improved 
significantly during the last decades but there is still prognostic variation across 
subtypes so that some subtypes carry higher relapse risk. Relapse remains the most 
common treatment failure in pediatric ALL and the poor response to early therapy 
is the strongest predictor of relapse risk. 
Transcriptional regulation of gene expression and cell signaling are critical players 
in cell differentiation, proliferation and survival. We sought to identify aberrantly 
expressed genes that show subtype-specific expression in ALL. Among these were 
PTP4A3 and SOX11. PTP4A3 is a dual-specificity phosphatase that can inactivate 
targets by dephosphorylating either serine, threonine or tyrosine residues. From the 
three PTP4A family members, PTP4A3 demonstrated a subtype-specific expression 
in ETV6-RUNX1 and BCR-ABL1 acute leukemias. We showed that ETV6-RUNX1 
fusion regulated PTP4A3 expression but no marked changes were seen in cell 
viability after knockdown of PTP4A3 gene or inhibition of its enzymatic activity.  
Developmental and neuronal transcription factor SOX11 was aberrantly 
expressed in ETV6-RUNX1 and TCF3-PBX1 subtypes of BCP-ALL. Knockdown 
of SOX11 led to alteration in the expression of genes typically associated with cell 
adhesion, migration and differentiation. High SOX11 expression was associated with 
DNA hypomethylation at SOX11 locus and favourable clinical outcome. These 
results indicate that SOX11 expression marks a group of patients with good outcome 
and encourage further studies of its use as a prognostic biomarker.  
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The prognosis of T-ALL has also improved during the last decade, but when 
relapsed, T-ALL patients rarely survive.  We performed in silico drug screening across 
4430 leukemia samples in order to find novel targeted therapies for T-ALL by 
matching leukemia gene expression data with drug target gene expressions. As a 
result, strong expression of LCK, a Src family tyrosine kinase, was detected in T-
ALL samples and in silico screening suggested dasatinib as a targeted therapy. This 
was confirmed by in vitro and ex vivo experimental studies in cell lines and patient 
samples where 30 % of the studied cases showed a response to dasatinib, suggesting 
the potential of dasatinib drug in the treatment of T-ALL patients. 
Finally, we studied the Sin3A-associated protein SAP30L, which is part of the 
Sin3A corepressor complex and regulates gene expression by stabilizing protein-
protein and protein-DNA interactions. Zebrafish (Danio rerio) was chosen as a model 
organism for studying the role of SAP30L as it only expresses SAP30L and not 
SAP30.  SAP30L showed ubiquitous expression in both embryonic and adult 
zebrafish tissues, and morpholino-mediated SAP30L knockdown resulted in cardiac 
abnormalities and reduced hemoglobin levels of red blood cells. A microarray 
analysis of SAP30L morphant gene expression revealed down-regulation of the 
heart-specific nkx2.5 gene and genes important for hemoglobin synthesis and 
erythropoiesis. Results demonstrated that SAP30L regulates cardiac development 
and erythropoiesis in zebrafish.  
In conclusion, this thesis identifies novel regulators of transcription (SOX11, 
SAP30L) and cell signaling (PTP4A3) in acute leukemia and hematopoiesis, and 
discover a novel potential targeted therapy for a subgroup of T-ALL patients. 
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TIIVISTELMÄ 
Leukemia kehittyy verisoluja muodostavassa kudoksessa ja sitä tavataan kaiken 
ikäisillä potilailla. Useat geneettiset ja epigeneettiset muutokset voivat aiheuttaa 
häiriöitä normaalien luuytimen varhaisvaiheen solujen erilaistumisessa, 
jakaantumisessa ja elinkyvyssä. Akuutit leukemiat voidaan jakaa myelooiseen ja 
lymfaattiseen tyyppiin riippuen siitä, mistä verisolulinjasta leukeemiset solut ovat 
saaneet alkunsa. Akuutit lymfaattiset leukemiat (ALL) voidaan puolestaan jakaa 
varhaisten B-solujen (B-ALL) tai T-solujen (T-ALL) leukemioihin. B-ALL-potilaille 
on tunnusomaisia erilaiset kromosomaaliset poikkeavuudet, joita voidaan käyttää 
myös ennusteellisina merkkeinä. T-ALL:ssa puolestaan tavataan aliryhmäkohtaisia 
geenien ilmentymismuutoksia. ALL on yleisempi lapsipotilailla ja tyypillinen 
esiintymispiikki ilmenee 2-5 vuoden iässä. Vaikka ALL-potilaiden selviytymisaste on 
parantunut huomattavasti viime vuosikymmeninä, on eri alityyppien välisissä 
ennusteissa edelleen merkittäviä eroja. Lasten ALL:ssa taudin uusiutuminen onkin 
yleisin syy hoidon epäonnistumiselle ja hidas alkuhoitovaste ennustaa tarkinten 
taudin uusiutumisriskiä. 
Geenien ilmentymisen säätely ja solujen signalointi ovat merkittävässä roolissa 
solujen erilaistumisessa, sekä niiden elin- ja kasvukyvyssä. Tarkastelimme 
leukemioissa ja niiden alityypeissä poikkeavasti ilmentyneitä geenejä ja tunnistimme 
tällaisiksi PTP4A3 ja SOX11 geenit. PTP4A3 on fosfataasi, joka muokkaa 
kohdeproteiiniensa toimintaa fosforitähteen poistolla seriini-, treoniini- tai 
tyrosiiniaminohaposta. Kolmesta PTP4A proteiiniperheen jäsenistä PTP4A3 
ilmentyi leukemiassa lähinnä ETV6-RUNX1- ja BCR-ABL1-alityypeissä. ETV6-
RUNX1-proteiinifuusion todettiin säätelevän PTP4A3:n ilmentymistä, mutta solujen 
kasvukyvyssä ei havaittu merkittävää muutosta PTP4A3 geenin hiljentämisen tai 
proteiinin entsymaattisen aktiivisuuden estämisen seurauksena. 
SOX11 on geenien ilmentymisen säätelytekijä (transkriptiotekijä), jonka toiminta 
on erityisen tärkeää aikaisessa sikiön kehittymisessä. SOX11 geenin ilmentymisen 
havaittiin olevan poikkeavaa ALL:n ETV6-RUNX1- ja TCF3-PBX1-alityypeissä. 
SOX11 geenin hiljentämisen seurauksena havaittiin ilmentymisen muutoksia 
geeneissä, jotka liittyvät solujen kiinnittymiseen, liikkumiseen ja erilaistumiseen. 
SOX11 geenin korkea ilmenemistaso oli yhteydessä SOX11 geenialueen vähäiseen 
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metylaatiotasoon ja parempaan kliiniseen ennusteeseen. Tulokset viittaavat siihe, että 
SOX11 proteiinia voitaisi hyödyntää hyväennusteisen potilasryhmän 
tunnistamisessa. 
T-ALL:n ennuste on parantunut viimeisen vuosikymmenen aikana, mutta taudin 
uusiutuessa potilaiden selviytymisennuste on heikko. Laajalle, 4430 leukemianäytettä 
sisältävälle aineistolle tehdyllä in silico-lääkeaineseulonnalla pyrittiin löytämään uusia 
kohdennettuja T-ALL:n lääkehoitoja. Lääkeaineseulonnassa yhdistettiin leukemiassa 
tavattujen geenien ilmentyminen lääkeaineen kohdegeenien ilmentymiseen. 
Tuloksena havaittiin Src proteiiniperheeseen kuuluvan tyrosiinikinaasin, LCK:n, 
voimakas ilmentyminen, jolle lääkeaineseulonnan perusteella mahdolliseksi 
kohdennetuksi lääkkeeksi soveltuisi dasatinib. In vitro- ja ex vivo-kokeet solulinjoilla ja 
potilasnäytteillä vahvistivat dasatinibin tehon noin 30 %:lla tutkituissa tapauksissa. 
Tulokset viittaisivat siihen, että dasatinibin käyttöä T-ALL:ssa kannattaa selvittää 
jatkotutkimuksilla. 
SAP30L (Sin3A-associated protein 30-like) proteiini kuuluu Sin3A-
proteiinikompleksiin, joka toimii pääasiassa geenien ilmentymisen hiljentäjänä 
stabiloimalla joko proteiini-proteiini tai proteiini-DNA interaktioita. Seeprakala 
(Danio rerio) ilmentää vain SAP30L proteiinia (eikä sukulaisproteiini SAP30:ta), mikä 
tekee siitä erinomaisen valinnan tutkittaessa kyseisten proteiinien toimintaa. 
Seeprakalassa SAP30L ilmentyy kaikkialla sekä poikasvaiheen että aikuisen yksilön 
kudoksissa. Morfoliino-välitteisen SAP30L-geenin hiljentämisen seurauksena 
havaittiin muutoksia sydämen morfologiassa sekä hemoglobiinitasoissa. DNA-
mikrosiruanalyysi osoitti SAP30L-morfanteissa ilmentymisen heikentymistä 
sydänspesifisessä nkx2.5. geenissä, sekä hemoglobiinisynteesin ja punasolujen 
kehittymisen kannalta tärkeissä geeneissä. Tulokset osoittavat SAP30L säätelevän 
sydämen kehittymistä sekä punasolujen muodostumista seeprakalassa. 
Tässä väitöskirjassa löydettiin uusia leukemian ja verenmuodostuksen geenien 
ilmentymisen säätelytekijöitä (SOX11, SAP30L) sekä poikkeava ilmentyminen 
solusignaloinnin (PTP4A3) säätelyproteiinissa. Lisäksi tutkimuksissa tunnistettiin 
uusi mahdollinen täsmälääkehoito T-soluiseen akuuttiin leukemiaan. 
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1 INTRODUCTION 
Leukemia is liquid cancer that originates from the blood-forming cells. The clinical 
behavior of the disease can be either slow (“chronic”) or fast (“acute”). While the 
chronic forms of leukemia are predominant in adults, the acute forms comprise the 
vast majority of cases in childhood. A cell of origin determines the type of leukemia, 
lymphoblastic or myeloid, and, again, there is a distinction between adults and 
children with the lymphoblastic form being the predominant in childhood by 
comprising approximately 85 % of acute leukemias (Inaba et al. 2013). 
Approximately 80-85 % of acute lymphoblastic leukemias (ALL) are of B cell origin 
while T cell ALLs are relatively rare in early childhood but becomes more common 
later in adolescents and adults (Tasian and Hunger, 2017). Malignant transformation 
of hematopoietic progenitor cells results from genetic and epigenetic alterations 
during lymphocyte development leading to changes in the normal cell differentiation, 
proliferation and survival (Van Vlierberghe and Ferrando, 2012). In childhood ALL, 
the first genetic alteration occurs often already in utero, while the disease onset 
requires additional genetic events after birth (Greaves and Wiemels, 2013). Current 
treatment of ALL consists of a long chemotherapy and survival rates in pediatric 
leukemias have risen to approximately 90 % level. However, some genetic subtypes 
still have a high risk of relapse (Oskarsson et al., 2016; Pierro et al., 2017). In addition, 
slow or poor early response to chemotherapy is a reliable marker for less favourable 
prognosis and increased risk of relapse (O`Connor et al., 2018). A number of studies 
have probed the genomic diversity of ALL at diagnosis, clonal evolution during 
therapy and their association to relapse (Mullighan et al., 2008; Hogan et al., 2011; 
Ma et al., 2015). While the prognosis of childhood ALL has improved markedly, 
there are plenty of unanswered questions related to disease pathogenesis. Clarity in 
pathogenesis could lead tho the design of more targeted therapies to reduce 
chemotherapy burden and treatment of relapsed patients. This thesis seeks to 
provide more detailed understanding of leukemia pathobiology to advance disease 
understanding and thereby lead to novel treatment opportunities. 
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2 REVIEW OF THE LITERATURE 
2.1 Hematopoiesis 
The process where blood cells are formed is called hematopoiesis, which in 
vertebrates is divided in two phases, primitive and definitive waves (Galloway and 
Zon, 2003). Primitive hematopoiesis is transitory and its primary function is 
erythrocyte production from the erythroid progenitors, which appear from the blood 
islands in the extraembryonic yolk sac in mammals. The erythroid progenitors in the 
primitive hematopoiesis are not pluripotent and do not have renewal capability 
(Orkin and Zon, 2008; Palis and Yoder, 2001). Definitive hematopoiesis follows later 
in the development giving rise to a multipotent hematopoietic stem cells (HSCs) 
which have potential to develop and differentiate into all blood cell lineages of adult 
organism (Cumano and Godin, 2007).  In most organisms, before the actual HSCs 
are formed there is a transient definitive wave where erythroid-myeloid progenitors 
are produced (McGrath et al., 2011; Bertrand et al., 2007). The definitive wave starts 
in the aorta-gonad-mesonephros (AGM) region where the HSCs are born. HSCs 
then migrate temporarily to the fetal liver and spleen and subsequently to the bone 
marrow, which is the main site of HSC-derived hematopoiesis (Cumano and Godin, 
2007). 
2.1.1 Hematopoiesis, lymphocyte differentiation and microenvironment 
HSCs are the source for all blood cell types, and the major site for the adult 
hematopoiesis is bone marrow. The blood system contains over ten different blood 
lineages with various functions, and a life span ranging from few hours to several 
years (Rieger and Schroeder, 2012). HSC differentiate to all blood and immune cell 
types through hierarchically organized system with progenitor cells and lineage 
restricted precursor cells (Figure 1). These various intermediates demonstrate the 
complexity of the blood cell development and maturation. Hematopoietic 
differentiation starts when long-term HSCs, which have life-long self-renewal ability, 
gives rise to short-term HSCs with limited self-renewal ability to sustain 
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hematopoietic system roughly six weeks. Short-term HSCs further gives rise to 
multi-potent progenitors (MPP) with ability to generate all mature blood cell types 
without self-renewal ability. MPPs seems to be the first step for the lineage 
commitment in blood cell development as it gives rise to lineage-restricted oligo-
potent progenitors making the binary choice for lymphoid or myeloid progenitor 
(Brown and Ceredig, 2009). Previously it was believed that HSCs or MPPs make the 
binary choice to become either myeloid or lymphoid progenitor. If committed to a 
lymhpoid lineage, cell becomes a common lymphoid progenitor (CLP) with 
capability to differentiate into any lymphoid cell types. This type of model is referred 
as classical model in Figure 1 (Akashi et al., 2000; Brown and Ceredig, 2009). 
However, recent studies have suggested revisions to this model by showing that 
myeloid progenitors are not a uniform population of cells with multi-lineage 
differentiation potential but instead a more heterogeneous mixture of progenitors 
committed to specific lineages (revised model in Fig. 1) (Paul et al., 2015; Perié et al., 
2015). 
During the lineage commitment, hematopoietic cells lose their promiscuous 
expression of different lineage specific genes, which is needed in HSCs and 
progenitors to keep up with differentiation plasticity. After the progenitors are 
committed to a specific lineage, the cells need to silence differentiation genes for 
other alternate lineage and cell types. Silencing other differentiation genes is 
associated with activation of specific maturation genes to promote the lineage 
specific maturation events (Brown and Ceredig, 2009). As the “classical” 
hematological tree has been under revision, it seems likely that in the future growing 
knowledge and methodological development will give more information about the 
lineage differentiations, relationships between lineages and even recognize new 
intermediates. 
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Figure 1.  Models for human hematopoiesis shown together with critical transcription factors 
essential for HSC self-renewal and lymphoblast maturation. Classical model based on the 
assumption that HSCs commit either to lymphoid or myeloid fate and then progressively 
narrow their differentiation potential. Revised model is based on the theory of early 
individual cell fate commitment. Abbreviations: LT-HSC=long-term hematopoietic stem 
cell, ST-HSC=short-term hematopoietic stem cell, MPP=multipotent progenitor, 
CLP=common lymphoid progenitor, CMP=common myeloid progenitor, mDC=myeloid 
dendritic cell. Adapted from Orkin and Zon, 2008; Mercier and Scadden, 2015; Paul et al., 
2015; Perié et al., 2015. 
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2.1.2 Hematological microenvironments for blood cell differentiation 
Bone marrow is the major maturation site of the hematopoietic cell lines with the 
exception of T cells, which mature in the thymus. Bone marrow is a complex and 
highly organized tissue composed of heterogeneous cell populations including 
hematopoietic, mesenchymal and endothelial cell lineages (Ho et al., 2015). Bone 
marrow resides in the bone cavity surrounded by hard cortical bone and it has its 
specific spatialized structure with specialized microenvironments or niches, 
endosteal and perivascular niche, where HSCs and progenitor cells localize and 
receive proper signals for their differentiation and function (Brown and Ceredig, 
2009; Ho et al., 2015). In the endosteal niche, stromal cells constitutes mainly from 
fully committed osteogenic cells called osteoblasts, which are derived from 
mesenchymal stem cells. Osteoblasts reside in the junction of cortical bone and bone 
cavity expressing adhesion molecules to retain the HSCs in the bone marrow and 
signal molecules to keep HSCs undifferentiated and quiescent (Brown and Ceredig, 
2009; Ho et al., 2015). Differentiating blood cells migrate from the endosteal niche 
towards the bone marrow core to the perivascular niche where stromal cells 
comprise from undifferentiated mesenchymal cells, sinusoidal endothelial cells and 
perivascular cells. Signals and chemokines in perivascular niche supports 
proliferation and differentiation of HSCs and eventual egression to the peripheral 
circulation (Brown and Ceredig, 2009; Ho et al., 2015). 
Thymus constitutes of the subcapsular zone, the cortex, the medulla, and the 
corticomedullary junction with specific developmentally essential 
microenvironments (Koch and Radtke, 2011). Earliest thymocytes differentiation 
events take place in the cortex, which constitutes from thymic epithelial cells (TEC), 
fibroblasts and macrophages. Corticomedullary junction constitutes mainly of 
endothelial cells and is the entry point of the thymus seeding progenitors. Medulla 
constitutes of dendritic cells and medullary TECs and is involved for the later events 
of the T cell development. TECs are mainly responsible for controlling homing, 
expansion, maturation and selection of developing thymocytes. Mature T-
lymphocytes that are produced in thymus have a critical role in the adaptive immune 
system against viruses, bacteria and fungi and also in the maintenance of self-
tolerance (Brown and Ceredig, 2009; Koch and Radtke, 2011). 
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2.1.3 Differentiation of B cells 
B cells are generated in the bone marrow from HSCs through multiple 
developmental stages. Maturation starts with lymphoid specification and lineage-
primed progenitor cells, followed by differentiation stages where B cells gain B-
lymphocyte identity, and finally enters a state of maintenance ultimately leading to 
terminal differentiation (Fig. 2). B cell development relies on sequential expression 
of selected transcription factors as well as expression of cell surface receptors and 
adhesion molecules required for the movement in the bone marrow during the 
differentiation process (Brown and Ceredig 2009; Kee et al., 2000). TCF3 proteins, 
together with PU.1 and IKAROS family zinc finger 1 (IKZF1), promote lymphoid-
primed progenitor development and it is also essential for the B cell differentiation 
together with EBF1 and PAX5 (Dias et al., 2008; Kee et al., 2000). V(D)J 
recombination is genetic recombination of antigen receptor genes occurring in 
developing lymphocytes during the early stages of T and B cell maturation (Brown 
and Ceredig, 2009). Pre-pro-B cells are the first to be fated for B-lymphocytes with 
DJ rearrangements of the immunoglobulin heavy chain (Igh). Immunoglobulin loci 
encode for the B cell receptor (BCR) subunits and V(D)J recombination of the 
immunoglobulin loci ensures diverse B cell antibody repertoire whereas the signaling 
through the pre-BCR/BCR is required for maturation and fate decision (Brown and 
Ceredig 2009). Up-regulation of PAX5 and successful rearrangement of the Igh locus, 
V(D)J rearrangement, and pre-BCR checkpoint at the pro-B stage allows the cells to 
proceed to the pre-B stage. Pre-B cells have a rapid proliferation and the 
immunoglobulin light chain (Igl) rearrangement also starts at this stage. After 
successful Igl rearrangement, immature B cells express a functional BCR and are 
ready to leave the bone marrow to secondary lymphoid organs (Brown and Ceredig 
2009). Mature B-lymphocytes then wait quiescently for the appropriate antigen for 
activation before they proliferate and mature into plasma cells (Brown and Ceredig 
2009). During the differentiation, pro-B and pre-B cells interact with the stromal cell 
populations at various points for specific cytokine signals such as interleukin-7 (IL7) 
through IL7 receptor which is important for the proliferation and survival during 
the B cell development (Clark et al., 2014).  
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Figure 2.  Core transcriptional regulators together with key checkpoints and differentiation stages of 
B cell differentiation. Abbreviations, MPP=multipotent progenitor, Pro-B=progenitor B cell, 
Pre-B=precursor B cell, BCR=B cell receptor. Adapted from Kee et al. (2000) and Brown 
and Ceredig (2009). 
2.1.4 Differentiation of T cells 
T cells differ from other blood cells as their main maturation site is the thymus and 
not the bone marrow. Thymic microenvironment gives T cells a unique niche to 
develop and differentiate from progenitor cells to different mature T cells (Brown 
and Ceredig, 2009; Krueger et al., 2017). T cell differentiation begins with migration 
of some early lymphoid progenitors to the thymus via blood circulation (Brown and 
Ceredig, 2009; Krueger et al., 2017). These progenitor cells enter the thymus at the 
corticomedullary junction and are called thymic seeding progenitors (Brown and 
Ceredig, 2009; Krueger et al., 2017). During the development, these thymocytes 
travel across the thymic microenvironment differentiating eventually to T cells 
(Fig. 3). Thymocytes start their differentiation as early thymic progenitors from the 
double negative (DN) stage (CD4-CD8-). DN thymocytes migrate from the 
corticomedullary junction to the outer cortex and achieve the T lineage commitment 
at the DN2 stage. During this stage, a somatic rearrangement of the T cell receptor 
(TCR) gene starts from the TCRβ, TCRδ and TCRγ loci (Brown and Ceredig, 2009; 
Krueger et al., 2017). TCR is responsible for the antigen recognition presented by 
major histocompatibility complex (MHC). During this stage T cells are also divided 
for TCRαβ and TCRγδ lineages based on the productive rearrangement of the TCR 
genes. Rearrangement of TCRδ and TCRγ loci leads to TCRγδ lineage and TCRβ 
rearranged cells move forward to DN3 stage and go through β-selection. Correctly 
rearranged TCRβ cells signal through pre-TCR, leading to a proliferation and 
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developmental progression towards double positive (DP) stage (CD4+CD8+), the 
most abundant thymocytes in the thymus. DP cells then have rearrangement of their 
TCRα loci, eventually producing the mature TCR and then followed by the positive-
negative selection. Based on the TCR affinity the selection ensures that the produced 
T cells recognizes peptide:MHC ligands but do not recognize self-antigens leading 
to the elimination of roughly 90 % of all thymocytes. Whether the selection is 
finished in the cortex or medulla variates, but thereafter the T cells will locate in the 
medulla and are committed to either CD4+ (T helper cells) or CD8+ (cytotoxic T 
cells) positive lines based on the glycoprotein expression on their cell surface (Brown 
and Ceredig, 2009; Krueger et al., 2017). Mature single positive T cells then leave the 
thymus via post-capillary venules and enter the peripheral blood circulation (Brown 
and Ceredig, 2009; Krueger et al., 2017).  
Figure 3.  Developmental stages and critical checkpoints of T cell maturation. Abbreviations: 
TSP=thymys seeding progenitor, DN=double negative, ETP=early thymic progenitor, 
DP=double positive, SP=single positive, TCR=T cell receptor. Adapted from Koch and 
Radtke (2011). 
2.2 Transcriptional regulators of hematopoiesis 
Transcription factors are proteins that recognize specific deoxyribonucleic acid 
(DNA) sequences (DNA binding motifs) with their DNA binding domains and 
thereby regulate activity of gene expression. Regulation can be positive (activation) 
or negative (repression), and some transcription factors can exert both functions in 
a context-dependent way (Latchman, 2001). Some transcription factors bind to a 
promoter sequence located near the transcription start site and help the transcription 
initiation complex to form. Other transcription factors function as transcriptional 
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enhancers by binding to regulatory sequences, which can in mammals locate even a 
million or more base pairs upstream or downstream from the transcription starting 
site, even within the introns of neighboring genes (Levine, 2010). Transcription 
factors are responsible for the unique gene expression patterns in different cell types 
and drive cell fate decisions at different developmental stages. Mutations in 
transcription factors and their regulators are a foundation for numerous human 
diseases (Lambert et al., 2018). 
Primitive and definitive hematopoieses are regulated by distinct transcription 
factors. In primitive hematopoiesis, the two transcription factors, GATA1 and PU.1, 
regulate primitive erythroid and myeloid fates with cross-inhibitory relationship 
(Cantor and Orkin, 2002). It has been shown that these two transcription factors 
interact physically and the switch towards myeloid or erythroid fate involves target 
gene competition between PU.1 and GATA1 (Cantor and Orkin, 2002; Cantor et 
al., 2002; Jagannathan-Bogdan and Zon; 2013). GATA1 acts as a master regulator of 
an erythrocyte development and it suppresses myeloid fate. Accordingly, in zebrafish 
(Danio rerio) GATA1 knockdown leads to myeloid specific gene expression 
(including PU.1) and switches blood cells to myeloid fate (Jagannathan-Bogdan and 
Zon; 2013). PU.1 is a master regulator in myeloid cell fate and GATA1 expression 
increases after knockdown of PU.1 (Scott et al., 1994; Rhodes et al., 2005).  
In definitive hematopoiesis, numerous transcription factors regulate self-renewal 
of HSCs and their differentiation to various blood cell lineages. Some of the 
transcription factors are essential for HSC formation, for example RUNX1, TAL1 
and LMO2, while others are more relevant in a lineage-specific differentiation like 
TCF3, PAX5 and IKZF1 (Orkin and Zon, 2008). Many of these transcription factors 
are partners to translocations, deleted or mutated and these genetic alterations lead 
to deregulation of gene expression and failure of normal differentiation process in 
hematopoietic malignancies (Orkin and Zon, 2008). The most relevant transcription 
factors that are required for the production, survival and self-renewal of the HSCs 
and maturation of lymphocytes are shown in Figure 1 and the most important 
transcription factors in this thesis are introduced in the following chapter. 
2.2.1 Hematopoietic transcription factors in definitive hematopoiesis 
RUNX1 (AML1) is a member of runt family of transcription factors and is required 
for the normal hematopoietic development in vertebrates (Wang et al., 1996). 
RUNX1 can regulate gene expression either via activation or repression. RUNX1 
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contains a DNA-binding domain, called runt domain (RD), a transactivation domain 
(TAD) and an inhibitory domain (ID) from which RD and TAD are essential for in 
vitro hematopoiesis and for embryonal development in mice (Wang et al., 1996; 
Goyama et al., 2004; Okuda et al., 2000). In adult mouse, RUNX1 is expressed in all 
blood cells except erythrocytes and RUNX1 expression is regulated in both a cell 
line and maturation specific manner. RUNX1 expression is highest in adult bone 
marrow HSCs. During B cell development, RUNX1 expression is initiated in early 
stage of development and is expressed uniformly throughout the subsequent 
developmental stages (Lorsbach et al., 2004). In thymus, the RUNX1 expression is 
highest in the DN thymocytes while in peripheral T-lymphocytes the CD4+ cells 
have two to three -fold higher expression level compared to CD8+ T cells (Lorsbach 
et al., 2004; North et al., 2004). The critical role of RUNX1 in definitive 
hematopoiesis in early development was first shown in mice where knockout of 
RUNX1 led to a loss of definitive erythroid, myeloid and lymphoid cells in fetal liver 
hematopoiesis (Wang et al., 1996; Okuda et al., 1996). Because of the embryonic 
lethality of RUNX1 knockout mice, the role of RUNX1 in adult hematopoiesis has 
been studied in bone marrow chimeras, which show that the loss of RUNX1 
expression does not have a marked impact on the long term HSC maintenance 
(Ichikawa et al., 2004; Cai et al., 2011). In addition, RUNX1 deletion led to an 
increase in myeloid and megakaryocytic progenitors and defects in lymphocyte 
development (Ichikawa et al., 2004; Growney et al., 2005). In zebrafish, RUNX1 
knockdown led to a loss of blood progenitors and a reduction of thymocytes at early 
phase of definitive hematopoiesis (Kalev-Zylinska et al., 2002; Burns et al., 2002; 
Gering and Patient, 2005; Burns et al., 2005). 
Mutations in RUNX1 are associated with multiple hematological malignancies 
such as familial platelet disorder, myelodysplastic syndrome and leukemias of 
myeloid and lymphoid lineages (Osato, 2004; Song et al., 1999). Chromosomal 
rearrangements of RUNX1 are frequently observed in ALL, acute myeloid leukemia 
(AML), and chronic myelomonocytic leukemia, which indicates its importance in the 
formation of blood cells (Sood et al., 2017).  
TAL1 (T cell acute lymphoblastic leukemia 1 / SCL, stem cell leukemia) is a 
transcription factor with basic helix-loop-helix (HLH) domain and it is one of the 
main transcription factors involved in specification of hematopoiesis in early 
development and regulation of hematopoietic differentiation in adults (Porcher et 
al., 2017). TAL1 is expressed in various blood cell lineages in different 
developmental stages. Expression is seen in HSCs, myeloid progenitors, mature 
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myeloid cells and with lower levels in lymphoid progenitors even though the 
expression is absent in differentiating and mature T- and B-lymphocytes (Mouthon 
et al., 1993; Hall et al., 2003 Akashi et al., 2000; Lacombe et al., 2010). TAL1 has 
multiple functions in adult hematopoietic system that vary depending on the 
hematopoietic lineage and the developmental stage. In murine models, TAL1 is 
essential for the long-term HSCs quiescence stage as it negatively regulates their 
G0/G1 transition and maintains their long-term stem cell competence (Lacombe et 
al., 2010). TAL1 also plays a role in determining the blood cell lineage fate of HSCs 
by regulating erythrocyte differentiation, mekagaryocyte maturation and 
proliferation of monocyte progenitors in adult organisms (Goardon et al., 2006; 
Chagraoui et al., 2011; Dey et al., 2010). The regulatory role of TAL1 in adult 
hematopoiesis is transmitted through associations and complexes that TAL1 forms 
with multiple other hematopoietic transcription factors like megakaryocyte lineage 
priming heptad complex (GATA2, LYL1, TAL1, FLI1, ERG, RUNX1, LMO2) 
(Wilson et al., 2010; Pimkin et al., 2014). TAL1 is aberrantly expressed in 40-60 % 
of T-ALL cases and TAL1 overexpression is associated with a differentiation block 
in double positive (CD4+CD8+) state of thymocytes (Sanda et al., 2012). 
LMO2 (LIM-only protein 2) is a member of the large zinc finger protein family, 
LIM-domain-only (LMO) proteins, which characteristically have two LIM domains 
(El Omari et al., 2011). As no interactions with DNA has been shown in vivo, LMO2 
is hypothesized to mediate gene expression through protein-protein interactions (El 
Omari et al., 2011). LMO2 interacts with excessive amount of proteins and it is 
thought to act as a scaffold protein in multiprotein complexes forming a DNA 
binding complex (El Omari et al., 2011). Based on studies in mouse, LMO2 is known 
to be associated with TAL1 transcription factor in erythroid cells and it is essential 
for erythroid development (Valge-Archer et al., 1994). In the absence of LMO2, no 
definitive hematopoiesis is observed in mouse (Yamada et al., 1998). Enforced 
expression of LMO2 in T cells can result from chromosomal rearrangements 
including translocations t(11;14)(p13;q11) and t(7;11)(q35;p13) and deletion 
del(11)(p12p13) (Royer-Pokora et al., 1991; Van Vlierberghe et al., 2006). Genetic 
LMO2 abnormalities are detected in 9 % of all pediatric T-ALL cases (Royer-Pokora 
et al., 1991; Van Vlierberghe et al., 2006; Wu et al., 2015). 
ETV6 (TEL) is a nuclear protein and a member of ETS (E-Twenty-Six) family of 
transcription factors (Mavrothalassitis and Ghysdael, 2000). ETV6 protein 
constitutes of an N-terminal pointed domain (PNT) also referred to as HLH domain, 
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C-terminal DNA-binding domain (ETS domain) and an internal domain (De 
Braekeleer et al., 2012). PNT domain is responsible for the protein-protein 
interactions and functions as a homo-oligomerization domain. ETS domain is 
responsible for the protein-protein interactions and a sequence-specific DNA 
binding. Functional studies have shown that ETV6 acts as a strong transcriptional 
repressor and the repression is mediated through PNT and internal domains (De 
Braekeleer et al., 2012). ETV6 is required for the hematopoiesis of all blood cell 
lineages in the bone marrow, but it is also essential for the embryonic development 
and blood vessel formation in the yolk sac of developing embryos (Fenrick et al., 
2000; Wang et al., 1997). ETV6 is known to be a fusion partner with multiple 
proteins via translocations. The most common translocation in pediatric ALL is the 
t(12;21) (p13;q22) creating the ETV6-RUNX1 (TEL-AML1) fusion protein 
(Romana et al., 1995a; Bhojwani et al., 2012; Liang et al., 2010). 
TCF3 encodes for two E-proteins, HLH transcription factors E12 and E47 that 
arise from an alternative splicing (Slattery et al., 2008). These proteins are thought to 
play a crucial role in regulation of commitment, cell growth and lymphocyte 
differentiation (Massari and Murre, 2000; Slattery et al., 2008). TCF3 proteins form 
homodimers and heterodimers with other HLH transcription factors, to alter their 
target gene expressions. Massari and Murre (2000) and Kee et al. (2000) summarized 
a model where the activation of B-lineage-specific gene expression is orchestrated 
by TCF3 proteins. Deletion studies in mice demonstrated that TCF3 proteins are 
essential for the initiation of B cell development at the pro-B cell stage and that they 
act upstream of EBF and PAX5 (Bain et al., 1997; Kwon et al., 2008). In addition, 
TCF3 protein-deficient mice showed impairment in the rearrangement of the Igh and 
Igl in B cells (Bain et al., 1997; Kwon et al., 2008). Later studies have also suggested 
that TCF3 proteins are already transcriptionally active in the CLPs and support the 
lymphoid lineage specification from the HSCs and (Dias et al., 2008). Loss of E47 
leads to a reduced CLP population which lacks V(D)J recombinase activity and D-
JH rearrangements in mice (Borghesi et al., 2005; Dias et al., 2008). TCF3 
rearrangements are present in approximately 5-7 % of pediatric BCP-ALL giving 
usually rise to t(1;19) (q23;p13) translocation encoding for the fusion protein TCF3-
PBX1 (Barber et al., 2007; Pui et al., 2011).  
PAX5 is member of paired box family of transcription factors. It plays a dual role in 
the hematopoiesis as it is essential in B cell diffenrentiation and maturation but also 
in inhibition of the differentiation of other lineages (Shahjahani et al., 2015). PAX5 
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is associated with multiple aspects of B cell differentiation, as it is involved in the 
commitment, immunoglobulin gene rearrangement and B cell survival (Shahjahani 
et al., 2015). Furthermore, deletions or inactivating mutations of PAX5 causes arrest 
in pro-B cell stage (Shahjahani et al., 2015). Somatic alterations of PAX5 are frequent 
in BCP-ALL and Shah et al. (2013) have associated PAX5 germline mutations with 
susceptibility to BCP-ALL (Hyde and Liu, 2013). 
IKZF1 (IKAROS family zinc finger 1) is a transcription factor, which acts as a zinc 
finger DNA binding protein. In hematopoietic system, IKZF1 primes the potential 
of lymphoid lineage and the lack of it impairs the lymphocyte production in mice 
(Georgopoulos, 2002). IKZF1 acts in chromatin remodeling and its association with 
nucleosome-remodeling and histone deacetylation complexes controls lymphocyte 
development (Zhang et al., 2011). In addition to its importance in lymphoid 
differentiation, IKZF1 acts as a tumor suppressor and the loss of function mutations 
in IKZF1 is associated with BCP-ALL (Payne and Dovat, 2011; Kastner et al., 2013). 
2.3 Zebrafish development and hematopoiesis 
Developmental stages of zebrafish can be divided in four stages: embryonic, larval, 
juvenile and adult. In laboratory conditions (28.5 °C), embryonic development, 
embryogenesis, takes place in 0-72 hours post fertilization (hpf). Larval stage starts 
after 3 days post fertilization (dpf) and transition to juvenile stage happens at 30 dpf 
when their total body length is approximately 10 mm. Zebrafish reach sexual 
maturity in 3 months and zebrafish are considered as adults after 90 dpf (ZF-
HEALTH; ZFIN). As adults, the total body length of zebrafish can be 4-5 cm and 
maximum lifespan in laboratory is typically 1.5-2 years (ZF-HEALTH; ZFIN).   
Compared to other vertebrate model organisms zebrafish has several advantages 
that make it powerful system for genetic analysis, imaging and for studying 
hematological diseases (Paik and Zon, 2010; Teittinen et al., 2012; Lohi et al., 2013). 
Zebrafish embryos are transparent and eggs are fertilized externally allowing the 
monitoring of the developing embryos immediately after fertilization. Zebrafish also 
produces large amounts of embryos whose genetic manipulation is rather 
straightforward (Lessman, 2011; Peal et al., 2010; Amsterdam and Hopkins, 2006). 
Zebrafish have a diploid genome which constitutes from 25 chromosome pairs and, 
based on the Zv9 genome assembly, approximately 70 % of the human genes have 
at least one orthologue in zebrafish genome (Fish Development and Genetics, 2004; 
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ZFIN; Howe et al., 2013). Zebrafish genome has undergone a partial duplication 
during teleost development and 26 % of zebrafish genes are retained as ancestral 
duplicates having two orthologues for a subset of human genes (Fish Development 
and Genetics, 2004; Howe et al., 2013). These gene duplicates, called ohnologues, 
might lead to a potential problem when genes are targeted, as it is possible that both 
ohnologues needs to be targeted to reveal the effects on phenotype (Vacaru et al., 
2014; Howe et al., 2013). 
In the beginning of the 21st century, zebrafish emerged as a new system to study 
hematopoietic development as it closely resembles human hematopoiesis.  Like in 
humans, the zebrafish hematopoiesis consists also from the primitive and definitive 
waves (Fig. 4). Primitive HSCs are born in the intermediate cell mass (ICM) and 
during the primitive wave, the embryo generates myeloid and erythroid cells which 
start circulating already after 24 hpf (Detrich et al., 1995; Paik and Zon, 2010). 
Definitive HSCs originate at 30 hpf from AGM progenitors in the ventral wall of 
the dorsal aorta and at 48 hpf these progenitors seed the caudal hematopoietic tissue 
(CHT) and kidney marrow. Kidney marrow, analogous to the bone marrow niche of 
humans and other mammals, gives rise to all blood cell lineages and, together with 
the thymus, produces all mature hematopoietic cells throughout zebrafish life 
(Davidson and Zon, 2004). CHT locates in the posterior part of the embryo and 
serves as an intermediate site of definitive hematopoiesis (erythropoiesis and 
myelopoiesis). Site of definitive hematopoiesis eventually switches to kidney marrow 
myelopoiesis which starts at 4 dpf followed by maturation of other blood cell 
lineages. Lymphopoiesis starts in thymus from 3 dpf and it serves as the site for 
lymphoid T cell maturation. (Paik and Zon, 2010; Jing and Zon, 2011; Chen and 
Zon, 2009) (Fig. 4).  
Despite some unique characteristics, zebrafish and other vertebrates regulate the 
hematopoiesis with common genetic programs (Paik and Zon, 2010). Mutual 
signaling pathways and transcription factors are involved in definitive hematopoiesis 
of zebrafish and mammalians. Notable examples are Hedgedog, VEGF and 
NOTCH signaling pathways in the initiation of definitive hematopoiesis and 
RUNX1 transcription factor which plays a role in mediating the NOTCH pathway 
(Gering and Patient, 2005; Burns et al., 2005). Zebrafish mutants have also revealed 
that IKZF1 transcription factor is required for larvae lymphopoiesis (between 3-14 
dpf) but not in adult lymphopoiesis (Schorpp et al., 2006) and TAL1 mutants do not 
initiate hematopoietic development (Bussmann et al., 2007). ETV6 knockdown 
studies demonstrated a regulative role in embryonic and larvae hematopoiesis 
impacting multiple lineages, including reducing erythrocytes in primitive and 
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definitive hematopoiesis and decreasing myeloid cells in definitive hematopoiesis 
(Rasighaemi et al., 2015).  
Besides many similarities in blood cell development and regulation, there are also 
morphological and physiological differences between mature blood cells between 
zebrafish and human. While mammalian erythrocytes have discoid biconcave shape, 
the zebrafish erythrocytes are elliptical and have retained their nuclei whereas 
mammalian erythrocytes lose nuclei during the maturation (Chen and Zon, 2009). 
Zebrafish megakaryocytes and their nuclei-containing thrombocytes originate from 
prothrombocytes, whereas mammalian thrombocytes have no nucleus and are 
derived from megakaryocytes (Carradice and Lieschke, 2008). Lack of antibodies for 
specific cell surface markers is a problem in the zebrafish hematopoiesis research 
and sorting of hematopoietic lineages is mostly done with transgenic lines expressing 
a lineage-specific fluorescence marker, which limits the isolation of subpopulations. 
Other challenge is the limitations in the in vitro and ex vivo cell culturing and 
differentiation of the HSCs and progenitors (Gore et al., 2017). 
Figure 4.  Sites and waves of zebrafish embryonic hematopoiesis during the early development. 
Adapted from Chen and Zon (2009), Paik and Zon (2010) and Jing and Zon (2011). 
Abbreviations: ALM=anterior lateral mesoderm. PLM=posterior lateral mesoderm, 
PBI=posterior blood island, AGM=aorta-gonad-mesonephros region. 
2.4 Acute leukemia 
Acute leukemias can be classified into two groups, myeloid and lymphoid, based on 
the lineage from where the leukemic cells arise. ALL occurs in people of all age but 
is more common in pediatric patients with peak incidence being between two and 
five years of age (Inaba et al., 2013). Survival in pediatric ALL patients with current 
treatments in developed countries is approximately 85-90 % but there is variation 
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between subtypes (Pui et al., 2015; Toft et al., 2018). Even though the cure rate in 
pediatric patients is good and has improved in adult patients, some subtypes, infants 
and many adults still have a marked relapse risk (Gatta et al., 2013; Hunger et al., 
2012; Pui and Evans, 2006; Nachman et al., 2007). AML is the most common acute 
leukemia amongst the adults making up roughly 60-80 % of the cases but is relatively 
rare in children accounting only 15-20 % of pediatric leukemias (Yamamoto and 
Goodman, 2008; De Kouchkosvky and Abdul-Hay, 2016; Linabery and Ross, 2008; 
Puumala et al., 2013; Dores et al., 2012). AML treatments for younger patients have 
also led to significant improvements with approximately 60-70 % survival rates 
(Rubnitz, 2017), but patients over 65 years have a 70 % chance of dying within 1 
year of diagnosis (Meyers et al., 2013). Chronic leukemias are very rare in children 
representing only 1-2 % of all childhood leukemias (Belgaumi et al., 2010).   
Environmental, biological and genetic factors play a role in leukemia susceptibility 
and development. Exposure to infections has been widely studied as causal 
mechanisms for the leukemia development: lack of infections during early life cause 
dysregulation in immune system, which leads to an abnormal response to common 
infections later in childhood (Greaves, 2018). Abnormal immune response creates 
strong pressure on lymphoid cells and trigger the secondary mutations needed for 
the leukemia development (Greaves, 2018). A number of possible environmental 
exposures has also been linked to ALL, but only ionizing radiation is universally 
accepted to have a causal effect on ALL development (Greaves, 2018). Exposures 
during pregnancy as maternal consumption (e.g. alcohol, coffee, tea) has also been 
studied but without a clear association to development of ALL (Greaves, 2018). 
Even though leukemia is not considered as an inheritable disease, there are some 
genetic factors that contribute to disease onset, with Down syndrome being the most 
well-known with 20-fold increased risk for ALL (Lee et al., 2016). Low hypodiploid 
ALL has been linked to Li-Fraumeni syndrome (mutation of TP53 gene) and is 
considered as a manifestation for the syndrome (Holmfeldt et al., 2013). There are 
also a number of genes whose mutation predispose carriers to ALL development 
(e.g. ARID5B, CEBPE, GATA3, ETV6, IKZF1 and PAX5) (Tasian et al., 2015). 
2.4.1 B cell precursor acute lymphoblastic leukemia 
BCP-ALL is the most common subtype of ALL in childhood. BCP-ALL can be 
further divided into separate subtypes according to non-overlapping chromosol 
aberrations, which also serve as prognostic factors. World health organization 
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(WHO) classified these subtypes in 2008 by the presence of certain fusion genes, 
chromosomal alterations or genetic rearrangements (Vardiman et al., 2009). In 2016, 
two provisional entities were added to the list (Arber et al., 2016). Together these 
subtypes cover roughly 80 % of all BCP-ALL cases. Recently, at least four additional 
subtypes were identified. The main subtypes and their prevalence in pediatric 
patients are shown in Figure 5 (data from Lilljebjörn and Fioretos, 2017). 
 
Figure 5.  BCP-ALL subtypes and their estimated frequencies from Lilljebjörn and colleagues (2016) 
in a pediatric cohort. Data consists of 195 pediatric (< 18 years of age) BCP-ALL cases 
from a population-based series. 
Two main types of genomic alterations present in childhood ALL are aneuploidy 
and chromosomal rearrangements. In aneuploidy, there is either gain or loss of 
whole chromosomes, whereas chromosomal rearrangements usually lead to chimeric 
fusion genes or aberrant expression of the rearranged gene. High hyperdiploid 
subtype, which encompasses approximately 25-30 % of childhood ALL, is 
characterized by the presence of more than 50 chromosomes and often involves 
chromosomes 4, 10, 14, 17 and 21 (Roberts and Mullighan, 2015). High hyperdiploid 
ALL is usually associated with favorable prognosis, whereas the converse event, 
namely the lack of chromosomes, hypodiploid ALL (less than 44 chromosomes), 
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carries poor prognosis. Hypodipdloid ALL can be further divided into subgroups 
based on the chromosome number, from which most common are near-haploid 
ALL (24-31 chromosomes), low-hypodiploid ALL (32-39 chromosomes) and high-
hypodiploid ALL (40-43 chromosomes) (Roberts and Mullighan, 2015).    
ETV6-RUNX1 fusion gene results from translocation t(12;21)(p13;q22) 
involving two hematopoietic transcription factors, ETV6 and RUNX1, and is the 
most common translocation in pediatric ALL comprising approximately 20-25 % of 
the cases (Romana et al., 1995a; Liang et al., 2010). The second most frequent 
chromosomal translocation in the pediatric ALL is t(1;19)(q23;p13) which produces 
TCF3-PBX1 fusion involving two transcription factors, TCF3 and PBX1 (Hunger et 
al., 1991). Prevalence of the TCF3-PBX1 subtype amongst pediatric BCP-ALL 
patients is approximately 5-7 % and it is associated with favorable prognosis with 
contemporary therapies (Roberts and Mullighan, 2015; Bhojwani etl al., 2015; 
Lilljebjörn et al., 2016). The t(9;22)(q34;q11) translocation generates fusion of two 
kinases, BCR and ABL1, and is better known as a Philadelphia chromosome. BCR-
ABL1 occurs in approximately 3 % of pediatric BCP-ALL cases and has less 
favourable prognosis with a risk of treatment failure and relapse despite use of 
targeted therapy (e.g. imatinib) (Biondi et al., 2018). KMT2A gene (known as mixed 
lineage leukemia, MLL) loci at chromosome 11q23 is a frequent target of chromosomal 
translocations and rearrangements with multiple partners. These KMT2A-
rearrangements manifest approximately 2-7 % of pediatric cases (Lilljebjörn et al., 
2016; Roberts and Mullighan, 2015; Bhojwani etl al., 2015). In infant leukemias 
(patients < 1 year), the KMT2A-rearrangement frequency is remarkably higher than 
in pediatric leukemias in general as the prevalence is approximately 60-80 % (Pieters 
et al., 2007; Mann et al., 2010; Ross and Robison, 1997).  
These genetic rearrangements alone are usually insufficient to generate an overt 
leukemia (KMT2A-rearrangement may be an exception). They serve as a “first hit” 
mutation and additional mutations are needed before BCP-ALL development. Such 
mutations can be deletions, amplifications and structural rearrangements in genes 
important for B-lymphocyte differentiation (e.g. PAX5 and IKZF1) (Mullighan et 
al., 2007; Mullighan et al., 2009). This hypothesis is supported by twin studies with 
ETV6-RUNX1 and high hyperdiploid subtypes where identical twins have the same 
primary chromosomal aberration, a pre-leukemic clone, but develop the leukemia 
independently after birth (Bateman et al., 2015; Bateman et al., 2010; Mori et al., 
2002; Greaves et al., 2013). Bateman et al. (2010) studied monozygotic twins with 
concordant ETV6-RUNX1 subtype and compared their copy number alterations 
(CNA) classified as “driver” and “passenger” mutations. All CNA drivers were 
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absent from their healthy co-twin, with same pre-leukemic clone, placing the driver 
CNAs as secondary mutations. 
2.4.2 T cell acute lymphoblastic leukemia 
Leukemia that arises from the malignant transformation of T cell progenitors is 
called T-ALL and accounts for approximately 10-15 % of pediatric and 25 % of adult 
ALL cases (Ferrando et al., 2002; Toft et al., 2018). Transformation of T cell 
precursors into malignant T-ALL lymphoblasts results from genetic and epigenetic 
alterations during thymocyte development that lead to changes in the normal growth, 
differentiation, survival and proliferation (Van Vlierberghe and Ferrando, 2012). T-
ALL has been divided into distinct molecular subgroups according to the gene 
expression signatures (Table 1), but unlike in BCP-ALL, T-ALL subtypes have no 
confirmed prognostic significance (Girardi et al., 2017; Liu et al., 2017).  
Transmembrane receptor protein NOTCH1 is normally involved in T cell 
development and activating mutations in NOTCH1 signaling are present in over 
50 % T-ALLs making it one of the most significant oncogenic pathways in T-ALL 
development (Weng et al., 2004). Deletion in the CDKN2A locus at 9p21, which 
contains the tumor suppressor genes p16/INK4A and p14/ARF, is present in over 
70 % of all T-ALL cases (Ferrando et al., 2002; Hebert et al., 1994).  T-ALL is also 
associated with several chromosomal translocations and aberrant expressions of 
transcription factors like basic HLH family members TAL1, LYL1, LMO2, TLX1, 
TLX3 and NKX2.1 in T cell progenitors (Van Vlierberghe and Ferrando, 2012). 
These transcription factors are often placed under the control of strong T cell 
specific enhancers, which locate in the TCRβ (7q34) and TCRα/TCRδ (14q11) loci 
(Van Vlierberghe and Ferrando, 2012). Cauwelier et al. (2006) demonstrated that 
aberrations in these loci were involved in 33 % of their T-ALL samples. 
In addition to translocated and deregulated transcription factors fusion genes are 
also present in T-ALL.  One of these fusion genes is SIL-TAL1 fusion where SIL 
promoter is placed in the vicinity of TAL1 gene and induces an abnormal expression 
of TAL1; this fusion variates between 15-25 % of T-ALL cases (Brown et al., 1990; 
Aplan et al., 1992; Wang et al., 2013). Graux et al. (2004) observed gene fusion 
between ABL1 and NUP214 creating the second most common ABL1 fusion, 
NUP214-ABL1, in hematopoietic malignancies with a frequency of about 5-6 % in 
T-ALL (Graux et al., 2009; De Braekeleer et al., 2011b). Other NUP214 gene fusion, 
SET-NUP214, in T-ALL was discovered by Van Vlierberghe et al. (2008) where they 
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suggested that SET-NUP214 binds promoter regions of HOXA genes, which may 
activate the HOXA genes and contribute to T cell differentiation arrest. 
Table 1.  Major subgroups of T-ALL. 
Subgroup Associated genes Rearrangement partners resulting in deregulated expression of target gene. 
LMO2/LYL1 RUNX1, FLT3, TCF7, NRAS TRA, TRB, CSTF3-LMO2, FOXJ3-LMO2 / TRB 
HOXA ETV6, MLLT10, STAT5B, JAK3, EZH2, CNOT3, KMT2A 
TRB, HOXA insertion, LINC01260-HOXA, 
POLR2E-HOXA 
TLX3 PHF6, DNM2, WT1, SMARCA4, BCOR, KDM6A, RPL5 
BCL11B-TLX3, CDK6-TLX3, TRB, TLX3-
CACS15, TLX3-TARBP1 
TLX1 CDKN1B, BCL11B, PTPN2, DLEU1, RB1 TRB, TRA, TLX1-upstream, LINC00502-TLX1 
NKX2.1 RPL10, LEF1 TRA, NKX2-1-BCL11B, CDK6-NKX2-1, NKX2-1-DIO2 
TAL1 PTEN, USP7, 6q del, PIK3R1 STIL, TRA, DHX9-TAL1, GNPAT-TAL1, TAL1-TARP 
Others * CDKN2A/B, NOTCH1, FBXW7, ABL1, IL7R  
*Genetic alterations not specifically enriched in any T-ALL subtype. Data adapted from Liu et al., 2017. 
2.4.3 Treatment and outcomes of acute lymphoblastic leukemia 
Treatment of ALL consists of chemotherapy, which lasts approximately 2-2.5 years, 
and can be divided into four phases: induction of remission, deepening of the 
remission (consolidation), intensification and maintenance therapies (Pui et al., 
2008). Treatment aims at complete eradication of disease and relapse prevention. 
Treatment stratification is based on biological features of leukemic cells, age, 
leukocyte count and treatment response (Inaba et al., 2013; Toft et al., 2018). In high 
risk cases, allogeneic hematopoietic stem cell transplantation is applied. With modern 
treatments, the cure rate for pediatric patients overall in ALL is above 85 % and, for 
adults, long-term survival is estimated around 75 % of the patients with the pediatric-
type protocols (Toft et al., 2018; Terwilliger et al., 2017). Eventhough the overall 
survival (OS) in pediatric patients is reaching 85 %, relapses with poor outcome 
remain approximately 15-20 % of the patients (Einsiedel et al., 2005; Nguyen et al., 
2008; Durinck et al., 2015). Very few targeted therapies have thus far been applied 
to ALL. However, one classical example is the use of tyrosine kinase inhibitors 
imatinib or dasatinib in BCR-ABL1-positive ALL resulting in significant 
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improvement in the event-free survival (EFS) and OS (Thomas et al., 2004; Schultz 
et al., 2009; Ravandi et al., 2010, Biondi et al.,2018). 
2.4.4 Genetic diversity and relapse 
Relapse remains the most common treatment failure in childhood ALL occurring in 
approximately 15-20 % of ALL cases in developed countries with relatively poor 
outcome (Einsiedel et al., 2005; Nguyen et al., 2008; Durinck et al., 2015). OS after 
the relapse variates between 40-70 % depending on the follow-up period and 
involved risk group (Oskarsson et al., 2016; Pierro et al., 2017; Saarinen-Pihkala et 
al., 2006). At relapse, the patients are risk stratified based on the time from initial 
diagnosis, anatomical site of relapse, immunophenotype and therapy response as 
measured by minimal residual disease (MRD) (Oskarsson et al., 2016). Additional 
independent unfavorable prognostic factors in relapse include age over ten years, 
Down syndrome, T cell immunophenotype with hyperleukocytosis and unfavorable 
cytogenetic aberration (Oskarsson et al., 2016). Cytogenetics of the relapsed ALL is 
not used in the risk stratification to individualize treatment as it is used in primary 
diagnosis (Oskarsson et al., 2016).  
During the last decade, numerous studies have investigated the genomic diversity 
of ALL at diagnosis and clonal evolution during therapy in relapsed ALL. One of 
the first genomic studies was conducted by Mullighan and coworkers (2008). They 
matched diagnostic and relapsed samples from 61 patients and analyzed differences 
in CNAs. Interestingly, they noted that diagnosis and relapse samples were 
genetically related but most relapse samples had striking degree of change in the 
CNAs that were present already in the original diagnosis sample. In BCP-ALL cases, 
the mean number of CNAs was increased at relapse, but no significant changes were 
observed in T-ALL cases. This difference between relapse and diagnosis samples 
originated from a common ancestral primary leukemia clone and abnormalities 
acquired in the relapse cases affected preferentially genes involved in B cell 
development and cell cycle regulation. Mullighan et al. (2008) suggested that genomic 
alterations contributing to relapse might be selected during the treatment because 
the relapse clone was often already present in the diagnosis as a minor sub-
population.  
Later studies have revealed more details about the genomic aberrations in 
relapsed ALL. Recurrent lesions in relapsed BCP-ALL might be candidate drivers 
for drug resistance. For example, genes involved in glucocorticoid signaling which 
 40 
acquired deletions that drive glucocorticoid resistance contributing to relapse 
(Hogan et al., 2011; Mullighan et al., 2008). In addition to mutations of single genes, 
activating mutations in certain pathways like WNT, MAPK and Ras have been 
associated with relapse and drug insensitivity and inhibition to these pathways have 
increased chemosensitivity (Hogan et al., 2011; Dandekar et al., 2014; Jones et al., 
2015; Irving et al., 2014).  
Ma et al. (2015) looked deeper into genetic heterogeneity and clonal evolution of 
pediatric BCP-ALL progression and relapse. They used high-coverage whole-exome 
sequencing to study 20 BCP-ALL cases from diagnosis to relapse and showed that 
clonal survival from diagnosis to relapse was not associated with mutation burden 
and that clonal diversity was comparable at diagnosis and relapse. They found 
frequently mutated pathways (e.g. CREBP, TP53, NRAS and IKZF1) with multiple 
sub-clonal mutations at diagnosis but remission-induction therapy disposed all but 
one. The surviving clone, usually a minor clone, acquired additional mutations and 
deepened the resistance to therapy and thus became a founder clone for the relapse. 
One example of relapse-acquired mutations due to treatment pressure are cases with 
NT5C2 mutations at relapse, which cause enhanced enzymatic activity of this 
enzyme and confers resistance to thiopurines used in maintenance therapy of ALL 
(Meyer et al., 2013; Tzoneva et al., 2013). Enrichment of mutations in epigenetic 
regulators have also been noted (Ma et al., 2015; Mullighan et al., 2011; Mar et al., 
2014). It seems that diversity of mutations most commonly towards key regulators, 
transcriptional or epigenetic, are contributing to relapse. Possible relapse routes from 
subclones or via evolutional mutations are presented in Figure 6. 
Two major points seem to underline the ALL relapse treatment: (i) Leukemia 
heterogeneity causes drug resistance via escape of minor resistant subclones, and (ii) 
slow progression of drug development in overall, as very few new drugs have been 
developed during past decades. Studies over prognostic factors, treatment outcomes 
and drug resistant phenotypes have been gaining insights for pathogenic properties 
of leukemia and relapsed leukemia. Despite the progress, relapse rate and outcomes 
remained unsatisfactory and more discoveries are needed from genomic studies and 
drug-screenings. One very promising opening is the targeted immunotherapies to 
cell surface antigens such as CD19 or CD22, which are evidently providing help to 
many patients with relapsed leukemias (Wang et al., 2017; Kaplan et al., 2015). 
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Figure 6.  Model for the clonal relationships of diagnosis and relapse in acute leukemia. A schematic 
illustration showing relationship between pre-leukemic clones, initial leukemia diagnosis 
and relapse. Relapse can arise from the treatment when either an original predominant 
subclone or a minor subclone survives. Third possible mechanism is that the treatment 
induces acquisition of additional mutation(s) into a diagnosis phase subclone. Fourth 
possible route for the relapse in minority of the cases is that novel leukemic clone 
originates from the pre-leukemic HSC clones. Adapted from Mullighan et al. (2008) and 
Jan and Majeti (2013). 
2.5 Regulators of transcription and signaling in leukemia 
Chromosomal translocations can create fusion genes (hybrid genes) which are 
recognized as important drivers in cancer in general. Gene fusions often lead to a 
dysfunction of either of the partner genes, creation of an oncogenic fusion protein 
or truncating the gene, creating a loss of function mutant (Latysheva and Babu, 
2016). In-frame fusions can generate fusion proteins such as transcription factor 
fusions ETV6-RUNX1 or TCF3-PBX1 in BCP-ALL. These fusions cause an 
aberrant transcriptional activity which leads to differentiation arrest and changes in 
normal proliferation and survival (O’Neil and Look, 2007; Shima and Kitabayashi, 
2011; Teppo et al., 2016). 
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2.5.1 Transcriptional fusion proteins in BCP-ALL 
ETV6-RUNX1 fusion gene is the second most common genetic rearrangement in 
pediatric BCP-ALL comprising about 20-25 % of the cases (Romana et al., 1995a; 
Liang et al., 2010). It is generated by translocation which fuses the 5’ region of the 
ETV6 (exons 1 to 5) (12p13.2) together with almost the entire coding region of 
RUNX1 (12q22.12) creating a chimeric fusion t(12;21)(p13;q22) (Golub et al., 1995; 
Romana et al.,1995b; De Braekeleer et al., 2012) (Fig. 7).  
Figure 7.  Schematic illustration of ETV6-RUNX1 fusion protein. Adapted from: Zelent et al. (2004) 
and Sood et al. (2017). 
Fusion gene retains the N-terminal PNT domain and a central repression domains 
from the ETV6 that are fused with RD and TAD domains from RUNX1 (Zelent et 
al., 2004). As a result, RUNX1 loses its transactivation properties converting the 
fusion protein to a repressor through functional domains of ETV6. ETV6-RUNX1 
fusion protein binds enhancer areas with RUNX1 motif, which leads to repression 
of the RUNX1 target genes (Zelent et al., 2004; Morrow et al., 2007; Teppo et al. 
2016). ETV6-RUNX1 fusion can also disrupt the function of normal ETV6 by 
dimerization via PNT domains (Rubnitz et al., 1999; De Braekeleer et al., 2011a; 
Gunji et al., 2004).  
Debate of the prevalence of ETV6-RUNX1 fusion at birth has been ongoing 
over a decade. Mori et al. (2002) suggested that ETV6-RUNX1 fusion was present 
in 1 % of cord blood in newborns (Mori et al., 2002). This was later questioned when 
Lausten-Thomsen et al. (2011) stated that the prevalence was actually much lower 
and present only in 0.01 % of newborns. Latest publication on this matter was 
presented by Schäfer et al. (2018) suggesting that as many as 5 % of newborns harbor 
the ETV6-RUNX1 fusion. It seems likely that the prevalence supposed by Schäfer 
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et al. (2018) might be the most accurate as they based their results on genomic DNA 
opposed to ribonucleic acid (RNA)-based methods used in other studies. Higher 
ETV6-RUNX1 prevalence amongst newborns compared to pediatric ETV6-
RUNX1 leukemia cases is also supported by animal studies. Studies with ETV6-
RUNX1 expressing zebrafish showed that roughly 3 % of the fish developed a 
leukemia (Sabaawy et al., 2006). In mice, ETV6-RUNX1 model did not develop 
leukemia under pathogen free conditions, but when exposed to infectious 
environment approximately 11 % of the mice developed leukemia (Rodríguez-
Hernández et al., 2017). 
TCF3-PBX1 fusion results from the chromosomal translocation in which the N-
terminal transcriptional activation domains from the TCF3 (1;q23.3) is fused with 
the C-terminal DNA-binding homeodomain of PBX1 (19;p13.3) (Hunger et al., 
1991). This translocation t(1;19)(q23;p13) (Fig. 8) creates a chimeric transcription 
factor which is found approximately 5-7 % of childhood ALL cases (Carroll et al., 
1984; Roberts and Mullighan, 2015; Bhojwani etl al., 2015; Lilljebjörn et al., 2016).  
Figure 8.  Schematic illustration of TCF3-PBX1 fusion protein. Adapted from: Bayly et al. (2004). 
Studies have demonstrated that the fusion protein needs both of its partners for the 
oncogenesis and the activation domains (AD1 and AD2) are vital but the 
homeodomain (HD) of PBX1 is dispensable (Monica et al., 1994; Chang et al., 1997). 
It has been demonstrated that there is a motif in the C-terminal part after the 
homeodomain and this Hox cooperativity motif is required for the oncogenic 
potential of TCF3-PBX1 (Monica et al., 1994; Chang et al., 1997). It has been 
proposed that TCF3-PBX1 causes aberrant activation in genes which are normally 
controlled by PBX/HOX complexes. Moreover, the fusion protein is known to 
form heterocomplexes with Hox proteins (Chang et al., 1997; Thorsteinsdottir et al., 
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1999). In addition to the interactions with other proteins, the activation domains of 
TCF3 portion in TCF3-PBX1 fusion protein interacts directly with CBP/p300 and 
induces proliferation in primary hematopoietic cells (Bayly et al., 2004; Bayly et al., 
2006). One downstream target of the TCF3-PBX1 fusion is Wnt-signaling pathway 
and the presence of TCF3-PBX1 fusion results in aberrant regulation of cell cycle 
control and apoptosis, which could compose to a driving force towards propagation 
and maintenance of TCF3-PBX1 leukemic phenotype (Casagrande et al., 2006; 
Mazieres et al., 2005; McWhirter et al., 1999; Diakos et al., 2014). Several studies 
have begun to reveal the functional mechanisms of TCF3-PBX1, from its regulation 
of target genes and its effects on signaling pathways leading from pre-leukemic clone 
to full-blown leukemia. Even though exact mechanisms of the oncogenic function 
of TCF3-PBX1 fusion protein is still unclear, the fusion needs additional genetic 
events for the leukemia initiation, like PAX5 insufficiency or activation of signaling 
pathways (e.g. JAK/STAT, RAS/MAPK) (Duque-Afonso et al., 2015). 
2.5.2 Sox family of transcription factors 
Sox (Sry -related high-mobility group box) family of transcription factors consists of 
20 members in most vertebrates and this protein family can be divided into eight 
subgroups (A-H) (Schepers et al., 2002; Lefebvre et al., 2007). The main feature for 
these SOX proteins is the DNA-binding domain called high-mobility group (HMG) 
box, which is similar to that of originally identified in HMG box of chromatin-
associated non-histone proteins (Laudet et al., 1993; Bianchi et al., 2005). Subgroup 
members are highly similar to each other and most of the SOXs have central roles 
in cell fate determination and differentiation into specific lineages (Dy et al., 2008). 
In humans, the SoxC family contains three proteins, SOX4, SOX11 and SOX12, 
which share high degrees of similarity in the HMG box and the C-terminal region 
where the TAD is located (Jay et al., 1995; Jay et al., 1997; van de Wetering et al., 
1993; Kuhlbrodt et al., 1998; Dy et al., 2008). Similar expression patterns of SoxC 
proteins suggest that these three protein members have similar functional properties 
and at least SOX4 and SOX11 are vital for the early development as these knockout 
mice die early (Dy et al., 2008). 
SOX11 is normally expressed with high level in the human fetus, central and 
peripheral nervous system and internal organs (Jay et al., 1995; Hargrave et al., 1997; 
Sock et al., 2004). Upregulations of SOX4 and SOX11 expression have been 
observed in many cancer types (Weigle et al., 2005; Liu et al., 2006; Pramoonjago et 
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al., 2006). SOX11 has been previously studied in mantle cell lymphoma (MCL) and 
its nuclear protein expression is a specific marker for MCL and used as a marker for 
monitoring minimal residual disease (Ek at al. 2008; Mozos et al. 2009; Zeng et al. 
2012; Szostakowska et al. 2018). Nuclear expression of SOX11 protein was also 
reported in two ALL studies, with mostly strong expression, and high SOX11 
messenger RNA (mRNA) expression seen in another study (Dictor et al. 2009; 
Mozos et al. 2009; Vegliante et al. 2011). Knockdown of SOX11 in MCL cell lines 
increased proliferation in vitro and led to more aggressive tumors in vivo (Conrotto et 
al. 2011). Overexpression of SOX11 promotes BCR signaling in B cells and produces 
a disease phenotype similar to human MCL (Kuo et al. 2018). SOX11 can be a useful 
tool in MCL diagnostics and as a prognostic marker but functional role in the 
malignancies remains poorly understood. 
2.5.3 Epigenetic regulation of gene transcription 
Epigenetic modifications can alter gene expression and therefore regulate multiple 
biological processes, like cell growth, differentiation, development and apoptosis. 
The main epigenetic mechanisms are DNA methylation and histone modification 
(Wu et al., 2018). DNA methylation is a process where a methyl group is added to 
DNA base (cytosine or adenine). Methylation at promoter region leads typically to a 
repression of gene transcription, whereas demethylation typically leads to a re-
activation of the repressed gene (Bernstein et al., 2007; Klose and Bird, 2006; Kohli 
and Chang, 2013). Histone modifications include acetylation, methylation, 
ubiquitination, phosphorylation and sumoylation (Wu et al., 2018). These 
posttranslational modifications regulate gene expression by changing the chromatin 
structure. Acetylation and deacetylation are mediated through histone 
acetyltransferases and histone deacetylases (HDACs), which add or remove an acetyl 
group. Acetylation usually activates gene expression by opening the chromatin 
structure (Wu et al., 2018; Peserico and Simone, 2011). Methylation usually has an 
opposing effect as it tightens chromatin structure, but this depends on the modified 
residue (arginine or lysine) and the number of modified methyl groups so histone 
methylation can also lead to gene activation (Greer and Shi, 2012; Black et al., 2012). 
Non-coding RNAs can also regulate the gene expression by binding 3’-untranslated 
regions of target mRNAs, which result in cleavage, degradation or translational block 
of the mRNA (Winter et al., 2009; Wu et al., 2018). 
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2.5.4 Sin3A corepressor and associated proteins SAP30 and SAP30L 
Histone acetylation and deacetylation play a role in gene expression by influencing 
the chromatin structure. Sin3A is an essential scaffold protein of a histone 
deacetylation multiprotein complex called Sin3A/HDAC corepressor complex. This 
multiprotein complex comprises from proteins including HDAC1, HDAC2, the 
histone binding proteins RbAp46 and RbAp48, the Sin3A associated proteins (SAP) 
18 and 30 and SDS3 (Silverstein and Ekwall, 2005). Sin3A acts as a platform bringing 
together chromatin remodelers and transcriptional regulators, which alter the 
chromatin structure and gene transcription causing changes in key biological 
processes (Silverstein and Ekwall, 2005). Based on knockdown studies, Sin3 plays a 
role in cell proliferation, differentiation, apoptosis and cell cycle regulation (Kadamb 
et al., 2013). SAP30 is a known component of the Sin3A co-repressor complex and 
it functions as a bridging and stabilizing molecule between the complex and its 
corepressors or DNA-binding transcription factors. In cell culture studies, SAP30 
was not necessary for Sin3 complex repression but it mediated repression by specific 
transcription factors (Zhang et al., 1998; Viiri et al., 2009a). SAP30 has a close 
homolog SAP30-like (SAP30L) with 70 % identity at protein sequence level 
(Lindfors et al., 2003). SAP30L interacts with Sin3A corepressor complex members 
and induces transcriptional repression via Sin3A recruitment (Viiri et al., 2006; 
Korkeamäki et al., 2008). 
2.5.5 Protein tyrosine kinases and phosphatases 
Phosphorylation and dephosphorylation are one of the most prevalent post-
translational modifications of proteins in multicellular organisms. Group of enzymes 
called protein kinases and phosphatases carries out these reactions in a concerted 
action to control signaling that underlie a broad spectrum of biological processes 
ranging from cell fate control to metabolism. Deregulation of such coordination can 
lead to malignancies. (Paul and Mukhopadhyay, 2004; Motiwala and Jacob, 2006).  
Members of the protein tyrosine phosphatase 4A (PTP4A) family, also known as 
phosphatases of regenerating liver (PRL), are dual specificity phosphatases with 
oncogenic properties (Campbell and Zhang, 2014; Park et al., 2013; Rios et al., 2013). 
This protein family consists of three members, PTP4A1-3, and all members are small 
sized proteins with molecular weight of approximately 20 kDa. PTP4A proteins 
share a high degree of sequence identity within the phosphatase domain (Campbell 
and Zhang, 2014; Stephens et al., 2005; Bessette et al., 2008; Rios et al., 2012). They 
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are involved in multiple cellular activities such as cell proliferation, migration and 
invasion (Campbell and Zhang, 2014), and they have been associated with several 
hematological malignancies (Zhou et al., 2011; Park et al., 2013; Beekman et al., 
2011). PTP4A3 overexpression correlates with poor prognosis and progression to 
metastasis in breast cancer, gastric cancer, and colorectal cancers (Campbell and 
Zhang, 2014).  
PTP4A3 is upregulated in patients with chronic myeloid leukemia (CML) and in 
CML cell lines (Juric et al., 2007; Zhou et al., 2012). PTP4A3 is a downstream target 
of BCR-ABL1 fusion, and it is upregulated in Ph+ ALL patients, but the exact 
mechanism is unknown (Zhou et al., 2012).  In AML with normal karyotype, the 
high expression of PTP4A3 has been associated with poor prognosis (Juric et al., 
2007; Zhou et al., 2012; Zhou et al., 2011; Park et al., 2013; Beekman et al., 2011). 
Overexpression of PTP4A3 is also present in multiple myeloma where knockdown 
of PTP4A3 inhibits cell migration (Fagerli et al., 2008). In addition, PTP4A3 
influences cell cycle regulation and depending on the expression levels the effect may 
either be positive or negative (Beekman et al., 2011). Knockdown studies by Hjort 
et al. (2017) demonstrated that PTP4A3 promoted cellular adhesion and migration 
in BCP-ALL cell lines. They also reported that PTP4A3 expression supported drug 
resistance towards cytarabine treatment.    
As stated earlier, kinases work opposite to phosphatases as they catalyze the 
phosphate group transfer to their substrates. Perhaps the best-known example of 
kinase involvement in leukemias is BCR and ABL1 kinases that form a BCR-ABL1 
fusion and cause acute and chronic leukemias (Quintás-Cardama and Cortes, 2009). 
Members of Src family kinases (SFKs) are key regulators of several fundamental 
cellular processes and operate via cytoplasmic signaling machinery. SFKs have a 
pleiotropic function as they regulate cell growth, differentiation, cell shape, migration 
and survival. Many of the SFK family members are identified as oncogenes. SFKs 
constitutes from nine members from which B cells are primarily expressing LYN, 
FYN and BLK and T cells LCK and FYN (Parsons and Parsons, 2004). Family 
members expressed in B cells are known to initiate B cell activation and to play a key 
role in B cell development possibly via pre-BCR signaling (Gauld and Cambier, 
2004). LCK and FYN have a role in T cell activation but also in the development via 
TCR signal transduction, as TCR based signaling is vital at several developmental 
stages e.g. pre-TCR signaling (Palacios and Weiss, 2004). In addition, SFKs have 
been associated with development of leukemias and lymphomas (ALL, AML, CML 
and Burkitt’s lymphoma) (Siveen et al., 2018). However, oncogenic mutations in 
SFKs have rarely been observed in these malignancies and the association comes 
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from the SFK activation, which dysregulates pathway signaling (Siveen et al., 2018). 
LCK has demonstrated overexpression and aberrant activation in BCP-ALL, T-ALL 
and chronic lymphocytic leukemia and has therefore been studied as a possible target 
for drug therapies (Cazzaniga et al., 2015; De Keersmaecker et al., 2014; Talab et al., 
2013). 
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3 AIMS OF THE STUDY 
The aim of the study was to identify regulators of transcription and signaling in 
pediatric ALL, and to search for novel targeted therapies. We also investigated the 
function of SAP30L in zebrafish hematopoiesis.  
The specific aims were: 
1) to study the expression and function of protein tyrosine phosphatase 
PTP4A3 in ALL (study I). 
2) to study expression and function of SOX11 transcription factor in ALL and 
its use as a prognostic marker in childhood ALL (study II).  
3) to identify novel targeted therapies for T-ALL (study III).  
4) to study the function of SAP30L in zebrafish hematopoiesis (study IV).  
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4 MATERIALS AND METHODS 
4.1 Cell lines and cell culture (I-III) 
The cell lines used in the studies are listed in Table 2. Cell lines were obtained either 
from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany) or American Type Culture Collection (J.Cam 1.6, 
Manassas, VA, USA). Cells were cultured according to cell line-specific instructions. 
NALM-6, REH, 697, RCH-ACV, KOPN-8, KASUMI-2, Jurkat, J.Cam1.6, MOLT-
16, P12-Ichikawa, HPB-ALL and CCRF-CEM cell lines were cultured in in RPMI 
1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 
10 % FBS (Gibco), 2 mM L-glutamine, 100 μg/ml streptomycin and 100 U penicillin 
at 37°C in 5 % CO2. MOLT-4, PEER, and MHH-CALL3 cell lines were cultured in 
same medium with 20 % FBS. All cell lines (except J.Cam1.6), were authenticated by 
short tandem repeat (STR)-genotyping (Eurofins Genomics, Ebersberg, Germany). 
Cell lines were regularly tested for the presence of mycoplasma. 
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Table 2.  Characteristics of cell lines used in studies I, II and III. 
Cell line Disease Genetics Donor age Study 
697 BCP-ALL TCF3-PBX1 12 years I, II, III 
CCRF-CEM T-ALL NKX2-5 expression 3 years I, III 
HPB-ALL T-ALL TLX3 subgroup* 14 years I, III 
Jurkat T-ALL TAL1 subgroup* 14 years I, III 
KOPN-8 BCP-ALL KMT2A-ENL 3 months I, III 
MOLT-4 T-ALL TAL1 (with LMO2) subgroup* 19 years III 
MOLT-16 T-ALL TAL1 subgroup* 5 years I, III 
NALM-6 BCP-ALL ETV6/PDGFRB, DUX4/ERG** 19 years I, II, III 
P12-Ichikawa T-ALL LYL1/LMO2 *** 7 years I, III 
PEER T-ALL LYL1/LMO2 *** NUP214-ABL1****  4 years III 
RCH-ACV BCP-ALL TCF3-PBX1 8 years II 
REH BCP-ALL ETV6-RUNX1 15 years I, II, III 
J.cam6.1 (Jurkat) T-ALL Jurkat with deletion of exon 7 14 years III 
KASUMI-2 BCP-ALL TCF3-PBX1 15 years II 
MHH-CALL-3 BCP-ALL TCF3-PBX1 11 years II 
*subgroup specification was carried out in our laboratory **Zhang et al., 2016 ***mixed subgroup 
specificated in our laboratory ****NUP214-ABL1 fusion confirmed in our laboratory. 
4.2 Cell viability assay (I-III) 
Cell viability was measured by using AlamarBlue® reagent (Life Technologies, 
Thermo Fisher Scientific, Waltham, MA, USA) in which the active ingredient is 
resazurin. In the assay, viable cells reduces resazurin to highly fluorescent resofurin 
and the fluorescence is measured after 2 h by using the Tecan fluorometer Infinite 
200 (Tecan, Männedorf, Switzerland) with excitation of 560 nm and emission of 590 
nm. Reagents are added to 10 % of the sample volume. Cell viability measurements 
were performed with three to four technical replicates per sample in each 
experiment. Depending on the cell line of interest, 10 000 to 50 000 cells per well 
were plated in the beginning of the experiment with culture media, supplements and 
drugs in 96-well plates. 
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4.3 Modification of gene expression 
4.3.1 Transient modifications (I-III) 
Transient modification of gene expression in suspension cells were performed with 
4D-Nucleofector™ (Lonza, Basel, Switzerland) mediated transfection. Transient 
gene knockdowns were carried out with small interfering RNAs (siRNA). Target 
gene specific siRNAs were used either as single siRNA oligos or as mixtures of many 
oligos. Commercial siRNA mixes and single oligos are listed in a Table 3. 
Nucleofections were carried out according to manufacturer’s instructions (see Table 
4 for details).  Depending on the chosen nucleofection method, the number of cells 
varied from 0.5 to 1 million per reaction. After transfections, the cells were assayed 
for cell viability or collected for RNA extraction. The success of knockdown was 
validated by quantitative reverse-transcription polymerase chain reaction (RT-qPCR) 
and/or western blot (WB). 
Table 3.  Characteristics of siRNAs used in studies I, II and III. 
Target gene Primers 5' -> 3' / Commercial name Origin/Source Catalog No. Study 
siSCR 
sense 
GUUGCGUAGCGUACGUCGCAA Own/Sigma  II 
siSCR 
antisense 
UUGCGACGUACGCUACGCAAC Own/Sigma  II 
siSOX11 
sense 
GAUAAGAUGUCGUGACGCA  
Kuo et al. 2015/ 
Sigma 
 II 
siSOX11 
antisense 
UGCGUCACGACAUCUUAUC 
Kuo et al. 2015/ 
Sigma 
 II 
PTP4A3 PTP4A3 (ID 11156) Trilencer-27 Human siRNA OriGene SR307645 I 
ABL1 ABL1 (ID 25) Trilencer-27 Human siRNA OriGene SR300017 III 
FYN FYN (ID 2534) Trilencer-27 Human siRNA OriGene SR301682 III 
LCK LCK (ID 3932) Trilencer-27 Human siRNA OriGene SR302659 III 
LYN LYN (ID 4067) Trilencer-27 Human siRNA OriGene SR302752 III 
MAP2K5 MAP2K5 (ID 5607) Trilencer-27 Human siRNA OriGene SR303764 III 
MAP4K5 MAP4K5 (ID 11183) Trilencer-27 Human siRNA OriGene SR307671 III 
Negative 
Control 
Trilencer-27 Universal Scrambled Negative 
Control siRNA Duplex 
OriGene SR30004 I, III 
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Table 4.  Nucleofection solutions and programs for the indicated cell lines. 
Cell line Nucleofection solution Nucleofection program 
REH SF CA-137 
697 SG CA-137 
Jurkat SE CL-120 
MOLT-4 SF CA-137 
P12-Ichikawa SF / SG CA-137 
RCH-ACV SF / SG CM-137 
4.3.2 Stable modifications (I) 
Stable cell lines with inducible expression of ETV6-RUNX1 in NALM-6 cell line 
and knockdown of ETV6-RUNX1 in REH cell line were created by Teppo et al. 
(2016). ETV6-RUNX1 expression was induced with 500 ng/ml doxycycline 
(Clontech, Fremont, CA, USA). 
4.4 Drug treatments and inhibitions 
4.4.1 In vitro drug treatments (III) 
Dasatinib (9052, Cell Signaling Technology, Danvers, MA, USA) was stored in 
dimethyl sulfoxide (DMSO) stock solution at -20°C. Dasatinib was used as 10-fold 
dilutions (1-1000 nM) in 96 well plate with 5000 – 10 000 cells/well. After 72 h 
incubation with the drug or DMSO-control, cell viability was assayed as previously 
described (section 4.2.). To obtain relative cell viabilities, drug-treated samples were 
normalized to DMSO control sample. Experiments were performed with three or 
four technical and two or three biological replicates in each experiment. 
4.4.2 Mononuclear cell isolation and ex vivo drug treatments (III) 
Bone marrow aspirates or peripheral blood samples were used as a starting material 
for mononuclear cells in the ex vivo drug treatments. Cells were incubated 72 h in 
drug media or DMSO control media before the cell viability measurements (see more 
details in Laukkanen et al., 2017, supplementary information). Collected data were 
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normalized to positive controls (containing 100 μmol/L benzethonium chloride, 
effectively killing all cells) and negative control (DMSO only). Data were used to 
calculate the drug sensitivity scores (DSS) from the dose-response curves as 
previously described (Pemovska et al., 2013). Dasatinib concentration range was 0.1-
1000 nM as a 10-fold dilutions and glucocorticoid (dexamethasone, prednisolone 
and methylprednisolone) concentrations were 1-10 000 nM. 
4.4.3 Inhibition of PTP4A3 phosphatase activity (I) 
PTP4A3 inhibition was performed with PRL-3 inhibitor I (Lot # 047K4614V, 
Sigma-Aldrich, St. Louis, MO, USA) which was stored in DMSO stock solutions at 
-20°C. Cells were plated in 96-well plates with the desired concentrations (0 – 50 
μM) of PRL-3 inhibitor I. Cell viability measurements were performed as previously 
described in section 4.2. with three technical and four biological replicates. 
4.5 Gene expression analysis 
4.5.1 RNA extraction (I-IV) 
Total RNA extractions accompanied with DNA removal from the cultured cells 
were performed using either GeneJET RNA Purification Kit (Thermo Fisher 
Scientific), DNA-free™ DNase Treatment & Removal kit (Bio-Rad, Hercules, CA, 
USA), or PureLink™ RNA Mini Kit with On-Column PureLink® DNase 
Treatment Protocol (Ambion® by Life Technologies and Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA). Total RNA extractions from adult zebrafish tissue 
and zebrafish embryos was performed with RNeasy Mini Kit (Qiagen, Venlo, 
Holland). The quality and concentration of the RNA were analyzed with nanodrop 
spectrophotometer (Thermo Fischer Scientific). 
4.5.2 Quantitative PCR (I-IV) 
Extracted total RNA (0.25-1 μg) was used for reverse transcription synthesis of 
complementary DNA (cDNA) with iScpript (Bio-Rad). Synthesized cDNA was used 
for the RT-qPCR which was performed with SsoFast EvaGreen® Supermix (Bio-
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Rad) according to manufacturer`s instructions. BioRad CFX96TM Real Time 
System (Bio-Rad) was run with the following program: initial denaturation at 96°C 
for 30 s, 39 cycles of denaturation at 96°C for 2 s, annealing/extension at 60°C for 
5 s, and plate read (melt curve 60°C → 95°C). Each RT-qPCR measurement was 
performed in triplicate, and the relative 2-ΔΔCT method was used for quantification 
(Livak et al., 2001). Chromatin immunoprecipitation (ChIP) qPCR runs from ChIP 
samples were performed from two independent biological replicates with duplicate 
runs and the samples were analyzed with percent input method to normalize the 
data. Used primers and their sequences are listed in Table 5.  
  
 56 
Table 5.  qPCR primer sequences. 
Target Primers 5' -> 3' Study Target Primers 5’->3’ Study 
SOX11 forw. CGGTCAAGTGCGTGTTTCTG II BLK rev. CCCCTTCATCCAGGCAGC III 
SOX11 rev. CACTTTGGCGACGTTGTAGC II LYN forw. CCTGGAGGAGCATGGAGAAT III 
GAPDH forw. TCCATGACAACTTTGGTATCGTGG I, III, IV LYN rev. CATCACCATGCACAGGGTC III 
GAPDH rev. GACGCCTGCTTCACCACCTTCT I, III, IV FRK forw. CCTGTGTGTCAAGCTGGGG III 
PBGD forw. CGCATCTGGAGTTCAGGAGTA I, II FRK rev. GTGCCTCCCTCAGGAAGTC III 
PBGD rev. CCAGGATGATGGCACTGA I, II KIT forw. GCATTGTTCTGTGGACCAGG III 
ETV6-RUNX1 forw. TGCACCCTCTGATCCTGAAC I KIT rev. GAAGTCACCGTGATGCCAG III 
ETV6-RUNX1 rev. AACGCCTCGCTCATCTTGC I PDGFRa forw. CTATGTGCCAGACCCAGATG III 
PTP4A3 forw. CGCCACGCTCAGCACCTTCA I PDGFRa rev. CGGTGGCCTCACAGATATAG III 
PTP4A3 rev. GAACTTGGCCTTCACCAGGC I PDGFRb forw. CTTTGTGCCAGATCCCACC III 
gGAPDH forw. CACAGTCCAGTCCTGGGAAC I PDGFRb rev. GTCCCCAATGGTGGTTTTGC III 
gGAPDH rev. TAGTAGCCGGGCCCTACTTT I BTK forw. GAGGTGAAGAGTCCAGTGAA III 
eITGA4 forw.1 CCAACCTCTCTGTTGGGGTC I BTK rev. GTCTGAGAGCAGCAGAGATAC III 
eITGA4 rev.1 GTGAGCAGGCTAGCAGCAG I TEC forw. GGTCATTTCAGTAGAGACGTAC III 
ePTP4A3 e1 forw.1 ACAGGAGCCAAGGTCAGTC I TEC rev. GGACACCACTTCACAGGAAAC III 
ePTP4A3 e1 rev.1 AGGCCGCCCCTGGGCTGGGA I BRK forw. GGACCCCGTGTACATCATCA III 
ePTP4A3 e1 forw.3 GGTCTGACCCCAAGTACCCG I BRK rev. CATGGGAGAGGTAGACGTC III 
ePTP4A3 e1 rev.3 AAGTCGACTGGGGCTAGGTC I ACK forw. GGATGAGTAAGGTGTTCAGTG III 
ePTP4A3 e1 forw.4  CTCAGGAGGCCGCTGTTTC I ACK rev. CACTTCACAGCCACACTCAC III 
ePTP4A3 e1 rev.4   CTTCCAGCCAGGGGTGTTC I EGFR forw. GTGACTGCTGCCACAACCA III 
ePTP4A3 e2 forw.1 CCTGAGAGTGTCTTGGGGTT I EGFR rev. GCCGTGATCTGTCACCACA III 
ePTP4A3 e2 rev.1 TCACGCTCACTTCCTCTTCA I DDR1 forw. CCACAGCAGGTTGGAGAGCA III 
ePTP4A3 e2 forw.3 GGAGGCCTTGTTTACCCCTC I DDR1 rev. CCTGAGATCACCTCCTGA CC III 
ePTP4A3 e2 rev.3 CACAGACCTCTGAGCCGATG I EPHA2 forw. CCAGGCAGGCTACGAGAAG III 
ePTP4A3 e2 forw.4 AGATGCTCTGCTGACGGATG I EPHA2 rev. GCAAGGCATCGACGCTGG III 
ePTP4A3 e2 rev.4 CTCCAGATGGCTTCCTGTGG I MAP2K5 forw. CCTGAAGGTGAATACTCGGG III 
ePTP4A3 e2 forw.5 CTTGTTTGTTGGGTGCCTGG I MAP2K5 rev. GCTTTGTAGACTGTGCCTCC III 
ePTP4A3 e2 rev.5 AGGGACCCTCCTGAGACATC I MAP4K5 forw. GGAGCCTGGAGATGATTTTTC III 
ePTP4A3 e2 forw.6 AATGGCCCTGAAAGGGAAGC I MAP4K5 rev. GCAAATAGGCAAGACCCTGTA III 
ePTP4A3 e2 rev.6 TCCGTCAAGTACAGCAGCTC I EPHB2 forw. CACCGTCTGCCGAGGTTGT III 
ePTP4A3 e3 forw.1 CTGGCTGGGCTTCCTCTTC I EPHB2 rev. GATGGTTGTGCAGGGCATG III 
ePTP4A3 e3 rev.1 CCTGCCGCCTAAATATAGCC I EPHB6 forw. GACAAGGCCTGCCAAGCCT III 
ePTP4A3 e3_forw.3 GGCCGCATTTCCATTTCCAA I EPHB6 rev. CCGATGGAGGACCAGTGCA III 
ePTP4A3 e3_rev.3 TGGGGAGGCCTGGACAGA I NUP214 exon 2, forw. * ACCCGGAGATGATCCCAACAAAAT III 
ePTP4A3 e4 forw.1 TCTTTCCCCACCCCAACTAC I NUP214 exon 20, forw. * CACCAAATCCTTGCCCAAAGTACC III 
ePTP4A3 e4 rev.1 CCCTAGGGCCCTGTAACAG I NUP214 exon 23, forw. CAATGCTTGCCACGAAAACC III 
LCK forw. GCATCCTGGAGCAGAGCGG III NUP214 exon 28, forw. TCACACCAACACCGTCTTCT III 
LCK rev. GCTCTCGCTCTCCCGGATG III NUP214 exon 29, forw.  TGGGTTCAGCTTTTGCCAAGCT III 
ABL1 forw. GTGGCCAGTGGAGATAACACT III NUP214 exon 31, forw. GGTTGGTTTCTTCAGTGGCCTTGG III 
ABL1 rev. CAGATACTCAGCGGCATTGCG III NUP214 exon 34, forw.  CTGGTTTTGGATCAGGCACAGGA III 
SRC forw. GATCCGCAAGCTGGACAGCG III ABL1 exon 3, rev * CCATTTTTGGTTTGGGCTTCACACC III 
SRC rev. CATCCACACCTCGCCAAAGC III ABL1 exon 1, forw. GTAGCCAAAGACCATCAGCG III 
YES forw. GCTGGTTTAACAGGTGGTGT III EF1A (dr), forw. ** CTGGAGGCCAGCTCAAACAT IV 
YES rev. CCAAAATACCATTCTTCTGCC III EF1A (dr), rev ** ATCAAGAAGAGTAGTACCGCTAGCATTAC IV 
FYN forw. GCTTCGGTGTGACCTCCAT III nkx2.5 (dr), forw. *** GCGAAGACCTTCAGGAGGACAAAGGCAAC IV 
FYN rev. GAGCGGGCTTCCCACCAAT III nkx2.5 (dr), rev *** CGAGGCTTCCTCCTCTTCCTCTGCTTGGG IV 
FGR forw. GGTGACTGGTGGGAGGC III ppox (dr), forw. GTGATCAGTAAAGGGACAGAA IV 
FGR rev. CTTCACATGATCGCCTCTGG III ppox (dr), rev. CTGCATGCCCCTCTTTAG IV 
HCK forw. GGACCAGATGGTGGTCCTA III SAP30L (dr), forw. AACGCG TCC TTC AGC AAG AGG AT IV 
HCK rev. TCGCACGGACAAAGAGTAGC III SAP30L (dr), rev. GTTGACCTGAAGCTGGAACAGATC IV 
BLK forw. CCAGGTCACTCGTCACAGG III    
* Burmeister et al., 2006, ** Tang et al., 2007, *** Targoff et al., 2008, dr = Danio rerio 
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4.5.3 Global Nuclear Run-On sequencing (I) 
Primary bone marrow or blood samples from ALL, BCP-ALL (hyperdiploid, ETV6-
RUNX1) and T-ALL, patients and healthy donor were used on global run-on 
sequencing (GRO-seq) assay together with modified REH cell lines. These samples 
were used to capture different transcriptional activity patterns between ALL samples, 
healthy donors and cell lines. Nuclei extractions and GRO-seq reactions were carried 
out as previously described in Heinäniemi et al. (2016). 
4.5.4 RNA-sequencing sample preparation (II) 
Specific siRNAs were used to knockdown expression of SOX11 and scrambled 
siRNAs for control samples. After 48 h of the nucleofection, 3 million cells per 
sample were collected and total RNA was extracted. The efficacy of knockdown was 
verified by RT-qPCR and WB. Three independent biological replicants were 
collected per cell line with 25 ng of RNA in 40 μl volume. Library preparation and 
stranded mRNA sequencing was done at the Finnish Functional Genomics Centre 
(FFGS, Turku, Finland). See more details in original study II. 
4.5.5 Chromatin immunoprecipitation (I) 
DNA-protein interactions were analysed by ChIP assay where DNA fragments were 
immunoprecipitated from crosslinked cells by using two pooled antibodies against 
ETV6 (sc-166835, Santa Cruz Biotechnology Inc., Dallas, TX, USA; 
RRID:AB_2101020 and HPA000264, Atlas Antibodies, Bromma, Sweden; 
RRID:AB_611466) as described in Teppo et al. (2016). Collected ChIP samples were 
used in ChIP-qPCR. 
4.5.6 Gene fusion detection: NUP214-ABL1 and SIL-TAL1 (III) 
RNA from patient samples was used as template for reverse transcription to cDNA 
to serve as a template to NUP214-ABL1 fusion detection. The known range of 
NUP214-ABL1 fusion breakpoints was covered using seven different primer pairs 
(Hagermeijer et al., 2010). RNA quality was controlled using additional primer pair 
targeting ABL1. This was done regardless of the sample’s fusion status. All primers 
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are listed in table 5. In one case the NUP214-ABL1 and SIL-TAL1 fusions were 
detected from RNA sequencing (RNA-seq) data (See details in Laukkanen et al., 
2017, supplementary information). 
4.6 Protein expression analysis 
4.6.1 Protein extraction and western blotting (II-IV) 
Cultured cells were lysed and proteins were extracted from the cell lines with M-PER 
reagent (Thermo Fisher Scientific) according to manufacturer’s instructions. The 
total protein concentrations were determined using DC Protein Assay (Bio-rad). 15-
20 μg of a protein per sample was loaded for the precasted 10 % Mini-PROTEAN® 
TGX Stain-FreeTM Gels (Bio-Rad) or casted on 10-12 % SDS–polyacrylamide gel. 
After the gel run, Trans-Blot® TurboTM Pack (Bio-Rad) was used to transfer proteins 
from the gel to the nitrocellulose membrane with Trans-Blot® TurboTM Transfer 
system according to manufacturer’s instructions (Bio-Rad). Proteins from casted gels 
were transferred to Amersham Protran Supported nitrocellulose membrane (GE 
Healthcare, Helsinki, Finland) under standard procedures. Prestained protein ladder 
PageRuler PLus (#26619, Thermo Fischer Scientific) was used as a protein size 
marker in WB. Chemiluminescence reaction by Amersham ECL reagent was 
detected with ChemiDocTM XRS+ using Image LabTM Software (Bio-Rad). 
Zebrafish samples for WB were prepared from larvaes at 2 dpf. 10 larvae / 50μl 
was collected to 2 x Laemmli buffer and samples were lysed by boiling and passing 
through a small needle. Lysate was centrifuged and the soluble fraction was collected 
for the WB analysis. Antibodies and their working dilutions are listed in Table 6. 
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Table 6.  Antibodies used for western blotting and immunofluorescence staining (Studies II, III 
and IV). 
Antibody Dilution (WB) Dilution (IHC/IF) Product # Manufacturer Study 
H3 1:75000  ab4729 Abcam II 
SOX11 1:1000  HPA000536 Sigma II 
SOX11  1:50 MRQ-58 Sigma-Aldrich II 
LCK 1:1000  2714 Cell Signaling Technology III 
FYN 1:2000  4023 Cell Signaling Technology III 
LYN 1:500  4576 Cell Signaling Technology III 
ABL1 1:250  2862 Cell Signaling Technology III 
β-actin 1:100000  sc-1615 Santa Cruz Biotechnology III 
Nucleophosmin (NPM) 1:8000 1:2000 35-5200 Invitrogen IV 
Prohibitin (PHB) 1:1000 1:50 sc-28259 Santa Cruz Biotechnology IV 
SAP30L 1:250  - Own; Korkeamäki et al. 2008 IV 
TDP-43 1:1000 1:150 T1705 Sigma-Aldrich IV 
TDP-43-N 1:1000 1:150 SAB4200006 Sigma-Aldrich IV 
Horseradish peroxidase 
conjugated anti-rabbit 1:2000/1:5000 
 P0217 Agilent Technologies II, III 
Horseradish peroxidase 
conjugated anti-mouse 1:5000 
 P0260 Agilent Technologies III 
4.6.2 Immunohistochemistry and fluorescence in situ hybridization (II) 
In order to analyze the expression of SOX11 protein in bone marrow biopsies, two 
pathologists analyzed the nuclear expression of SOX11 stained slides independently 
with a light microscope without knowledge of the clinical data. Antibodies and their 
working dilutions are listed in Table 6. In the case of different scoring, a third 
pathologists analyzed the data to decide the score. Formalin fixed paraffin embedded 
(FFPE) MCL sample was used as positive control and remission bone marrow 
sample as negative control. Cases with less than 20 % of immunohistochemically 
positive SOX11 cells were classified as negative, cases with 20-50 % of positive cells 
were graded positive and cases with over 50 % of nuclear positive cells were 
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considered strongly positive. Fluorescence in situ hybridization (FISH) was 
performed for cases that were not tested at diagnosis with current methods. Bone 
marrow culture or FFPE samples were used for the FISH with following probes: 
Metasystems E2A Break Apart Probe 19p13 (lot# 18216), Metasystems XL MLL 
plus Break Apart Probe 11q23 (lot 18451), Metasystems XL BCR/ABL1 plus (lot# 
19082) and Metasystems XL t(12;21) (lot 19133). See more details in original 
study II. 
4.6.3 Flow cytometry analysis (II) 
Cells permeabilization was carried out with Fix&Perm reagent according to 
manufacturer’s instructions (GAS003, Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) for flow cytometry analysis and the data collection with 
Beckman Coulter Navios cytometer (Beckman Coulter, Brea, CA, USA) using Red 
laser (638nm) and 660/20 bandpass filter. After permeabilization cells were stained 
with Alexa Fluor 647® conjugated rabbit anti-human SOX11 antibody [EPR8191 
(2)] (ab198540, Abcam, Cambridge, UK), while CD3-APC antibody (345767) 
(Becton Dickinson, Franklin Lakes, NJ, USA) served as a negative control. Data 
were analyzed with Kaluza software (Beckman Coulter, Brea, CA, USA). 
4.7 Clinical data and patient samples (II-III) 
Patient data in study II included 126 pediatric acute lymphoblastic leukemia cases 
treated in Tampere University Hospital from the year 1990 onwards (POTTI 
registry). Patients under 18 years old were included in this study with additional 
clinical information (age at diagnosis, leukocyte count, blast percentage, gender, 
relapses, deaths, stem cell transplantation, duration of treatment and genetics). Case 
classification was based on the WHO 2017 Classification of tumors of hematopoietic 
and lymphoid tissues (Swerdlow et al., 2017). 
For ex vivo drug treatments, 22 T-ALL patient samples (bone marrow or 
peripheral blood) were used in study III. 
 61 
4.8 Zebrafish methods (IV) 
4.8.1 Zebrafish maintenance 
Wild type AB zebrafish were maintained at the Tampere zebrafish core facility under 
standard conditions at 28.5°C as described in Westerfield (1995). Animal care was 
carried out in accordance with the Finnish Laboratory Animal Welfare Act 62/2006 
and the Laboratory Animal Welfare Ordinance 36/2006. 
4.8.2 Microinjections: Morpholino knockdown and mRNA rescue 
Zebrafish embryos at their 1-4 cell stage were used for the microinjections, where 1 
nl of the injection mix was injected into the yolk sac. Injection mix contained 
morpholino, mRNA (where indicated) and rhodamine dextran as a marker color. 
Injections were carried out with The PV830 Pneumatic PicoPump injection system 
(WPI, Inc.). Two independent antisense morpholino oligonucleotides (SAP30L-
MO1: CCTCCTCCGTGCTGAAGCCGTTCAT and SAP30L-MO2: 
TCATCCCGGAGACCGGACACCGAGC) were used to target the start site of the 
zebrafish SAP30L mRNA (Ensembl ID: ENSDARG00000030213). Morpholino 
targeting TP53 (Robu et al., 2007) and the random control morpholino (RC-MO: 
CCTCTTACCTCAGTTACAATTTATA) were used as controls. All morpholinos 
were purchased from Gene-Tools, LLC (Philomath, OR, USA). The effective 
morpholino concentrations were determined experimentally by titration. In the 
mRNA rescue experiments SAP30L-MO1 or SAP30L-MO2 were co-injected with 
a capped synthetic mRNA encoding the full-length zebrafish SAP30L or full-length 
zebrafish nkx2.5. Corresponding plasmid templates and a T7 mMESSAGE 
mMACHINE Kit (Ambion) were used to synthesize the required mRNAs according 
to the manufacturer’s instructions. 
4.8.3 Whole-mount in situ hybridization  
Linearized plasmids containing the full-length zebrafish SAP30L cDNA (in the 
sense or antisense orientation) under the T7 promoter control were used as templates 
for the DIG-labeled probes. DIG RNA Labeling Mix (Roche Diagnostics, Espoo, 
Finland) was used to prepare the sense and antisense probes for the zebrafish 
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SAP30L (Thisse and Thisse, 2008). Whole-mount in situ hybridization (WISH) was 
performed for the collected zebrafish larvae. Larvae were collected at 12, 24, 36, 48, 
and 72 hpf as previously described by Thisse and Thisse (2008). WISH was 
performed according to Thisse and Thisse (2008) with alkaline phosphatase 
detection and the BM Purple substrate (Roche Diagnostics). The following 
modifications were used in the protocol: 2 ml eppendorf tubes were used during the 
entire experiment, hybridization was carried out at 65°C, sense and antisense probe 
concentrations were 130 ng per reaction and dilution ratio for the anti-DIG antibody 
(sheep anti-digoxigenin-AP Fab fragments, Roche Diagnostics) was 1: 2000. After 
the desired level of the staining was obtained, the reaction was stopped and 
dissecting microscope was used to photograph and analyze the fish. Anatomical 
images by Haffter et al. (1996) were used as reference to assess the localizations of 
the staining. 
4.8.4 O-dianisidine staining 
Hemoglobin in red blood cells of 3 dpf zebrafish larvae was detected with o-
dianisidine staining as previously described in Ransom et al. (1996). Staining was 
visually scored for each specimen as normal, reduced or severely reduced based on 
the level of the staining. In the normal staining category, staining was comparable to 
the wild type larvae. Larvae with in the reduced category had o-dianisidine staining 
visibly decreased compared to the wild-type specimens and in the severely reduced 
group there was very little to no visible staining. 
4.8.5 Analysis of heart morphology and function 
Heart morphology of zebrafish larvae was assessed visually at 5 dpf and categorized 
as normal or deformed. Unanaesthetized 5 dpf larvae were observed visually to 
determine the heart rates in morphant and control larvaes. Heart function, 
ventricular and atrial performance, were analyzed with 10-20 s time-lapse videos. 
The function was calculated from the longitudinal fractional shortening according to 
the formula (LDd-LDs)/LDd, where LDd is the longitudinal diameter at diastole 
and LDs the diameter at systole. 
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4.8.6 Histological staining 
The zebrafish larvae were fixed with 4 % PFA-PBS at + 4°C followed by embedding 
in 2 % agarose. Larvae samples were dehydrated by incubating them in rising ethanol 
solution series (70 %, 96 %, and abs EtOH) for 1-2 hours per solution before the 
final incubation xylene for at least 1 hour. Dehydration was followed with paraffin 
embedding which enabled cutting of 5 mm-thick sections in longitudinal orientation 
and fixing on glass slides. Fixed sections were then deparafinized by incubation in 
xylene (2 x 4 min), abs EtOH (2 x 3 min), 96 % EtOH (2 x 3 min), and 70 % EtOH 
followed by rinsing once in water. Samples were then hematoxylin-eosin stained by 
incubation with the following protocol and solutions: Mayer’s hematoxylin (2 min), 
running water (2 min), water (1.5 min), 70 % EtOH (15 s), eosin Y (15 s), 96 % 
EtOH (2 x 30 s), abs EtOH (2 x 1 min), and xylene (1–4 min). Thereafter, slides 
were mounted and BX60 microscope with Cell^D program (Olympus) was used to 
take pictures. 
4.9 Gene expression data and data analysis (I-IV) 
Three different data sets were utilized to study differential gene expressions of 
PTP4A3 and SOX11 (study I-II). A combined microarray-based gene expression 
data set (GeneChip™ Human Genome U133 Plus 2.0 Array, Thermo Fisher 
Scientific) processed by Heinäniemi et al. (2016) and Pölönen et al. (2019), and two 
independent data sets with gene expression profiles from patients with pediatric 
ALL, GSE47051 (Nordlund et al., 2013) and from St. Jude Children`s Research 
Hospital’s Pediatric Cancer data portal (referred from now as St. Jude data) (PeCan). 
For study II, differential gene expression of SOX11 knockdown was investigated 
using RNA-seq (GSE123943) by using edgeR R-package and differentially expressed 
genes were filtered with adjusted p-value (p<0.05). Differentially expressed genes 
were illustrated with Venn diagram (Interactive Venn online tool, 
http://www.interactivenn.net/) and a heatmap (ComplexHeatmap R-package). 
Gene set enrichment analysis was performed with GSEA 3.0 software and 
enrichment of GO terms was studied with GSEA software and GOrilla online tool 
(study II). For more detailed information see original study II. SOX11 mRNA 
expression levels were further studied from previously published transcriptomic data 
from 116 BCP-ALL patients and correlated with clinical parameters (Marincevic-
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Zuniga et al., 2017). 112 samples out of the 116 also had methylation data available 
(GSE47051) (Marincevic-Zuniga et al., 2017). 
For study III, normalized microarray data was first transformed with Principal 
Component Analysis to reduce uninteresting variance effect of the data. Optimized 
parameter k for k-means clustering was used to find suitable clustering 
complementing the subgroups of T-ALL according to chosen transcription factors 
(TAL1, TLX1, TLX3, HOXA10, NKX2-1 and LYL1). For more detailed 
information, see Laukkanen et al. (2017). 
For study IV, zebrafish total RNA samples were prepared according to 
manufactures recommendation (Santa Clara, CA, USA) to Agilent’s 4 × 44K 
Zebrafish V3 Gene Expression Microarray. Zebrafish microarray data were analyzed 
using the R programming language and environment (R Development Core Team, 
2008) and its Bioconductor module (Gentleman et al., 2004). Statistical testing was 
performed with the Limma Package (Smyth, 2005) with filtering thresholds (fold 
change FC≥|3| and p-value p≤0.001). For more detailed information see Teittinen 
et al. (2012). 
4.10 Statistical analysis (I-IV) 
Expression levels of mRNA measured by RT-qPCR were evaluated with Mann-
Whitney U-test (study I). Differential expression of target genes between distinct 
leukemia subgroups were evaluated with Kruskal-Wallis H-test and/or Mann-
Whitney U-test (study I, II, III). Cell viability differences between treated and control 
cells were evaluated with Student’s t-test (study I) or Mann-Whitney U-test and 
correlation coefficients with Spearman method (study III). Clinical status of the 
patient samples were analyzed with Kaplan-Meier survival analysis and Chi-squared 
test was performed on SOX11 expression and clinicopathological prognostic 
variables (study II). In study IV, all quantitative data is given as mean ± standard 
deviation. Differences between groups, when appropriate, were evaluated with two-
tailed Student t-test or the χ2 test for crosstabulation. 
4.11 Ethical considerations (I-IV) 
Commercial cell lines were used and gene expression data from patients were 
retrieved from publicly available databases (studies I-III).  In study II, National 
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supervisory authority of welfare and health (VALVIRA, Helsinki, Finland) approved 
the usage of primary patient samples under the ethics committee approval code 
R16054. Furthermore, patient samples from Tampere University Hospital were 
collected under the Pirkanmaa Hospital District Ethics committee permit number 
R13109. For study III, collection of bone marrow and peripheral blood samples were 
carried out following written informed consent by protocols approved by local 
institutional review boards and in accordance with the Declaration of Helsinki. 
Zebrafish experiments in study IV were carried out at the Tampere Zebrafish core 
facility under the permission of the State Provincial Office of Western Finland 
(permission LSLH-2007-7254-/Ym-23). Zebrafish embryos and larvae that were 
used in these studies were under the age of seven days, so no separate permission 
was required according to the effective practice in Finland. 
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5 RESULTS 
5.1 Expression and role of PTP4A3 in BCP-ALL 
5.1.1 PTP4A3 is expressed in a subtype-specific manner in BCP-ALL 
A previously described gene expression data set (Heinäniemi et al., 2016) was utilized 
to investigate expression of different PTP4A family member across acute leukemias 
and healthy cells of hematopoietic origin. To visualize the expression patterns, a 
Hemap cancer-map was used which projects the data in two dimensions by using a 
t-SNE algorithm (Pölönen et al., 2019; van der Maaten and Hinton, 2008). PTP4A1 
showed no difference in expression between disease and healthy controls, whereas 
PTP4A2 showed elevated expression for some of the T-ALL samples. PTP4A3, on 
the other hand, showed markedly increased expression in BCP-ALL samples and 
also in a few T-ALL cases (see Fig. 1A in study I). When we examined the PTP4A3 
expression across all hematological malignancies, the strongest expression was 
observed in ETV6-RUNX1- and BCR-ABL1-positive ALL cases. Multiple myeloma 
showed overexpression but in other malignancies the expression level was low or 
was not detectable (Fig. 9). 
  
 67 
 
Figure 9.  Expression levels of PTP4A3 in hematological malignancies and BCP-ALL subtypes 
shown in a t-SNE-based two-dimensional map. Expression level is indicated with colors 
blue (ND = not detected), white (low expression), red (high expression). Disease subtypes 
are indicated in the right side of the figure with colors. Abbreviations: AML = acute myeloid 
leukemia, B-CLL = B cell chronic lymphocytic leukemia, BCL = B cell lymphoma, BCP-ALL 
= precursor B cell acute lymphoblastic leukemia, CML = chronic myeloid leukemia, Hd = 
hypodiploid, HeH = hyperdiploid, KMT2Are = KMT2A-rearrengement, MM = multiple 
myeloma, pM = proliferative myeloid, pL = proliferative lymphoid, t(1;19) = TCF3-PBX1, 
t(9;22) = BCR-ABL1, t(12;21) = ETV6-RUNX1, T-ALL = T cell acute lymphoblastic 
leukemia, TCL = T cell lymphoma. 
When compared to other BCP-ALL leukemias, the ETV6-RUNX1 subtype showed 
three to four-fold higher expression of PTP4A3 (see Fig. 1B in study I; Mann-
Whitney U-test, p = 1.894997e-52). To further validate results, two more leukemia 
data sets were retrieved and analyzed. PTP4A3 showed similarly high expression in 
ETV6-RUNX1 and BCR-ABL1 positive leukemia subtypes in both data sets: 
GSE47051 (Nordlund et al., 2013) and St. Jude data (PeCan) (see Fig. 1B in study I). 
Interestingly, KMT2A-rearranged leukemias showed evidence of low level of 
PTP4A3 expression in all three data sets. 
5.1.2 Expression of PTP4A3 is regulated by ETV6-RUNX1 fusion protein 
Since PTP4A3 showed higher expression in ETV6-RUNX1 leukemia samples, we 
next sought to investigate if ETV6-RUNX1 fusion regulates expression of PTP4A3. 
As a first step, we screened expression of PTP4A3 in a panel of leukemia cell lines 
with RT-qPCR. Strongest expression was demonstrated in REH cell line, which 
carries endogenously the ETV6-RUNX1 fusion, while moderate expression was 
seen in two BCP-ALL cell lines (KOPN-8 and 697) and in healthy B cells and T 
cells. (see Fig. 2A in study I). NALM-6 cell line showed a low level of PTP4A3 
expression. We chose the REH cell line for knockdown experiments and NALM-6 
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cell line for overexpression studies to see if ETV6-RUNX1 fusion regulates the 
PTP4A3 expression directly (Teppo et al., 2016). In the inducible NALM-6-ETV6-
RUNX1 cell line model, expression of ETV6-RUNX1 fusion can be controlled by 
addition of doxycycline into the cell culture media (Teppo et al. 2016). Induction of 
ETV6-RUNX1 increased expression of PTP4A3 (see Fig. 2B in study I) while no 
marked downregulation was seen with the knockdown of ETV6-RUNX1 in the 
REH cell line (see Fig. 2C in study I). We also investigated transcription of PTP4A3 
at primary transcript level by GRO-seq, and the signal decrease in at PTP4A3 locus 
was more evident in REH-shETV6-RUNX1 as compared to control cells (see Fig. 
3A in study I). GRO-seq also revealed robust expression of PTP4A3 in patient 
samples so that ETV6-RUNX1 cases had notably higher expression as compared to 
other subtypes (see Fig. 3A in study I). These data indicated that ETV6-RUNX1 
fusion protein might regulate PTP4A3 either directly or indirectly. We looked for 
the possible direct interactions of ETV6-RUNX1 fusion protein in the putative 
regulatory regions upstream of PTP4A3 with targeted ChIP-qPCR and ETV6 
antibodies from NALM-6 cell lines with induced ETV6-RUNX1. All of these 
PTP4A3 regulatory regions failed to detect any binding of ETV6-RUNX1 fusion 
into the possible binding sites (see Fig. 3A-B in study I). 
5.1.3 Functional role of the PTP4A3 in ETV6-RUNX1 leukemia 
It has been previously shown that depending on the expression level, PTP4A3 may 
affect cell cycle regulation either positively or negatively (Beekman et al., 2011). To 
investigate the role of PTP4A3 further in ALL, we knocked down expression of 
PTP4A3 by transient siRNA transfection. Two different cell lines, REH and 697, 
were used for knockdown studies and the level of the knockdown was confirmed by 
RT-qPCR. After 48 h of transfection, RT-qPCR showed 42 % decrease in the 
expression of PTP4A3 in REH cells and 63 % in 697 cells. Confirmation of the 
knockdown at protein level was not possible due to the absence of antibodies that 
detect PTP4A3 in WB experiments. After the knockdown, the cells were plated and 
cell viability was measured with Alamar Blue -assay for every 24 h up to 96 h with 
two biological replicates. These Alamar Blue -assays did not show any changes in cell 
viability. Similarly cell cycle or apoptosis did not reveal any changes after the 
knockdown. As our PTP4A3 knockdown did not have any significant effect on cell 
viability, we sought for other possibilities to disrupt or block the PTP4A3 function 
in leukemia cells. A rhodamine derivative can be used to inhibit the enzymatic 
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activity of PTP4A3 with an IC50 value of 0.9 μM (Min et al., 2013). The potency of 
this PRL-3 inhibitor I to suppress proliferation of ETV6-RUNX1 positive leukemia 
cells was tested in an assay with increasing drug concentration and the results were 
compared between the ETV6-RUNX1 positive and negative leukemia cell lines. We 
noticed reduction in cell viability after the concentrations exceeded 10 μM (see Fig. 
4 in study I). A mild resistance towards this inhibitor was observed in ETV6-RUNX1 
positive cells, possibly due to higher expression of PTP4A3. In addition to this, we 
also tested a combination of PRL3-inhibitor I with a mixture of different leukemia 
drugs (vincristine, doxorubicin and prednisone). These combination experiments 
were done with variations of different drug and inhibitor concentrations in NALM-6 
and REH cell lines, but no additive effect was seen in cell viabilities in the studied 
time points. 
5.2 SOX11 transcription factor in BCP-ALL 
5.2.1 SOX11 overexpression in acute lymphoblastic leukemia 
We sought to identify novel transcriptional regulators of BCP-ALL, and to this end 
we utilized a large microarray gene expression data set by Heinäniemi et al. (2016). 
We identified SOX11 as an aberrantly expressed transcription factor gene with 
subtype-specificity. When we compared all leukemias and lymphomas, SOX11 
expression was highest in MCLs but increased expression was also observed in BCP-
ALL. We saw a subtype-specific overexpression in ETV6-RUNX1 and TCF3-PBX1 
subtypes when compared to other acute leukemia subtypes (Fig. 10), approximately 
four to five-fold higher expression was noted in ETV6-RUNX1 and TCF3-PBX1 
subtypes (see Fig. 1A in study II). These results were further confirmed by two 
additional gene expression data sets, namely GSE47051 (Nordlund et al., 2013) and 
St. Jude data (PeCan) (see Fig. 1A in study II).  Similar subtype specific expression 
pattern of SOX11 was also seen in cell lines and patient samples (see Fig. 1B in 
study II). 
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Figure 10.  Expression levels of SOX11 in acute leukemias shown in a t-SNE-based two-dimensional 
map. Expression level is indicated with colors blue (ND = not detected), white (low 
expression), red (high expression). Leukemia subtypes are indicated in the right figure with 
colors. Abbreviations: HeH = hyperdiploid, KMT2Are = KMT2A-rearrangement, t(1;19) = 
TCF3-PBX1, t(9;22) = BCR-ABL1, t(12;21) = ETV6-RUNX1, T-ALL = T cell acute 
lymphoblastic leukemia. 
5.2.2 SOX11 expression affects survival in acute lymphoblastic leukemia 
Having previously shown that SOX11 is strongly expressed in subgroups of pediatric 
ALLs at the RNA level, we next sought to analyze its expression at protein level. To 
this end, a cohort of 119 primary FFPE bone marrow biopsy samples of childhood 
B cell acute lypbhoblastic leukemia (B-ALL) cases were analyzed with 
immunohistochemical (IHC) staining by SOX11 antibody (see Table 1 and 2 in study 
II). 79 out of 119 cases were deemed as negative with less than 20 % of positive cells. 
35 cases were SOX11 positive (nuclear positivity 20 – 50 %) while 5 cases were 
deemed strongly positive (positivity over 50 %) (Fig. 11 and Table 2 in study II). 
From the 40 positive cases, 29 demonstrated either ETV6-RUNX1 or TCF3-PBX1 
subtype with statistically significant association with ETV6-RUNX1 subgroup (p-
value <0.001). KMT2A-rearrangement and BCR-ABL1 translocation cases did not 
express SOX11 protein and majority of hyperdiploid cases were negative. In addition 
to IHC staining, we studied the suitability of flow cytometry to discriminate SOX11 
positive cases based on the cytoplasmic expression. SOX11 antibody staining was 
able to readily separate high expressing (REH, RCH-ACV) from low expressing 
(NALM-6, KOPN-8) cell lines (see Fig. 5B in study II). 
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Figure 11.  Immunohistological stainings of SOX11 in FFPE samples. A) Positive control, B) Negative 
control, C Positive BCP-ALL, D) Strong positive BCP-ALL. 
Next step was to evaluate the clinical significance of SOX11 expression in B-ALL. 
In our patient cohort, OS was better in the SOX11 positive compared to SOX11 
negative group (p=0.039) (see Fig. 2B in study II) and no deaths were reported 
amongst SOX11 positive group. Similar trends were also seen in EFS and relapse-
free survival (RFS) but without statistical significance (see Fig. 2B in study II). 
Favourable trend was seen in univariate analysis of SOX11 positivity in EFS among 
the ETV6-RUNX1 subtype (HR = 0.27, 95 % CI 0.04, 1.60, p = 0.149) and other 
subtypes (HR = 0.28, 95 % CI 0.04, 2.07, p = 0.212). Good early therapy response 
was also associated with SOX11 positivity at the end of induction therapy (OR = 
0.49, 95 % CI 0.19, 1.19, p = 0.123). Positive IHC for SOX11 remained statistically 
significant in multivariate analysis of EFS (see Table 3 in study II) indicating its 
independent value as a prognostic marker. 
We next sought to validate our findings in an external data set and, therefore 
analyzed SOX11 expression from transcriptomic data of a patient cohort comprising 
116 BCP-ALL cases (Marincevic-Zuniga et al., 2017). This data set supported our 
protein expression data, as high expression of SOX11 mRNA was associated with 
favourable EFS, even though no statistical significance was reached (see Fig. 3A in 
study II). 
5.2.3 Hypomethylation of SOX11 locus in BCP-ALL 
Next, we investigated the biology behind the increased expression of SOX11 in 
leukemia. When patient samples with available genomic data were analysed, no 
aberrant enhancer activity in primary transcription (GRO-seq) or somatic mutations 
in whole-genome sequencing (WGS) were observed in the nearby regions of SOX11, 
suggesting that perhaps epigenetic mechanisms could be involved. As 
hypomethylation partially drives increased expression of SOX11 in MCL (Vegliante 
et al. 2011), we utilized available genome-wide CpG methylation data from the BCP-
A                          B                           C                          D 
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ALL patient cohort (Marincevic-Zuniga et al., 2017). A total of 23 CpG sites were 
located within the SOX11 locus and patients with high SOX11 mRNA expression 
demonstrated a strong DNA hypomethylation at SOX11 gene locus (see Fig. 3B 
and C). SOX11 loci with hypomethylated CpG sites were associated with better EFS 
although no statistical significance was reached (see Fig. 3A). 
5.2.4 Knockdown of SOX11 in BCP-ALL cell lines 
In order to study the functional role of SOX11, we decided to knock down the 
expression of SOX11 in cell lines with high expression of SOX11 and for this, we 
chose siRNA oligos targeting SOX11. After transient transfection of siRNA oligos, 
we observed marked down-regulation of SOX11 expression so that 20-40 % of 
expression were left, depending on the cell line, as compared to controls (see Fig. 
4A-B in study II). Down-regulation was further confirmed by WB. Then we assessed 
the impact of knockdown of SOX11 into cell viability by using Alamar Blue -assay, 
but no marked effect on cell viability was observed in any of the studied cell lines 
(see Fig. 4B in study II). In addition to this, we investigated if knockdown had any 
effect on steroid (dexamethasone and prednisolone) sensitivity but no effect was 
seen. 
SOX11 knockdown effect in gene expression was further studied with RNA-seq 
in REH, 697, RCH-ACV cell lines. Gene ontology (GO) annotations demonstrated 
altered GO-terms related to cell migration, adhesion and differentiation. Gene set 
enrichment analysis on the other hand implied altered expression MYC and EF2 
target genes (see Fig. 4C in study II and Appendix 1). As summarized in the heatmap, 
after knockdown of SOX11, all three cell lines differentially expressed 18 genes, 
whereas 15 were concordantly regulated (same direction) (see Fig. 4E in study II and 
Appendix 2). Gene alterations were seen in genes related to leukemia cell motility, 
adhesion, differentiation and drug response. SOX11 silencing led to a down-
regulation of WW Domain Binding Protein 1 Like (WBP1L), a direct target of ETV6 in 
ALL (Neveu et al., 2016). Increased WBP1L expression (2.8-fold) in ETV6-RUNX1 
subtype (Yeoh et al., 2002) coincides with SOX11 overexpression and may suggest 
co-regulation in same subtype. SOX11 knockdown silenced a secreted growth factor 
Midkine (MDK) which promotes cell growth and migration and is associated with 
adverse prognosis in ALL (Jia et al., 2016). Another gene regulated by SOX11 and 
involved with cell regulation and migration was WD Repeat Domain 1 (WDR1), which 
is also involved in megakaryocyte maturation (Kuhns et al., 2016; Standing et al., 
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2017). MLLT11, a gene associated with hematopoiesis (Tse et al., 1995) found to be 
downregulated by SOX11. MLLT11 is involved in lymphoid regulation and is a 
known partner in rare leukemia translocations (Tse et al., 1995; Ney Garcia et al., 
2017). Downregulated Coiled-coil domain containing 28A (CCDC28A) is similarly a 
known partner of NUP98 in AML. SOX11 also regulated genes associated with drug 
response. Association of MKD with adverse prognosis in ALL is possibly via 
increased drug resistance (Hu et al., 2010) and Lipopolysaccharide Induced TNF Factor 
(LITAF) was recently suggested to sensitize leukemia cells to chemotherapeutic 
drugs (Liu et al., 2016). CANT1 was down regulated by SOX11 and is involved in 
pyrimidine metabolism and could be related with cytarabine metabolism and therapy 
response in ALL (Fridley et al., 2011). Only few of the genes were overlapping with 
previous studies with pro-B (Lord et al., 2018) and MCL cells (Vegliante et al., 2013; 
Conrotto et al., 2011; Kuo et al., 2015; Wang et al., 2010; Kuci et al., 2016). No 
marked effect was seen in Id1 and Tal1 as reported in pro-B cells (Lord et al., 2018) 
or PAX5 in MCL (Vegliante et al., 2013). MDK, which is involved in cell migration 
and growth, was downregulated by SOX11 knockdown in our study with similar 
manner of SOX11 knockdown in MCL cell line Z138 (Conrotto et al. 2011). 
5.3 Targeted therapies for T-ALL 
5.3.1 In silico screening for potential targets and matching drugs 
T-ALL has a less favorable prognosis than BCP-ALL, especially after relapse. We 
therefore searched for novel targeted therapies for T-ALL by utilizing the gene 
expression profiles of 4430 leukemia samples that were retrieved from the Gene 
Expression Omnibus (GEO) in an in silico drug target screening (Heinäniemi et al. 
2016). In the target screening, expression profiles were compared to known drug 
targets in the Drug signature database (DsigDB) containing Food and Drug 
Administration approved and novel investigational drugs. This approach matched a 
target, LCK kinase, with a drug, dasatinib tyrosine kinase inhibitor. LCK showed 
strong expression in a portion of T-ALL cases as compared to other leukemias and 
normal T cells (see Fig. 1A in study III). In a kinase activity assay, dasatinib treatment 
decreased the activity of LCK kinase to 1 % at 100 nM concentration when 
compared to controls (Yoo et al., 2015). Elevated expression of few other potential 
targets of dasatinib were similarly noticed in T-ALL patients (see Fig. 1B and Suppl. 
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Fig. S1 in study III). These data suggested that dasatinib could serve as a potential 
candidate targeted therapy for T-ALL patients. 
5.3.2 Dasatinib decreases cell viability of Jurkat cells and targets LCK 
kinase 
We next evaluated the potency of dasatinib experimentally in a panel of seven T-
ALL cell lines. In an assay with 10-fold concentration changes of dasatinib 
(1-1000 nM), cell viability was measured after 72 h treatment. From the studied cell 
lines, Jurkat cells showed the most significant response with 31 % decrease in cell 
viability at 10 nM concentration (n=3, P = 0.0039; see Fig. 1C and Suppl. Fig. S2 in 
study III). Three other cell lines (Molt-16, Molt-4 and PEER) responded for 
dasatinib with higher concentrations or milder effect on cell viability (see Suppl. Fig. 
S2 in study III). In a follow up study LCK knockdown in a dasatinib sensitive Jurkat 
cell line decreased cell proliferation in a significant manner (14 % decrease, P = 
0.0289, n = 7, see Fig. 1E in study III). We next utilized a genetically engineered 
variant of Jurkat cells (J.CaM1.6), where a deletion of exon 7 of LCK kinase renders 
it inactive. Accordingly, these cells were insensitive to dasatinib treatment (see Fig. 
1F in study III). LCK knockdown in a relatively dasatinib-insensitive P12-Ichikawa 
cell line did not cause any significant change in cell proliferation (see Suppl. Fig. S4E 
in study III). 
As dasatinib has several targets and inhibits multiple key regulators of cellular 
proliferation, we next sought to study other possible target genes and analyze their 
expression in T-ALL cell lines. Totally, 21 possible targets (9 targets based on the in 
silico screening and 12 other well-known targets from the literature) were identified 
and selected for the screening with RT-qPCR and WB. Expression levels of the other 
possible targets in T-ALL cell lines were lower or nonexistent when compared to 
LCK expression (see Fig. 1D and Suppl. Fig. S3 in study III). Gene knockdown of 
other possible targets, FYN, ABL1, MAP2K5 and MAP4K5, with lower expression 
levels did not cause any significant effect on Jurkat cells proliferation (see Suppl. Fig. 
S4A-D in study III). 
5.3.3 One third of T-ALL cases are sensitive to dasatinib 
We next utilized an ex vivo drug testing to see if T-ALL patient samples respond to 
dasatinib treatment. 6 cases out of 22 (27 %) had a significant response to dasatinib 
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according to DSS (using a cutoff value of 10, see Fig. 2A in study III) (Yadav et al., 
2014). Half-maximal growth inhibition concentrations (IC50) ranged between 1.3 
and 16 nM, while the IC50 values for the control samples were >1000 nM (see Suppl. 
Fig. S5 in study III). In addition to this, we also noted a negative correlation in DSS 
between dasatinib and glucocorticoid (see Suppl. Fig. S6 in study III). None of our 
patients had the NUP214-ABL1 fusion (Quintás-Cardama et al., 2008; Deenik et al., 
2009; Crombet et al., 2012) (see Suppl. Fig. S7 in study III). From the dasatinib 
targets under examination, LCK expression was prominent in four out of five (RNA 
unavailable for one of the six samples) dasatinib-responsive samples whereas other 
targets were expressed either at low (LYN, ABL1) or medium level (FYN, MAP2K5 
and MAP4K5) (see Suppl. Fig. S8A in study III). We also noted a statistically 
significant correlation between LCK expression and the TAL1 subgroup of T-ALL 
(see Fig. 2C-D and Suppl. Fig. S10 in study III). 
5.4 The role of SAP30L in zebrafish hematopoiesis 
5.4.1 Expression of SAP30L in zebrafish 
Sin3A corepressor complex is an important regulator of gene expression (Silverstein 
and Ekwall, 2005). SAP30L is part of the Sin3A co-repressor complex but its 
function in vivo has remained unknown (Viiri et al., 2006; Korkeamäki et al., 2008). 
For that matter, we studied SAP30L mRNA expression in zebrafish with RT-qPCR 
from whole embryos and used WISH to determine the localization of SAP30L 
expression. During the early developmental stages of zebrafish, expression of 
SAP30L was observed in tissues of embryos and larvae at several time points (see 
Fig. 1A-B in study IV). During the embryogenesis, the SAP30L mRNA was widely 
expressed and after 24 hpf the expression was strongest in the brain (see Fig. 1A in 
study IV). At 36 hpf, expression was visible in pectoral fin buds and, at 72 hpf, a 
strong expression was detectable in pectoral fins (black arrows in Fig. 1A in 
study IV). The heart area stained positively in pericardial cavity at 24 hpf and later 
also the heart tissue itself. After 36 hpf, the staining of SAP30L mRNA could be 
seen in the common cardinal vein (marked with white arrows in Fig. 1A in study IV). 
In addition, moderate mRNA expression is seen in the trunk, including ICM, and 
weak staining in blood islands of some embryos. Adult zebrafish shows strong 
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expression of SAP30L in the brain and moderate levels in muscle, eye, gonad and 
heart (see Fig. 1C in study IV). 
5.4.2 SAP30L knockdown affects heart morphology and hematopoiesis 
After studying the SAP30L expression and localization during the embryogenesis, 
we investigated the role of SAP30L during the early development of zebrafish. 
Effects of the SAP30L depletion was studied using morpholino oligonucleotides 
(MO) -based silencing. MOs block the translation of mRNA and can be used to 
silence the expression of gene of interest. Schematic illustration of the microinjection 
is shown in Figure 12. SAP30L knockdown experiments were carried out with two 
independent MOs (SAP30L-MO1 and SAP30L-MO2) targeting the translation 
initiation site and their efficacy was demonstrated in vivo with reducing SAP30L 
protein levels in MO-treated zebrafish embryos (see Fig. 2 in study IV). Embryos 
were injected with the morpholinos at the 1- to 4-cell stage and the phenotypic 
development was observed up to 5 to 6 dpf. During the observation period, the 
morphants displayed prominent and progressive pericardial edema and almost 90 % 
of them had deformed cardiac morphology (see Fig. 3A in study IV). Heart 
malformation was visible in a single plain as a string-like heart instead of a healthy 
three-dimensional complex heart (see Fig. 3B in study IV). Compared to the control 
larvae, the morphants already demonstrated at 3 dpf an impaired cardiac function 
with marked reduction in heart rates and decreased performance of the atrium and 
the ventricle (see Fig. 3C-D in study IV). Both morpholinos gave similar results for 
the phenotypes of injected zebrafish (morphants). Gene expression analysis by 
microarray of the SAP30L morphants revealed downregulation of nkx2.5 gene at 
12 hpf (see Fig. 4 in study IV). Nkx2.5 is known to regulate cardiac development 
(Chen and Fishman, 1996; Targoff et al., 2008). Nkx2.5 down-regulation was 
confirmed with RT-qPCR (see Fig. 5A in study IV). In a rescue experiment, SAP30L-
MO1 was co-injected with nkx2.5 mRNA which led to partial rescue of the 
deformed cardiac morphology (see Fig. 5B in study IV). 
 77 
 
Figure 12.  Schematic illustration of zebrafish embryos microinjection. Freshly fertilized embryos were 
injected with morpholino solution directly in to the embryos yolk sack during the 1-4 cell 
stage. After the injection the embryos were transferred to a petri dish for the development 
of the embryo to larvae. PTU=1-phenyl 2-thiourea, dpf=days post fertilization. 
When observing the SAP30L morphant fish, we noticed that red blood cells 
appeared paler compared to control larvaes. We determined the hemoglobin levels 
of the morphant and control fish by o-dianisidine staining. Staining was performed 
in 3 dpf larvae and the intensity of staining was analyzed by visual observation. 
SAP30L morphants demonstrated markedly reduced staining indicating that 
hemoglobin levels were decreased in the red blood cells (see Fig. 3E in study IV). In 
microarray analysis of gene expression, downregulation of genes involved in 
erythropoiesis and hemoglobin synthesis were observed. For example, 
downregulation of ppox and alas2 genes was observed at 24 hpf (Dailey and Dailey, 
1996; Brownlie et al., 1998) (see Fig. 4 in study IV and Supplementary Figure S5 
from Teittinen et al. 2012). These results were further confirmed with RT-qPCR 
where morphants showed diminished expression of ppox (see Fig. 5C in study IV). 
These results suggest a role for SAP30L in TGF-β signaling and point to a notable 
role in multiple transcription factor regulation (see Fig. 4 in study IV and 
Supplementary Figure S5 from Teittinen et al. 2012). 
 78 
6 DISCUSSION 
6.1 PTP4A family of phosphatases in acute lymphoblastic 
leukemia 
The first aim of this thesis was to study the expression and functional role of 
PTP4A3 in ALL (study I). Normally, expression of PTP4A3 is restricted to non-
hematological tissues such as the brain, skeletal muscle, heart and vasculature (Matter 
et al., 2001). This expression pattern suggests that PTP4A3 overexpression in 
hematological malignancies is driven by cancer-associated factors. Earlier findings 
by Zhou and colleagues (2012) supported this hypothesis when they demonstrated 
PTP4A3 as a novel downstream target of BCR-ABL1 signaling pathway. From other 
protein family members, high PTP4A1 and PTP4A2 expressions have been linked 
to AML, and PTP4A2 expression to AML cell proliferation (Arora et al., 2012; 
Kobayashi et al., 2017). Strongest expression of PTP4A3 mRNA in our microarray 
data set was seen in BCR-ABL1 and ETV6-RUNX1 subtypes of BCP-ALL whereas 
PTP4A1 and PTP4A2 expression levels were not detectable. In T-ALL, we saw some 
patients with high expression of PTP4A2 and PTP4A3. Kobayashi et al. (2014) 
reported similar results of PTP4A2 and PTP4A3 upregulation in T-ALL. 
We focused on the ETV6-RUNX1 fusion and its role in the regulation of 
PTP4A3 expression since the ETV6-RUNX1 subtype is the second most common 
subtype of childhood acute leukemia whereas BCR-ABL1 represents approximately 
3 % of childhood ALL (Lilljebjörn et al., 2016). We showed that ETV6-RUNX1 
fusion regulates expression of PTP4A3. By looking at the binding sites for ETV6-
RUNX1 at the vicinity of PTP4A3 gene, a number of potential chromatin binding 
sites were identified from the RUNX1 ChIP-seq data from SEM leukemia cells. This 
suggested for the possibility of direct DNA binding of ETV6-RUNX1 fusion 
protein. However, we failed to confirm the binding of ETV6-RUNX1 fusion into 
any of the tested sites (see Fig. 3A-B in study I) thus hinting that there is no direct 
regulation by ETV6-RUNX1. However, this might also be a consequence of several 
other factors. First, we used the NALM-6 cells, while the ChIP-seq data was 
generated in the SEM cells. Secondly, we only tested a few putative binding sites 
based on the known RUNX1 binding motifs, and this could lead to missing potential 
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binding sites. Thirdly, we only focused on the binding sites upstream of the 
transcription start site of PTP4A3 even though the regulatory elements can reside 
even far away in either direction from the transcription starting site. An unbiased 
ChIP-seq experiment in the NALM-6 cells would solve this issue and will be needed 
if the function of PTP4A3 in ALL is pursued further in the future. 
PTP4A family members are dual-specificity phosphatases meaning that they can 
inactivate targets by dephosphorylating both tyrosine and serine/threonine residues. 
PTP4A family members regulate several important signaling pathways such as Src 
and PTEN (Campbell and Zhang, 2014). We studied the role of PTP4A3 in leukemia 
pathogenesis by using two inhibitory approaches: knockdown of PTP4A3 through 
siRNA oligos and with an in vitro treatment of cell by a specific inhibitor of PTP4A3 
enzyme activity (PRL-3 inhibitor I).  Experiments were performed in BCP-ALL cell 
lines since primary samples from children with ALL were scanty causing inability to 
perform multiple biological replicates with and without other leukemia drugs and in 
a time-series manner. Transient knockdown of PTP4A3 did not have any effect on 
the cell viability and, similarly, the inhibitor had only modest effect on cell viability 
with high concentrations (μM). Similar trend with decreasing cell viability was noted 
in different cell lines. We also studied the effect of PRL3 inhibitor I together with 
conventional ALL induction drugs (prednisone, doxorubicin and vincristine), but no 
additive effect was evident in these experiments. These results imply that PTP4A3 
does not play a major role in the pathogenesis of ETV6-RUNX1 or BCR-ABL1 
subtypes of ALL. One could also argue that the inhibitor used in this study was less 
than optimal for targeting of PTP4A3, or that high expression of PTP4A3 and its 
enzymatic activity are not correlated. In the case of knockdown and cell viability 
experiments, it is possible that the PTP4A3 knockdown was not efficient enough at 
protein level or the half-life of the siRNA was too short to make an impact on the 
cell viability. It is also noteworthy that cell viability assay is quite robust technique 
and could masquerade most subtle effects. 
In summary, we demonstrated that PTP4A3 is highly expressed in selected 
subtypes of pediatric ALL and regulated by the ETV6-RUNX1 fusion protein. 
However, we failed to elucidate the exact functional role of PTP4A3 in BCP-ALL. 
One caveat in our experiments is that the expression data was solely based on the 
level of mRNA expression.  In future, the role of PTP4A3 should be studied at 
protein level, which takes into account also the enzymatic activity and not just the 
expression state. It has also been shown that the mRNA expression does not always 
correlate with the protein levels (Latonen et al., 2018). What effect does the change 
in enzymatic activity have on the leukemia cell proliferation and viability? 
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Intracellular cell signaling is a tightly regulated and dynamic system, which is often 
derailed in malignancies (Tesio et al., 2016). PTP4A3 is known to have an important 
role in multiple cellular functions that are related to cancer, like cell migration, 
adhesion and invasion. Interestingly, Hjort et al. (2017) demonstrated very recently 
that PTP4A3 inhibition/knockdown reduced cell migration towards an SDF-1α 
gradient in two BCP-ALL cell lines, and also cell adhesion towards fibronectin was 
reduced in REH cells. Hjort et al. (2017) inferred that PTP4A3 could represent a 
novel target in the treatment of BCP-ALL due to its promotion of cell resistance to 
cytarabine, an antimetabolite prodrug. 
6.2 High expression of SOX11 in acute lymphoblastic leukemia 
The second aim of this thesis was to study expression and function of SOX11 
transcription factor in ALL and its use as a prognostic marker in childhood ALL 
(study II). First, we looked at the microarray expression data for the SOX11 
expression across all hematological malignancies. The highest expression of SOX11 
was detected in MCL patient which corroborated previous studies (Ek et al., 2008; 
Zeng et al., 2012; Mozos et al., 2009). Patients with BCP-ALL also showed tendency 
towards the elevated expression of SOX11, and when we looked more closely at the 
subtypes, we noticed higher SOX11 expression in ETV6-RUNX1 and TCF3-PBX1 
subtypes. In our patient cohort, SOX11 expression had statistically significant 
(p<0.001) association with ETV6-RUNX1 subtype. There was no statistical 
association with SOX11 expression and TCF3-PBX1 subtype, but this was most 
likely due the low number of TCF3-PBX1 cases, with three SOX11 positive out of 
four cases. These findings fall in line with previous studies. Dictor et al. (2009) found 
nuclear expression of SOX11 in majority (8 out of 9) of B cell ALLs/lymphomas 
but they did not specify the protein expression levels (no subtype-specific data were 
reported either). Mozos and colleagues (2009) identified strong nuclear SOX11 
expression in five T cell lymphoblastic leukemias/lymphomas and one B cell 
lymphoblastic leukemia /lymphoma cases, and Vegliante et al. (2011) associated high 
SOX11 mRNA expression to ETV6-RUNX1 and TCF3-rearranged cases in a small 
cohort study. Our results of SOX11 expression are thus not fully original but the 
breadth of the data is by far the most extensive. 
We next investigated the impact of high SOX11 expression as prognostic markers 
in pediatric BCP-ALL. Bone marrow biopsies from primary diagnostic samples of 
ALL were evaluated for SOX11 protein expression by IHC and a correlation to 
 81 
patient survival was evaluated. Interestingly, SOX11 positive patients had statistically 
significantly better OS as compared to SOX11 negative patients in Kaplan-Meier 
analysis (see Fig. 2A in study II). EFS and RFS also had similar trends on survival 
time but without statistical significance. As our patient cohort with 119 patients from 
which 40 were SOX11 positive was still relatively small, we sought to validate the 
findings in external data set. Importantly, the other data set where SOX11 expression 
was based on transcriptomic expression profiles showed similar survival trends 
(Marincevic-Zuniga et al., 2017). Studies in MCL have shown that mRNA or nuclear 
protein expression of SOX11 can be used as a diagnostic marker in classical MCL 
morphology (Ek et al., 2008; Zeng et al., 2012; Mozos et al., 2009).  Wang et al. 
(2008) associated nuclear positivity of SOX11 in MCL with better OS but this 
finding was contradicted by Fernandez et al. (2010). In our study, SOX11 positivity 
retained its prognostic significance in multivariate analysis, including subtype 
information, which suggests that (high) SOX11 expression might be a useful 
biomarker even in low-risk cases of BCP-ALL. It should be mentioned that our 
BCP-ALL case series spans over two decades and the patients were treated with 
three successive NOPHO ALL chemotherapy protocols (Toft et al., 2018; 
Schmiegelow et al., 2010). As the most recent NOPHO protocol has reported the 
best survival results (Toft et al., 2018), it is necessary to investigate the prognostic 
value of SOX11 also in the most recent protocols in future. 
As bone marrow biopsies are no longer taken routinely in all treatment centres 
and IHC staining is time consuming, we tested flow cytometry based screening for 
SOX11 positivity with cell lines. As we were able to distinguish cell lines with flow 
cytometry based on SOX11 expression, it would be worthy use primary ALL samples 
to look further if SOX11 could be used as clinical biomarker and possibly include it 
in flow cytometry panels in future. 
SOX11 is a known developmental and neural transcription factor but its 
functional mechanisms have remained partly unknown. For leukemia studies, it 
would be beneficial to collect ChIP-seq data from leukemia cell lines and primary 
patient samples to identify SOX11 targets in genome. This could give an insight for 
the matter why SOX11 positive ALLs seem to have a better prognosis. From the 
other point of view, it would be interesting to solve what causes the altered SOX11 
expression in some leukemias and other hematological malignancies whereas adult 
stem cells and normal hematopoietic cells do not express SOX11. We showed that 
SOX11 expression might be regulated by DNA hypomethylation of SOX11 locus in 
a similar manner as Vegliante et al. (2011) reported in MCL and five ETV6-RUNX1 
positive BCP-ALL cases. Vegliante et al. (2011) characterized the epigenetic 
 82 
mechanism leading to the SOX11 deregulation but they did not demonstrate which 
upstream transcription factors and histone modifying enzymes are behind this 
alteration. 
In knockdown experiments, SOX11 silencing had no marked effect on cell 
viability in any of the studied cell lines implicating that SOX11 does not play a central 
role in the BCP-ALL cell viability. In addition to cell viability, we also looked for the 
transcriptional profiling of SOX11 knockdown cells, to look for the target genes and 
alterations in pathways. Two noteworthy points for interpreting our SOX11 
knockdown studies are as follows: (i) changes in gene expression profiling were 
mostly from mild to moderate, (ii) other SoxC family members, SOX4 and SOX12, 
might mitigate the effects of SOX11 knockdown. 
Previous studies with MCL cell models have given contradictory results regarding 
to cell proliferation.  Constitutive SOX11 knockdown by Conrotto et al. (2011) and 
Kuci et al. (2016) led to an increased cell growth rate in MCL cell model. These 
studies are in concordance with transient siRNA-mediated knockdown studies of 
SOX11 by Gustavsson et al. (2010) and Kuci et al. (2016). In contrary, Wang et al. 
(2010) reported that transient siRNA-mediated knockdown of SOX11 did not have 
any significant effect on MCL cell line proliferation. SOX11 overexpression 
repressed cell proliferation in MCL (Kuo et al., 2015) and pro-B cells (Lord et al., 
2018). Balsas et al. (2017) found in their MCL xenograft transplantation studies that 
SOX11 positive cells had higher cell migration, invasion and proliferation over 
SOX11 knockdown cells. In future, animal models with cell or tissue specific 
knockdown and overexpression of SOX11 in BCP-ALL should be created to solve 
the issue. 
6.3 Dasatinib as a targeted therapy for T-ALL 
Approximately 15 % of childhood acute leukemias are of T cell origin. Although the 
prognosis of T-ALL has improved with the modern treatment protocols, it is still 
lagging behind the BCP-ALL, and is dismal at relapse. We therefore sought to 
identify novel targeted therapies for T-ALL (study III). Previously, it was reported 
that dasatinib had clinical utility on NUP214-ABL1 cases, which only represent 4 to 
10 % of T-ALL patients (Quintás-Cardama et al., 2008; Burmeister et al., 2006). We 
and others (Frismantas et al. 2017) showed that approximately 30-40 % of T-ALL 
cases are sensitive to dasatinib, suggesting that other targets beyond ABL1 exist. 
Recently, Serafin et al. (2017) published an article where they had functionally 
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validated LCK as a therapeutic target to reverse glucocorticoid resistance in T-ALL. 
Co-treatments with dasatinib and dexamethasone and LCK knockdown with 
dexamethasone treatment reduced cell viability and increased cell death (Serafin et 
al., 2017). Our results are thus corroborated by several other recent publications. 
We identified nine possible dasatinib targets based on the in silico screening of 
DSigDB, and expanded this list with 12 more targets based on the literature. The 
expression of these target genes was measured in T-ALL cell lines and thereby we 
were able to narrow down to five genes that were further tested one-by-one in a 
siRNA-mediated knockdown. Selected target genes were LCK, FYN, ABL1, 
MAP2K5 and MAP4K5, and from these candidates, LCK knockdown caused the 
most significant decrease in cell viability (see Fig. 1E and Suppl. Fig. S4A-E in study 
III). Second highest expression was seen in FYN, and the knockdown of FYN had 
slight reduction in cell viability. Importantly, Jurkat cell line with genetic mutation of 
LCK kinase did not respond to dasatinib, indicating the central role played by this 
kinase. 
We confirmed the findings of Frismantas et al. (2017) and were the first to imply 
LCK as the major target of dasatinib in T-ALL. Frismantas et al. (2017), in turn, 
associated dasatinib sensitivity to SRC kinase expression and the phosphorylation 
status by using a SRC inhibitor KX2-391. However, based on the DsigDB, both SRC 
and LCK are targets of KX2-391. We did not find any marked difference in SRC 
expression levels between normal T cell and T-ALL samples, and the overall 
expression level of SRC mRNA was low compared to LCK. Based on these results, 
we are more confident that LCK, and not SRC, plays a central role in response to 
dasatinib treatment. We also noted that dasatinib sensitivity was higher on T-ALL 
cell lines with higher LCK expression. However, our studies do not fully exclude 
other possible targets for dasatinib, which are part of the receptor signaling pathways 
related to cell proliferation and survival. For examples LCK and FYN are both part 
of the TCR signaling cascade and also have partially overlapping functions (Salmond 
et al., 2009). 
Our results also revealed that patients belonging to the TAL1 subgroup of T-
ALL are more likely to respond to dasatinib even though their response was not 
exclusive. We saw a statistically significant correlation between LCK expression and 
TAL1 subgroup even though TAL1 itself did not seem to directly regulate expression 
of LCK (data were reproduced from Sanda et al., 2012). Dasatinib is known to 
suppress healthy T cells, (Blake et al., 2008; Lee et al., 2010; Schade et al., 2008) but 
in our study, the patient samples had significantly higher LCK expression as 
compared to normal T cells and higher sensitivity to dasatinib was seen in T-ALL 
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cells when compared to bone marrow cells. It is noteworthy that our patient cohort 
was small and further studies are needed. Dasatinib is currently approved for Ph+ 
CML treatment in imatinib resistant cases and in the second-line treatment of Ph+ 
ALL. This finding by us and others suggest that dasatinib could be applied to a subset 
of T-ALL, although the exact predictive biomarker is still not known. There is a 
urgent need to explore the biomarker findings and deepen the knowledge of the 
mechanistic functions of dasatinib. 
6.4 SAP30L participates in development of zebrafish cardiac 
system and erythropoiesis 
SAP30 and SAP30L are part of the Sin3A-corepressor complex and they participate 
in regulation of gene expression through this complex (Laherty et al., 1998; Zhang 
et al., 1998; Viiri et al., 2006; 2009b). In zebrafish, only one member of the SAP30 
protein family, SAP30L, has been identified (Viiri et al., 2009a). Therefore, the 
function of SAP30 protein family in hematopoiesis can be studied by modulating the 
expression of a single gene in zebrafish (study IV). The fact that zebrafish genome 
has only one copy of SAP30/SAP30L was an advantage as it enabled us to study 
the functional role of the SAP30L without potentially overlapping functions. We 
showed that SAP30L mRNA is widely expressed during early development of 
zebrafish with strongest expression in the brain, but was also visible in the cardinal 
vein, the heart area and in the blood islands of some of the embryos. 
We also carried out a series of knock down experiments with two different MOs 
(MO1 and MO2). These MOs targeted the translation initiation site and blocked the 
translation of the SAP30L mRNA leading to a significantly reduced SAP30L protein 
expression. One advantage of using zebrafish as a disease model is its transparency 
so that the embryonal development can be easily followed by microscope and naked 
eye. The most marked effect in the morphants (MO1 or MO2 injected embryos and 
larvae) was the prominent pericardial edema and cardiac deformation and reduced 
cardiac function. Both morpholinos caused similar defects but MO2-morphants had 
a slightly delayed onset accompanied with SAP30L protein levels that were less 
decreased. This could be explained by the differences between the morpholinos. 
MO1 targets the downstream sequence of the start codon and MO2 the upstream 
region of the SAP30L start codon and therefore it seems that the upstream targeting 
is not as effective. Interestingly, Starkovich et al. (2016) recently suggested that 
SAP30L may contribute to the congenital heart defect in humans based on the 
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chromosome 5q33 deletions where SAP30L is located, even though they could not 
exclude other genes deleted from the same chromosome. In another study, a long 
non-coding RNA, ENSMUST00000117266 was involved in regulation of 
cardiomyocyte proliferative activity and the authors suggested that this long non-
coding RNA was likely to function via SAP30L, which is its neighboring coding gene 
(Sun et al. 2017). 
The specificity of the observed phenotype can be further confirmed by 
performing mRNA rescue experiments where mRNA of gene of interest is co-
injected with the morpholino (Eisen and Smith, 2008). The microarray of the 
SAP30L morphants revealed down-regulation of nkx2.5 gene, which is known to 
regulate a cardiac development and therefore we used it in an mRNA rescue 
experiment (Chen and Fishman, 1996; Targoff et al., 2008). Co-injection of nkx2.5 
mRNA with SAP30L-MO1 rescued partially the cardiac phenotype, which suggests 
that SAP30L plays a role in the regulation of nkx2.5 expression. Previous studies in 
other model organisms have also stated that nxk2.5 might have a role in multiple 
processes of cardiac development (Targoff et al., 2008). Because SAP30L is part of 
a repressor complex and only binds DNA nonspecifically it is likely that the effect 
on nkx2.5 expression is indirect. Failure of the complete rescue may be due to 
multiple different reasons like short half-life of the injected mRNA or its inability to 
reach the right tissue. The morpholino injection only gives a transient knockdown 
during early development and these results would be interesting to verify and extend 
in a stable knockdown/knockout model. Today, this is often feasible using CRISPR-
Cas9-based mutagenesis especially for those genes that are highly expressed during 
early developments (Uusi-Mäkelä et al., 2018). 
Other interesting effect of the MO mediated knockdown was seen in the red 
blood cells as some of the morphants demonstrated paler red blood cells compared 
to the control embryos. Based on this observation we performed o-dianisidine 
staining for the embryo at 3 dpf to assess the hemoglobin levels of the morphants. 
Both morphant types demonstrated weaker staining intensities, which indicates 
reduced hemoglobin levels compared to the controls. MO1-morphants had more 
severely affected stainings over MO2-morphants. The reduced hemoglobin staining 
is in concordance with the WISH results showing SAP30L expression in the cardinal 
vein and in ICM, which is the primary site for erythroid lineage development 
(Davidson and Zon, 2004). Our mRNA rescue experiment with SAP30L-MO2 and 
SAP30L mRNA co-injection had no restoring effect on the reduced hemoglobin 
staining which might be because of the short mRNA half-life or other reasons 
discussed in the previous paragraph. Based on our microarray data, SAP30L 
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morphants demonstrated a downregulation of ALAS2 and PPOX genes which both 
take part in heme biosynthesis. ALAS2 gene is required for the first step in heme 
biosynthesis and deficiency leads to an iron accumulation and maturation arrest in 
primitive erythropoiesis but does not interfere definitive erythropoiesis (Harigae et 
al., 2003). Mutations in ALAS2 can cause X-linked sideroblastic anemia and X-
linked dominant protoporphyria in humans (Brownlie et al., 1998; Whatley et al., 
2008). PPOX is a protoporphyrinogen oxidase and it catalyzes the second-to-last 
step of the heme biosynthesis and mutations in PPOX can cause variegate porphyria 
(Sassa and Kappas, 2000; Dooley et al., 2008). 
Our results showed that SAP30L knockdown reduced the level of hemoglobin 
in the red blood cells in zebrafish and altered the expression of genes involved in the 
heme biosynthesis. One plausible explanation might be that SAP30L silences 
inhibitors in heme biosynthesis, but we cannot exclude the possibility that the 
hemoglobin deficiency is caused by another mechanism causing impaired 
erythropoiesis. An interesting experiment would be an mRNA rescue with either 
ALAS2 or PPOX mRNA to see if either of these could restore the hemoglobin 
staining levels from SAP30L morphants. Dooley et al. (2008) were able to partially 
restore the anemia with human PPOX mRNA in montalcino mutants, which are PPOX 
deficient as well as hemoglobin deficient and anemic. Notable point from our 
microarray data from erythropoietic view is that it was collected during the primitive 
erythropoiesis at the point when erythrocytes start circulating (24 hpf) whereas 
definitive hematopoiesis starts around 26 hpf (Gore et al., 2018). None of the 
embryonic specific hemoglobin genes (hbae1.1, hbae3, hbae5, hbbe1.1, hbbe1.2, hbbe1.3, 
hbbe2, hbbe3) showed changes in our microarray data (Gore et al., 2018). It would also 
be interesting to look a similar data from later developmental stage (3-6 dpf) to see 
possible differences between primitive and definitive erythrocytes. 
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7 CONCLUSIONS 
This study was carried out in order to shed light on the function of a variety of 
differentially expressed genes, ranging from transcription factors to kinases and 
phosphatases, in acute lymphoblastic leukemia and hematopoiesis. The major 
conclusions are as follows. 
 
1) PTP4A3 has a subtype specific overexpression in BCP-ALL and the 
PTP4A3 expression is elevated alongside with the ETV6-RUNX1 
overexpression. The effect of transient knockdown of PTP4A3 on cell 
proliferation was not different between the ETV6-RUNX1 positive and 
negative cell lines. However, inhibition of PTP4A3 enzymatic activity 
showed modest reduction on proliferation in an ETV6-RUNX1 specific 
manner. 
2) We confirmed high expression of SOX11 in the ETV6-RUNX1 and TCF3-
PBX1 subtypes of BCP-ALL. High expression of SOX11 was associated 
with DNA hypomethlyation in SOX11 loci and favourable prognosis in 
pediatric BCP-ALL. 
3) We identified that dasatinib is a potential novel targeted therapy for T-ALL, 
and that LCK kinase is the prime target. 
4) SAP30L plays a significant role in cardiogenesis and hematopoiesis 
(erythropoiesis) of zebrafish embryos. 
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APPENDICES 
Appendix 1. Supplementary information 4 from study II.  
 
 
Supplementary information 4. A. Enrichment of hallmark gene sets retrieved from molecular 
signature database in REH, RCH-ACV and 697 cell lines. Adjusted p-value of enrichment 
for all gene sets < 0.01. B. Enrichment of founder gene sets of "MYC targets V2" gene set 
in REH, RCH-ACV and 697 cell lines. Adjusted p-value of enrichment for all gene sets < 
0.02. 
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a  b  s t r a c  t
Cell  signalling, which is  often  derailed in  cancer, is  a network  of  multiple interconnected pathways  with
numerous  feedback  mechanisms.  Dynamics  of cell  signalling is intimately  regulated  by addition  and
removal  of  phosphate groups  by kinases  and phosphatases. We  examined expression  of members  of the
PTP4A  family of  phosphatases across acute  leukemias. While  expression of  PTP4A1 and  PTP4A2 remained
relatively  unchanged across  diseases, PTP4A3 showed marked  overexpression  in ETV6-RUNX1  and BCR-
ABL1  subtypes  of  precursor  B cell acute  lymphoblastic leukemia. We  show  that PTP4A3  is  regulated by
the  ETV6-RUNX1  fusion,  but  noticed no  marked impact  on cell  viability either after PTP4A3 silencing or
treatment  with  a PTP4A3 inhibitor. Regulation  of  PTP4A3 expression  is altered  in speciﬁc subgroups  of
acute  leukemias  and  this is  likely brought  about by  expression of the aberrant  fusion  genes.
© 2016  Elsevier  Ltd. All rights reserved.
1. Introduction
Acute leukemia is the most common cancer in childhood. ETV6-
RUNX1 (E/R) fusion gene is  present in around 25% of cases of
childhood precursor B cell acute lymphoblastic leukemia (pre-
B-ALL) [1]. E/R fusion is  generated by translocation between
chromosomes 12 and 21 (t[12,21][p13;q22]) and creates an
aberrant fusion transcription factor which induces repression of
regulatory sequences and gene transcripts genome-wide [2]. Pres-
ence of E/R fusion is associated with good prognosis so  that the
overall survival exceeds 90% [3].
Adept regulation of  cellular signalling is essential in control-
ling cellular proliferation. Kinases and phosphatases maintain a
precise balance of intracellular signalling activity, and this bal-
ance is often deregulated in malignancies. The protein tyrosine
phosphatase 4A (PTP4A) (also  known as phosphatases of  regen-
Abbreviations: E/R, ETV6-RUNX1; pre-B-ALL, precursor B cell acute lymphoblas-
tic  leukemia; PTP4A, the protein tyrosine phosphatase 4A;  PRL, the phosphatases of
regenerating  liver; AML,  acute myeloid leukemia; CML, chronic myeloid leukemia;
shRNA,  short hairpin RNA;  GRO-seq, global nuclear run-on sequencing.
∗ Corresponding author at: University of Tampere, Tampere Center for Child
Health  Research, P.O. Box 100, 33014 University of Tampere, Tampere, Finland.
E-mail  address: toni.gronroos@staff.uta.ﬁ (T. Grönroos).
erating liver, PRL) are small, approximately 20 kDa proteins with
dual speciﬁcity phosphatase activity [4]. The family consists of
three members (PTP4A1-3) that share a high degree of sequence
identity and harbour a phosphatase domain. Further, they contain
a C-terminal consensus prenylation motif CaaX, which is impor-
tant for  localization to the plasma membrane and  early endosomal
compartments [4–7]. Phosphatases of PTP4A family participate in a
wide range of  cellular activities, including cell proliferation, migra-
tion and invasion [4].
In  colorectal, breast, and gastric cancers, PTP4A3 overexpression
is correlated with poor prognosis and progression to metastasis [4].
In a murine model of  colon carcinogenesis, PTP4A3 knockout mice
exhibited signiﬁcantly fewer tumors than wild-type mice [8]. High
expression of  PTP4A3 is associated with poor prognosis in  acute
myeloid leukemia (AML) with normal karyotype [9–11].  It is  upreg-
ulated in human chronic myeloid leukemia (CML) cell lines, primary
CML  patient samples and Ph  + ALL patients [12,13]. PTP4A3 is a
downstream target of BCR-ABL1 fusion although the mechanism
of action is  unknown [13]. In  multiple myeloma, PTP4A3 is  overex-
pressed and its knockdown inhibits cell migration [14]. Depending
on expression level, PTP4A3 may exhibit either positive or negative
effects on  cell cycle  regulation [11].
Members of the  PTP4A family of phosphatases have been asso-
ciated with several hematological malignancies. This  motivated us
http://dx.doi.org/10.1016/j.leukres.2016.12.005
0145-2126/© 2016 Elsevier Ltd. All  rights reserved.
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to investigate their expression across acute  leukemias, and specif-
ically the role of PTP4A3 in  ALL.
2. Materials and methods
2.1. Cell lines and cell culture
Previously created stable cell  line models with an inducible E/R
fusion in NALM-6 cells and E/R short hairpin RNA (shRNA) knock-
down in REH cells were used [2].  Cells were cultured in  RPMI (Gibco,
Thermo Fisher Scientiﬁc, Waltham, MA,  USA), 2 mM  L-glut, 100 U
penicillin, 100 g/ml streptomycin and  10% Tet System Approved
FBS (Clontech) (NALM-6-Tet-cells) or 10% FBS (Gibco) (REH, NALM-
6) at 37 ◦C in 5% CO2.  The expression of  E/R was induced with
500 ng/ml doxycycline (Clontech). The shRNA knockdown and  the
induced expression of E/R were conﬁrmed with RT-qPCR (Ssofast
EvaGreen, BioRad, Hercules, CA, USA) with fusion gene speciﬁc
primers (Supplemental Table 1).
2.2. Quantitative PCR
Total RNA extractions were performed using either GeneJET
RNA Puriﬁcation Kit (Thermo Fisher Scientiﬁc) and DNA-freeTM
DNase Treatment & Removal kit (BioRad), or using PureLinkTM RNA
Mini Kit with On-Column PureLink
®
DNase Treatment Protocol
(Ambion
®
by Life Technologies). 1 g of  RNA was used as a starting
material to perform cDNA synthesis with iScpript (BioRad). RT-
qPCR reactions were performed with SsoFast EvaGreen
®
Supermix
(BioRad) according to manufacturer’s instructions. BioRad CFX96TM
Real Time System (BioRad) was run with the following program:
initial denaturation at 96 ◦C  for 30 s,  39  cycles of  denaturation at
96 ◦C for 2 s, annealing at 60 ◦C  for 5 s, and plate read. RT-qPCR mea-
surements were repeated from three independent experiments
performed in triplicate, and the  relative 2−CT method was  used
for quantiﬁcation [15]. ChIP-qPCR was performed in  duplicate runs
from two independent biological replicates and the percent input
method was used to normalize the data (2% of  starting material as
input). All qPCR primer sequences are listed in Supplemental Table
1. The level of PTP4A3 mRNA expression between cell lines  was
evaluated with Mann-Whitney U  test.
2.3. Chromatin immunoprecipitation, GRO-seq assay, and
microarray data sets
Cells were crosslinked and  DNA-protein interactions were
immunoprecipitated using two pooled antibodies against
ETV6 (sc-166835, Santa Cruz Biotechnology Inc., Dallas, TX,
USA; RRID:AB 2101020 and HPA000264, Atlas Antibodies,
RRID:AB 611466) as described in Teppo et al. [2].  Nuclei were
extracted and the global nuclear run-on (GRO-seq) reaction was
performed as described in  Heinäniemi et al. [16]. To study  dif-
ferential gene expression, a previously combined and processed
database containing microarray samples was utilized [16]. Two
other data sets containing gene expression proﬁles in  patients
with pediatric ALL, GSE47051 [17],  and data from Pediatric Cancer
data portal (St. Jude Children‘s Research Hospital) [18], were
retrieved. Differential expression of PTP4A3 in distinct subgroups
was evaluated with Kruskal-Wallis H test and Mann-Whitney U
test.
2.4. Cell viability assays and inhibition of  PTP4A3
Fresh media was changed on the REH and NALM-6 cells,  and
cells were plated at 1 million/ml on 6 well plates. To induce E/R or
luciferase expression in NALM-6 cells, doxycycline (Clontech) was
added at 500 ng/ml. After incubating plated cells for 24 h,  10 000
cells  per well were plated in 96  wells with  the desired concentra-
tion of  PRL-3 inhibitor I  (Sigma, Lot # 047K4614V) concentrations.
The doxycycline treatment was continued in E/R induction sam-
ples during the entire experiment. Cells were allowed to grow up
to 96 h. 10 l Alamar Blue reagent (Life technologies) was  added
to each well at each time points. After 2 h,  ﬂuorescence was mea-
sured with  excitation of 560 nm and emission of  590 nm using the
Tecan ﬂuorometer Inﬁnite 200 (Tecan, Switzerland). Three tech-
nical replicates per sample were included in each  proliferation
experiment. Difference in cell viability between inhibitor cultured
cells and control cells was  evaluated with Student’s t-test.
3.  Results
3.1.  High expression of PTP4A3 in the t(12;21) and t(9;22)
subtypes of  ALL
We investigated expression of members of PTP4A family
of phosphatases across acute leukemias and healthy cells of
hematopoietic origin. To this end, a large collection of  previously
combined and processed microarray samples was utilized [16].
Subgroup consisting of leukemic and normal healthy samples was
selected and a “leukemia-map” was  generated by using t-SNE algo-
rithm to visualize the data in two  dimensions [19], and expression
of  the PTP4A  family members was  examined. As shown in Fig.  1A,
PTP4A1 was  expressed indifferently across diseases and healthy
cells, whereas PTP4A2 showed increased expression among some
T-ALL samples. In contrast, PTP4A3 showed markedly increased
expression among pre-B-ALL and  a few T-ALL cases (Fig.  1A). Strong
expression of PTP4A3 co-occurred mostly with the fusion positive
subtypes of  ALL, namely the E/R  and BCR-ABL1/t(9;22) cases.
The expression of  PTP4A3 in  the E/R subtype was  approximately
three to four-fold higher as compared to other pre-B-ALL leukemias
(Fig. 1B), and  this difference was statistically signiﬁcant (Mann-
Whitney U  test p = 1.894997e-52 when E/R  is  compared to other
subtypes, see Supplemental Table 2 for details). As further valida-
tion, we retrieved two more leukemia data  sets (GSE47051 [17]  and
PeCan [18]), and PTP4A3 showed similarly high expression among
E/R and BCR-ABL1 positive leukemias in both data sets (Fig. 1B). At
the same time, MLL-rearranged leukemias exhibited low level  of
PTP4A3 across all three data sets.
3.2.  PTP4A3 expression is regulated by E/R  fusion
We  next sought to determine if E/R fusion directly regulates
PTP4A3. To  this end, a  panel of  leukemia cell lines  was screened
by RT-qPCR for the expression of  PTP4A3 (Fig. 2A). REH cells, which
endogenously carry the  E/R fusion, exhibited strongest expression
while KOPN-8, 697 and healthy T-cells and B-cells showed mod-
erate expression. Another pre-B cell line  NALM-6 evidenced low
expression along with majority of the tested T-ALL lines. We gen-
erated two additional cell line models: a NALM-6 cell line with an
inducible E/R fusion (NALM-6-E/R) and a REH cell line  with knock-
down of endogenous E/R fusion (REH-shE/R) [2]. As shown in  Fig.  2B,
induction of E/R in NALM-6 cells increased PTP4A3 mRNA level.
Knockdown of  endogenous E/R fusion in REH cells did  not signiﬁ-
cantly decrease expression of PTP4A3 at the level of  mature mRNA
transcript (Fig. 2C). However, when the transcription was examined
at primary transcript level, as assayed by  GRO-seq, the decrease in
signal intensity was  more evident (Fig. 3A). When leukemia patient
samples were proﬁled using the  GRO-seq assay, PTP4A3 showed
robust expression in  E/R cases and also to varying degrees among
other subtypes (Fig. 3A).
Our data  suggested that PTP4A3 expression may  be  regulated
by the E/R  fusion itself, either directly or indirectly, and this moti-
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Fig. 1. PTP4A3 is overexpressed in  speciﬁc subtypes of precursor B-ALL.
A)  Expression levels of the members of PTP4A family in leukemias is  shown in a t-SNE-based two  dimensional map.  Expression level is  indicated with colours: blue (ND  = not
detected),  white (low expression), and red (high expression). Disease subtypes are indicated in the  right-most ﬁgure with colours. HeH  =  high hyperdiploid. B) Boxplots of
PTP4A3  expression in various leukemias, disease subtypes, and normal cells from three independent data sources: Combined microarray data  set [16],  GEO  series GSE47051
[17], and publicly available BCP-ALL data from Pediatric Cancer data portal [18]. For sample sizes see Supplemental Table 3.
Fig. 2. PTP4A3 expression is associated with expression of the  E/R fusion.
A)  Expression of PTP4A3 in ALL cell  lines and healthy B- and T-cells as  measured by  RT-qPCR. B) and C) E/R and  PTP4A3 expression in NALM-6  and REH cells with either
induced  overexpression (NALM-6-E/R) or knockdown (REH-shE/R) of E/R, respectively, as measured by RT-qPCR. Expression of inducible E/R fusion (NALM-6-E/R) increases
expression  of PTP4A3 as compared to control cells (NALM-6-LUC). *) Mann-Whitney test, p-val. 0.00042. Expression level is shown as relative to a housekeeping gene (GAPDH).
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Fig. 3. GRO-seq indicates expression of PTP4A3 transcript in patient samples.
A)  GRO-seq signal tracks at PTP4A3 locus. Two biological replicates of REH-shLUC and  REH-shE/R samples are shown with different shades of color. Two  E/R-positive patient
samples,  and one high hyperdiploid (HeH), T-ALL, and normal karyotype samples are shown. Signals above and below the axis indicate plus and minus strands, respectively.
RUNX1  ChIP peaks in SEM cells (GSE42075 [20])  are shown in light red overlaid with the  input control in purple. ChIP-seq track for H3K27ac in GM12878 B-cells indicates
active  sites and  is retrieved from the  ENCODE [25]. PCR regions tested in ChIP-qPCR are shown as strokes. B) No direct binding of  E/R was  detected by ChIP-qPCR at putative
regulatory  regions (1–5 as marked in A) upstream of PTP4A3 after induction of E/R expression in NALM-6  cells. Negative antibody control (IgG-ChIP) was  performed in
NALM-6-E/R  cells. The promoter region of ITGA4  was  used as a positive control and  GAPDH  as a negative control (see Supplemental Table 1 for primer sequences).
vated further analyses on regulatory regions. As  E/R fusion binds
its target sequences predominantly through RUNX1 sites [2],  we
retrieved RUNX1 ChIP-seq peaks in SEM (GSE42075 [20])  and HSC
cells (GSE45144 [21]) and aligned them jointly with the GRO-seq
data on cell lines and patient samples (Fig. 3A). Guided with this
information, we performed targeted ChIP-qPCR assays using ETV6
antibodies, but failed to detect direct binding of  E/R fusion into
these regions (Fig. 3B).
3.3. Knockdown and inhibition of PTP4A3 in leukemia cells
To investigate the role of  PTP4A3 in leukemia, we knocked
down its expression by transient transfection using three  dis-
tinct siRNA oligos (see Supplemental methods). Since  none of  the
tested antibodies against PTP4A3 performed reliably, we conﬁrmed
the knockdown by RT-qPCR, showing a  decrease in expression by
approximately 42% (SD 7.8%) in REH cells  and 63% (SD 4.0%) in
697 cells after 48 h  of transfection. In  two  biological replicates,
knockdown of PTP4A3 showed no effect on cell viability (data not
shown).
PTP4A3 is a dual phosphatase whose enzymatic activity can be
inhibited by  a rhodamine derivative with  an IC50 value of 0.9  M
[22]. We therefore examined the potency of this inhibitor to inhibit
proliferation in leukemia cells. In an assay  with 10-fold increases
in drug concentrations, cell viability was reduced after  concentra-
tions exceeding 10 uM (Fig. 4). At these concentrations, we noticed
a  statistically signiﬁcant difference between cells that  have high or
low expression of E/R  fusion, possibly implying increased resistance
among cells with high expression. We also  tested potential synergy
with conventional ALL  induction chemotherapy (prednisone, dox-
orubicin and vincristine) but did not ﬁnd  additive effect (data not
shown).
T. Grönroos et al.  /  Leukemia Research 54  (2017) 1–6  5
Fig. 4. Reduced cell viability at high  concentrations of PTP4A3 inhibitor.
E/R  positive cells are less sensitive to PTP4A3 inhibition as  compared to  control cells. Cell viability was  assessed by Alamar Blue and is shown relative to cells treated with
the  vehicle control. *) Student’s t-test, p-val. 0.00936.
4. Discussion
Intracellular cell signalling is tightly regulated network with
multiple interconnected pathways and elaborate feedback sys-
tems. Addition and removal of phosphate groups by kinases and
phosphatases, respectively, dynamically alters  signalling intensity
and direction, and are often derailed in malignancies with PTEN
being the prime example [23].  Here we focused on members of
the PTP4A family of phosphatases and examined their expression
across acute leukemias. While expression of PTP4A1 and PTP4A2
remained relatively unchanged across diseases, PTP4A3 showed
marked overexpression in  E/R and BCR-ABL1 subtypes of  precur-
sor B-ALL. We  provide evidence of regulation of  PTP4A3 by  the E/R
fusion. The functional consequences of  PTP4A3 overexpression in
ALL remain a  subject of further studies since no  marked impact on
cell viability was evident either after PTP4A3 silencing or treatment
with a PTP4A3 inhibitor.
The expression results presented here are based on publicly
available microarray data deposited in GEO. In  order to diminish
variation between various datasets, we  utilized data that were gen-
erated using a single array platform [16]. It has  been previously
reported that PTP4A3 is  either downregulated [11] or upregulated
in AML [10], and upregulated in CML  and Ph+ ALL [9,11–13]. We
found similarly high expression of PTP4A3 in high expression of
PTP4A3 in BCR-ABL1 fusion positive cases.
In healthy tissues, PTP4A3 expression is  primarily restricted to
the heart, skeletal muscle, vasculature, and brain  [24],  suggest-
ing that overexpression in  hematological malignancies is  driven
by cancer-associated factors. This was already suggested by Zhou
et al. [13] who identiﬁed PTP4A3 as  a downstream target of  BCR-
ABL1. We  provide evidence that E/R fusion, which is  a fusion of two
hematopoietic transcription factors, regulates expression of  PTP4A3
either directly or indirectly. A RUNX1 ChIP data  from SEM leukemia
cells suggested direct binding. Our inability to prove direct binding
of E/R fusion to these sites  in NALM-6 cells may  be due to  low sen-
sitivity of ChIP-qPCR assay. We  tested potential binding sites only
upstream of the transcription start site and since the location of  reg-
ulatory elements may  reside far away from the  host gene in  both
directions, we may  have lost  the real site(s).
The expression data presented here are at the level of  mRNA.
As proteomic approaches develop, PTP4A3 protein levels and
even enzymatic activity assays would be worth studying in
hematological malignancies. Dual-speciﬁcity phosphatases can
dephosphorylate both tyrosine and serine/threonine residues,
and thereby inactivate targets. Several important signalling path-
ways are regulated by PTP4A enzymes, including Src/ERK1/2 and
PTEN/PI3K/AKT [4]. We  reasoned that if  PTP4A3 played an  essen-
tial role  in leukemia pathogenesis, it would be evident in  the  cell
viability assay. However, transient knockdown had  no effect on cell
viability and a speciﬁc inhibitor of PTP4A3 displayed only modest
effect at  high concentrations. This may imply that  PTP4A3 does not
play a central role in precursor-B ALL. Alternatively, the efﬁcacy of
inhibitor could be  less than optimal as this  class of  enzymes is  hard
to effectively target [4]. Thirdly, it is  possible that high expression
is not accompanied by similarly increased enzymatic activity, or
PTP4A3 could have  function(s) independent of  its  enzymatic activ-
ity. Finally, since PTP4A3 has  been shown to be important in cell
adhesion, invasion, migration, and metastasis, functional studies
should be directed towards these processes in future.
Acknowledgements
The work was  supported by grants from the Academy of  Finland
(project no. 277816, OL; 276634, MH), The  Foundation for Pediatric
Research (OL), Jane and Aatos Erkko Foundation (OL), Competitive
State Research Financing of the Expert Responsibility area of  Tam-
pere University Hospital (Grant numbers 9S032, OL), The Finnish
Cultural Foundation (Interdisciplinary Science Workshops, MH),
and The Väre Foundation for Pediatric Cancer Research (TG).
Appendix A. Supplementary data
Supplementary data associated with this article can be  found,
in the online version, at http://dx.doi.org/10.1016/j.leukres.2016.
12.005.
References
[1]  H. Inaba, M. Greaves, C.G. Mullighan, Acute lymphoblastic leukaemia, Lancet
381  (2013) 1943–1955, http://dx.doi.org/10.1016/S0140-6736(12)62187-4.
[2]  S. Teppo, S. Laukkanen, T. Liuksiala, J. Nordlund, M. Oittinen, K. Teittinen, T.
Grönroos,  A.-C.  Syvänen, M. Nykter, K. Viiri,  M.  Heinäniemi, O. Lohi,
Genome-wide repression of eRNA and target gene loci by  the ETV6-RUNX1
fusion  in acute leukemia, Genome Res. 26 (11) (2016) 1468–1477.
[3]  D. Bhojwani, D. Pei, J.T. Sandlund, S. Jeha, R.C.  Ribeiro, J.E. Rubnitz, S.C.
Raimondi,  S. Shurtleff, M. Onciu, C. Cheng, E.  Coustan-Smith, W.P. Bowman,
S.C.  Howard, M.L. Metzger, H. Inaba, W. Leung, W.E. Evans, D. Campana, M.V.
Relling,  C.H. Pui, ETV6-RUNX1-positive childhood acute lymphoblastic
leukemia:  improved outcome with contemporary therapy, Leukemia 26
(2012)  265–270, http://dx.doi.org/10.1038/leu.2011.227.
[4]  A.M.  Campbell, Z.Y. ZhangY, Phosphatase of regenerating liver: a novel target
for  cancer therapy, Expert Opin. Ther. Targets 18 (2014) 555–569, http://dx.
doi.org/10.1517/14728222.2014.892926.
[5]  B.J. Stephens, H. Han,  V. Gokhale, D.D.  Von  Hoff, PRL: phosphatases as
potential  molecular targets in cancer, Mol.  Cancer Ther. 4  (2005) 1653–1661.
6 T.  Grönroos et al.  /  Leukemia Research 54 (2017) 1–6
[6]  D.C. Bessette, D. Qiu, C.J. Pallen,  PRL  PTPs: mediators and markers of cancer
progression,  Cancer Metastasis Rev. 27 (2008) 231–252, http://dx.doi.org/10.
1007/s10555-008-9121-3.
[7]  P. Rios, X. Li, M.  Köhn, Molecular mechanisms of the PRL  phosphatases, FEBS J.
280  (2013) 505–524, http://dx.doi.org/10.1111/j.1742-4658.2012.08565.x.
[8]  M.W.  Zimmerman, G.E. Homanics, J.S. Lazo, Targeted deletion of the
metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon
cancer,  PLoS One  8 (2013) e58300, http://dx.doi.org/10.1371/journal.pone.
0058300.
[9]  J. Zhou, C. Bi, W.J. Chng, L.L. Cheong, S.C. Liu,  S. Mahara, K.G. Tay, Q. Zeng, J. Li,
K.  Guo, C.P. Tan, H. Yu,  D.H.  Albert, C.S. Chen, PRL-3, a metastasis associated
tyrosine  phosphatase, is involved in FLT3-ITD signaling and  implicated in
anti-AML  therapy, PLoS One 6 (2011) e19798, http://dx.doi.org/10.1371/
journal.pone.0019798.
[10]  J.E. Park, H.F. Yuen, J.B. Zhou, A.Q.  Al-Aidaroos, K. Guo, P.J. Valk, S.D. Zhang,
W.J.  Chng, C.W. Hong, K. Mills, Q.  Zeng, Oncogenic roles of PRL-3 in FLT3-ITD
induced  acute myeloid leukaemia, EMBO Mol.  Med. 5  (2013) 1351–1366,
http://dx.doi.org/10.1002/emmm.201202183.
[11]  R. Beekman, M. Valkhof, S.J. Erkeland, E. Taskesen, V.  Rockova, J.K. Peeters, P.J.
Valk,  B. Löwenberg, I.Å. Touw, Retroviral integration mutagenesis in mice and
comparative  analysis in human AML identify reduced PTP4A3 expression as a
prognostic  indicator, PLoS One 6 (2011) e26537, http://dx.doi.org/10.1371/
journal.pone.0026537.
[12]  D. Juric, N.J. Lacayo, M.C. Ramsey, J. Racevskis, P.H. Wiernik, J.M. Rowe, A.H.
Goldstone,  P.J. O’Dwyer, E.  Paietta, B.I. Sikic, Differential gene expression
patterns  and interaction networks in BCR-ABL-positive and  -negative adult
acute  lymphoblastic leukemias, J. Clin. Oncol. 25 (2007) 1341–1349.
[13] J. Zhou, L.L. Cheong, S.C. Liu, P.S. Chong, S. Mahara, C. Bi, K.O.  Ong, Q. Zeng, W.J.
Chng,  The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel
mediator  of oncogenic function of BCR-ABL in human chronic myeloid
leukemia,  Mol. Cancer 11 (2012) 72, http://dx.doi.org/10.1186/1476-4598-
11-72.
[14] U.M.  Fagerli, R.U. Holt, T. Holien, T.K. Vaatsveen, F. Zhan, K.W.  Egeberg, B.
Barlogie,  A. Waage, H. Aarset, H.Y. Dai, J.D. Shaughnessy Jr., A. Sundan, M.
Børset,  Overexpression and involvement in migration by  the
metastasis-associated phosphatase PRL-3 in human myeloma cells, Blood 111
(2008)  806–815.
[15] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using
real-time  quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods 4
(2001)  402–408.
[16] M. Heinäniemi, T.  Vuorenmaa, S. Teppo, M.U.  Kaikkonen, M. Bouvy-Liivrand, J.
Mehtonen,  H. Niskanen, V.  Zachariadis, S. Laukkanen, T. Liuksiala, K. Teittinen,
O.  Lohi, Transcription-coupled genetic instability marks acute lymphoblastic
leukemia  structural variation hotspots, Elife 5  (2016), http://dx.doi.org/10.
7554/elife.13087.
[17]  J. Nordlund, C.L. Bäcklin, P.  Wahlberg, S. Busche, E.C. Berglund, M.L. Eloranta,
T.  Flaegstad, E. Forestier, B.M. Frost,  A. Harila-Saari, M. Heyman, O.G.  Jónsson,
R.  Larsson, J. Palle, L. Rönnblom, K.  Schmiegelow, D. Sinnett, S. Söderhäll, T.
Pastinen,  M.G.  Gustafsson, G. Lönnerholm, A.-C. Syvänen, Genome-wide
signatures  of differential DNA methylation in pediatric acute lymphoblastic
leukemia,  Genome Biol.  14 (2013) r105, http://dx.doi.org/10.1186/gb-2013-
14-9-r105.
[18]  https://pecan.stjude.org/home/ (Accessed 27 October 2015).
[19]  L. van der  Maaten, G. Hinton,  Visualizing data using t-SNE, J.  Mach. Learn. Res.
9  (2008) 2579–2605.
[20] A.C.  Wilkinson, E. Ballabio, H. Geng, P. North, M.  Tapia, J. Kerry, D. Biswas, R.G.
Roeder,  C.D. Allis, A. Melnick, M.F. de Bruijn, T.A.  Milne, RUNX1  is a key target
in  t(4;11) leukemias that contributes to gene activation through an AF4-MLL
complex  interaction, Cell Rep. 3  (2013) 116–127, http://dx.doi.org/10.1016/j.
celrep.2012.12.016.
[21]  D. Beck, J.A. Thoms, D.  Perera, J. Schütte, A. Unnikrishnan, K. Knezevic, S.J.
Kinston,  N.K.  Wilson, T.A. O’Brien, B. Göttgens, J.W. Wong, J.E. Pimanda,
Genome-wide analysis of transcriptional regulators in human  HSPCs reveals a
densely  interconnected network of  coding and noncoding genes, Blood 122
(2013)  e12–e22, http://dx.doi.org/10.1182/blood-2013-03-490425.
[22]  G. Min,  S.K. Lee, H.N. Kim,  Y.M.  Han,  R.H. Lee, D.G.  Jeong, D.C. Han, B.M. Kwon,
Rhodanine-based PRL-3 inhibitors blocked the migration and  invasion of
metastatic  cancer cells, Bioorg. Med.  Chem. Lett.  23 (2013) 3769–3774, http://
dx.doi.org/10.1016/j.bmcl.2013.04.092.
[23]  M. Tesio, A. Trinquand, E. Macintyre, V. Asnaﬁ, Oncogenic PTEN functions and
models  in T-cell malignancies, Oncogene 35 (30) (2016) 3887–3896, http://
dx.doi.org/10.1038/onc.2015.462.
[24]  W.F. Matter, T. Estridge, C. Zhang, R. Belagaje, L.  Stancato, J. Dixon, B. Johnson,
L.  Bloem, T. Pickard, M. Donaghue, S. Acton, R. Jeyaseelan, V.  Kadambi, C.J.
Vlahos,  Role of PRL-3 a human muscle-speciﬁc tyrosine phosphatase, in
angiotensin-II signaling, Biochem. Biophys. Res. Commun. 283  (2001)
1061–1068.
[25] ENCODE  Project Consortium, An integrated encyclopedia of DNA elements in
the  human genome, Nature 489  (2012) 57–74, http://dx.doi.org/10.1038/
nature11247.
PUBLICATION
II
High expression of SOX11 is associated with favourable prognosis in
childhood acute lymphoblastic leukemia
Grönroos T, Mäkinen A, Laukkanen S, Mehtonen J, Nikkilä A, Oksa L, Rounioja
S, Marincevic-Zuniga Y, Nordlund J, Pohjolainen V, Paavonen T, Heinäniemi M,
Lohi O.
Submitted manuscript

PUBLICATION
III
In silico and preclinical drug screening identifies dasatinib as a targeted
therapy for T-ALL
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J,
Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M,
Lohi O.
Blood Cancer Journal. 2017. 7(9):e604. doi: 10.1038/bcj.2017.87.
Publication reprinted with the permission of the copyright holders.

OPEN
LETTER TO THE EDITOR
In silico and preclinical drug screening identiﬁes dasatinib as a
targeted therapy for T-ALL
Blood Cancer Journal (2017) 7, e604; doi:10.1038/bcj.2017.87;
published online 8 September 2017
Systematic development of combination chemotherapies has
signiﬁcantly improved the prognosis of acute lymphoblastic
leukemia (ALL). Patients with T-cell ALL (T-ALL) still have less
favorable outcomes, and the prognosis of relapsed T-ALL is
dismal.1 In order to ﬁnd novel targeted therapies for T-ALL, we
retrieved the gene expression proﬁles of 4430 leukemia samples
from the Gene Expression Omnibus (GEO) and performed an in
silico drug target screening, where the expression proﬁles were
compared with known drug targets in the Drug signature
database (DsigDB).2,3 This compound library contains both FDA
(Food and Drug Administration) – approved and novel investiga-
tional drugs. Strong expression of Src family tyrosine kinase LCK
was detected in T-ALL samples, exceeding that of other leukemias
and normal T cells (Figure 1a), whereas a LCK-targeting drug,
dasatinib, decreased the kinase activity of LCK to 1% in
comparison with the control at a 100 nM concentration.4 Dasatinib
is known to have multiple intracellular targets, and we noticed
that some of them had a similarly elevated expression in T-ALL
patients (Figure 1b and Supplementary Figure S1). Therefore, our
combinatorial drug/target screening suggests dasatinib as a
candidate targeted therapy for T-ALL patients.
To experimentally evaluate the potency of dasatinib, we treated
T-ALL cell lines with increasing concentrations of dasatinib (1–
1000 nM). After 72 h, the most signiﬁcant response was seen in
Figure 1. The in silico and in vitro results indicate dasatinib as a potential drug for T-ALL with LCK as its prime target. (a) LCK expression in
different hematological sample groups: acute leukemia (n= 4430), pre-B-ALL (n= 1304), T-ALL (n= 385) and T lymphoids (n= 247). (b) The
ﬁltered list of targets of dasatinib from in silico screening. The list contains targets with a lower expression in normal cells (myeloid, B lymphoid
and T lymphoid) in comparison with their leukemic counterparts; a signiﬁcant expression difference between T-ALL and T-lymphoid samples
(adjusted Po0.001 and a41.25-fold change) and dasatinib is capable of inhibiting them with high efﬁciency. Percentage of control (POC) or
Kd values were used to estimate the efﬁcacy of dasatinib against its targets. The POC value indicates the percentage of remaining activity after
inhibitor treatment in comparison with the untreated control sample. In addition to 0.5 μM, POC values at 100 nM concentrations were also
available for LCK and ABL1, and they were 1 and 0, respectively. (c) Effect of dasatinib for cell viability in several T-ALL cell lines measured by
alamarBlue assay after 72 h of incubation in 10-fold dasatinib dilution series (1–1000 nM). Values are relative cell viabilites in comparison with
dimethyl sulfoxide (DMSO) control and results are median values from three independent experiments performed in triplicate, except for
CCRF-CEM and HPB-ALL that are from two independent experiments. (d) The expression of 21 potential dasatinib targets in Jurkat cells. Bars
indicate median values. (e) The effect of LCK knockdown for Jurkat cell proliferation measured in time series (0h, 24h, 48 and 72 h) with
alamarBlue assay. Proliferation trend lines are drawn through median values. At time point 72 h, the proliferation had decreased by 14% in
comparison with the mock-treated control (P= 0.0289, Mann–Whitney U-test). The data consist of seven individual experiments performed in
triplicate, and each time point is normalized to the 0 h time point. RT-qPCR and western blot results show the efﬁciency of LCK knockdown.
(f) The effect of dasatinib on cell viability in the LCK-deﬁcient Jurkat cell line in comparison with the normal Jurkat cell line measured by
alamarBlue assay after 72 h of incubation in a 10-fold dasatinib dilution series (1–1000 nM). The difference between the two cell lines was
statistically signiﬁcant already at a 10 nM concentration (P= 0.014, Mann–Whitney U-test). The values are relative cell viabilities in comparison
with the DMSO control, and the results are the median values from three independent experiments performed in triplicate. The error bars
indicate 95% conﬁdence intervals.
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Jurkat cells, with a 31% viability decrease at a 10 nM concentration
(n= 3, P= 0.0039; Figure 1c and Supplementary Figure S2). As
dasatinib inhibits several kinases that are key regulators of cellular
proliferation and viability, we chose a panel of likely candidates (9
targets based on the in silico screening and 12 other well-known
targets from the literature), and analyzed their expression in T-ALL
cell lines by quantitative reverse transcriptase-PCR (RT-qPCR) and
western blotting. LCK was the most prominently expressed gene
in T-ALL cell lines, whereas FYN, ABL1, MAP2K5, MAP4K5 and LYN
were expressed at lower levels (Figure 1d and Supplementary
Figure S3). Knockdown of LCK in a dasatinib-sensitive cell line
(Jurkat) signiﬁcantly decreased cell proliferation (14% decrease,
P= 0.0289, n= 7, Figure 1e), whereas knockdown of FYN, ABL1,
MAP2K5 and MAP4K5 had no signiﬁcant effect (Supplementary
Figures S4a–d). Importantly, Jurkat cells with reduced LCK activity
due to a deletion of exon 7 (cell line J.CaM1.6) lost dasatinib
sensitivity (Figure 1f). Moreover, LCK knockdown did not cause
statistically signiﬁcant decrease of proliferation in relatively
dasatinib-insensitive P12-Ichikawa cell line (Supplementary
Figure S4e). These results suggest that LCK is the prime target
of dasatinib in T-ALL.
We next performed ex vivo drug testing of 22 primary T-ALL
samples. In 6 cases (27%), the response to dasatinib was
signiﬁcant based on drug sensitivity scores (DSS, using a cutoff
value of 10, Figure 2a).5 Half-maximal growth inhibition concen-
trations (IC50) ranged between 1.3 and 16 nM, whereas the control
samples had an IC50 of 41000 nM (Supplementary Figure S5). We
also noted a negative correlation between dasatinib and
glucocorticoid DSS scores (Supplementary Figure S6). Previously,
dasatinib sensitivity has been reported in T-ALL cases with
NUP214-ABL1 fusion.6–8 In contrast, none of the dasatinib
responders in our sample set carried the fusion gene based on
either genomic PCR or RNA-sequencing analysis (Supplementary
Figure S7). LCK was strongly expressed in four out of the ﬁve
dasatinib-responsive patient samples, whereas the expression of
other potential targets varied from a low (LYN, ABL1) to medium
level (FYN, MAP2K5 and MAP4K5, Supplementary Figure S8a). As
LCK was also relatively strongly expressed in dasatinib-insensitive
patient samples, no correlation between dasatinib response and
LCK expression was observed (Supplementary Figure S8b).
As T-ALL subgroups can be separated by expression of speciﬁc
transcription factors, we explored whether dasatinib sensitivity
was associated with any speciﬁc subgroups.9 In addition to Jurkat
cells that belong to the TAL1 subgroup, ﬁve out of six dasatinib-
sensitive patient samples showed either prominent TAL1 expres-
sion (Figure 2b) or carried SIL-TAL1 fusion (data not shown). There
was also increased expression of LMO2 and HOXA9/10 genes in
some samples (Supplementary Figure S9). 6q deletions have also
Figure 2. Dasatinib-sensitive subgroup of T-ALL samples. (a) Drug sensitivity scores (DSS) of dasatinib in a cohort of 22 patient samples. These
DSS values are calculated from growth inhibition measurements after 72 h of treatment in a 10-fold dasatinib dilution series (0.1–1000 nM),
and a DSS value of 10 was used as the threshold for dasatinib sensitivity. (b) The expression of the T-ALL subtype deﬁning transcription factor
TAL1 in T-ALL patient samples and cell lines measured by RT-qPCR. The threshold for ectopic TAL1 expression (dashed line) is deﬁned by the
expression of TAL1 in SIL-TAL1 fusion-positive cell lines, indicated with black columns, and the striped columns represent the dasatinib-
sensitive samples.17 Patient sample 4 was processed in a separate RT-qPCR batch. (c) The heat map of LCK, FYN, MAP2K5, MAP4K5, ABL1 and LYN
expression in a separate GEO-based T-ALL sample data set (n= 385). Samples are clustered based on the expression of T-ALL subtype-deﬁning
transcription factors: TAL1 (n= 61+103), NKX2-1 (n= 18), TLX1 (n= 33), TLX3 (n= 51), HOXA (n= 56) and LYL (n= 63). (d) LCK expression in T-ALL
subtype clusters. The difference between TAL1 clusters and any other cluster was statistically signiﬁcant (Po0.001, Mann–Whitney U-test).
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been associated with the TAL1 subgroup, and three out of six
samples carried the 6q deletion in cytogenetic analyses
(Supplementary Table S1).9 When LCK expression was correlated
with the subgroup information in our GEO-based gene expression
data set, a statistically signiﬁcant correlation was found between
LCK expression and the TAL1 subgroup (Figures 2c and d and
Supplementary Figure S10). However, no direct transcriptional
regulation of LCK by TAL1 was seen when the expression of TAL1
was knocked down (Supplementary Figure S11, data reproduced
from Sanda et al.10).
Taken together, the combination of in silico, in vitro and ex vivo
data indicate that dasatinib exerts clinical utility beyond the
originally suggested NUP214-ABL1 cases that only represent 4–
10% of T-ALL patients.6,11 Our results are in line with the data by
Frismantas et al.12 who identiﬁed a slightly higher percentage of
dasatinib-sensitive patients (30–40%) in their T-ALL cohorts. In
addition to conﬁrming their main ﬁndings, we expand on them in
two different ways. First, we identiﬁed LCK tyrosine kinase as the
potential prime target of dasatinib, whereas Frismantas et al.12 did
not recognize any recurrent gene fusions, mutations or transcrip-
tome proﬁles associated with dasatinib sensitivity; rather, they
associated SRC expression and phosphorylation status with
dasatinib sensitivity. They supported their hypothesis by reporting
a positive correlation between dasatinib and SRC inhibitor KX2-
391 responses in T-ALL patient samples.12 However, DsigDB
identiﬁes both SRC and LCK as targets of KX2-391. In our GEO-
based gene expression data set and T-ALL cell lines, the
expression of SRC was very low when compared with LCK, and
there was no difference in the expression levels of T-ALL and
normal T-cell samples (Supplementary Figure S1). A low level of
SRC expression was also observed in the data set of Frismantas
et al.12 Importantly, the LCK-mutant derivative of the Jurkat cell
line failed to respond to dasatinib, thus strongly suggesting the
central role played by LCK itself. We failed to detect an association
between the phosphorylation status of LCK kinase and dasatinib
sensitivity in T-ALL cell lines (data not shown).
Second, we show here that patients belonging to the TAL1
subgroup are the most likely to respond to dasatinib, although not
exclusively. A high expression of LCK associates with the TAL1
subgroup, but TAL1 does not directly regulate LCK expression. As
up to 60% of T-ALL patients belong to the TAL1 subgroup and
only 30–40% respond to dasatinib, there is clearly a need for more
accurate biomarkers to be identiﬁed.
Dasatinib is known to suppress proliferation of healthy T cells
by LCK inhibition.13–15 We noticed a signiﬁcantly higher
expression of LCK in T-ALL samples compared with healthy
T cells (a 1.46-fold change, Po0.001), and a higher sensitivity of
T-ALL cells toward dasatinib compared with healthy bone
marrow cells. Although we identiﬁed LCK as the main target
of dasatinib, our results do not exclude the contribution by
other kinases, including other Src family kinases. Many of the
target candidates function in receptor signaling pathways
related to cell proliferation and survival. LCK and FYN are
components of the T-cell receptor (TCR) signaling cascade.16
During T-cell development, LCK is required for the normal
development of thymocytes, whereas in mature T cells, FYN is
capable of activating several TCR signaling pathways in the
absence of LCK, including the Ras/extracellular signal-regulated
kinase and phosphatidylinositol 3-kinase pathways.16 In knock-
down experiments, we observed reciprocal feedback mechan-
isms between LCK and FYN (data not shown), in agreement with
their known partially overlapping functions.
Dasatinib is a tyrosine kinase inhibitor that is currently approved
for imatinib-resistant Philadelphia chromosome-positive (Ph+)
chronic myeloid leukemia and the second-line treatment of Ph+
ALL. We report here the potential utility of dasatinib in the
treatment of a subset of T-ALL. As our patient cohort is relatively
small, further studies are needed to explore the biomarker
ﬁndings and to deepen the mechanistic basis before embarking
on animal and human studies.
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ABSTRACT
The Sin3A-associated proteins SAP30 and SAP30L share 70% sequence identity and are part of the multiprotein Sin3A corepressor complex.
They participate in gene repression events by linking members of the complex and stabilizing interactions among the protein members as well
as between proteins and DNA. While most organisms have both SAP30 and SAP30L, the zebraﬁsh is exceptional because it only has SAP30L.
Here we demonstrate that SAP30L is expressed ubiquitously in embryonic and adult zebraﬁsh tissues. Knockdown of SAP30L using
morpholino-mediated technology resulted in a morphant phenotype manifesting as cardiac insufﬁciency and defective hemoglobinization of
red blood cells. A microarray analysis of gene expression in SAP30L morphant embryos revealed changes in the expression of genes involved
in regulation of transcription, TGF-beta signaling, Wnt-family transcription factors, and nuclear genes encoding mitochondrial proteins. The
expression of the heart-speciﬁc nkx2.5 gene was markedly down-regulated in SAP30L morphants, and the cardiac phenotype could be
partially rescued by nkx2.5 mRNA. In addition, changes were detected in the expression of genes known to be important in hemoglobin
synthesis and erythropoiesis. Our results demonstrate that SAP30L regulates several transcriptional pathways in zebraﬁsh embryos and is
involved in the development of cardiac and hematopoietic systems. J. Cell. Biochem. 113: 3843–3852, 2012.  2012 Wiley Periodicals, Inc.
KEY WORDS: ZEBRAFISH; SAP30L; TRANSCRIPTION; MICROARRAY; HEMATOPOIESIS; CARDIOGENESIS
A cetylation and other covalent modiﬁcations of histones playfundamental roles in chromatin dynamics and regulation of
gene expression. Deacetylation of histones is carried out by a
multiprotein corepressor complex in which Sin3A is an essential
scaffold protein. Sin3A is composed of domains that mediate
protein–protein interactions and thereby forms a platform to which
several enzymes, DNA-binding transcription factors, and other
bridging proteins bind [Silverstein and Ekwall, 2005]. The core
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Sin3A-HDAC corepressor complex contains the histone deacety-
lases HDAC1 and HDAC2, the histone-binding proteins RbAp46 and
RbAp48, the Sin3A-associated protein 18 (SAP18), SAP30, and
SDS3 [Silverstein and Ekwall, 2005].
The Sin3A-associated proteins SAP30 and SAP30L (SAP30-like)
have been shown to be present in various corepressor complexes
[Laherty et al., 1998; Zhang et al., 1998; Viiri et al., 2006]. We have
previously reported that these proteins bind DNA directly and this
association is regulated by nuclear monophospholipids [Viiri et al.,
2009b]. SAP30 and SAP30L are small and basic, and contain nuclear
(NLS) and nucleolar (NoLS) localization signals [Viiri et al., 2006].
The main difference between the two proteins lies in their N-termini,
where SAP30 contains a 38 amino acid insertion relative to SAP30L.
Both proteins are able to localize to the nucleus or the nucleolus, and
they can direct Sin3A to the nucleolus [Viiri et al., 2006].
While a range of biochemical and cell biological results implicate
SAP30 and SAP30L in repression of gene expression, the function(s)
of these proteins in the setting of a living organism has not been
established. In order to study this, we chose the zebraﬁsh as a model
organism. The zebraﬁsh has only one of these proteins, SAP30L
[Viiri et al., 2009a], enabling us to study the role of SAP30L without
interference of potentially overlapping functions of SAP30. Our
results suggest an important role for SAP30L in diverse transcrip-
tional pathways in zebraﬁsh embryos.
MATERIALS AND METHODS
ZEBRAFISH MAINTENANCE AND MICROINJECTIONS
Wild type AB zebraﬁsh were maintained under standard conditions
at 28.58C as described [Westerﬁeld, 1995]. In microinjection
experiments, embryos at the 1-4-cell stage were injected into the
yolk sac with 1 nl of injection mix, which contained the morpholino,
mRNA (where indicated) and rhodamine dextran. The PV830
Pneumatic PicoPump injection system (WPI, Inc.) was used, and the
injection volume was calibrated to 1 nl using 1mmMicrometer scale
(S48, Ted Pella Inc.). The care of the animals was in accordance with
the Finnish Laboratory Animal Welfare Act 62/2006 and the
Laboratory Animal Welfare Ordinance 36/2006.
WHOLE-MOUNT IN SITU HYBRIDIZATION (WISH)
DIG-labeled sense and antisense probes for zebraﬁsh SAP30L were
prepared using the DIG RNA Labeling Mix (Roche Diagnostics)
according to the manufacturer’s instructions, as described [Thisse
and Thisse, 2008]. Linearized plasmids containing the full-length
SAP30L cDNA (in the sense or antisense orientation) under the
control of the T7 promoter were used as templates. Zebraﬁsh larvae
were collected and processed as described [Thisse and Thisse, 2008]
at 12, 24, 36, 48, and 72 hpf. Whole-mount in situ hybridization
(WISH) using alkaline phosphatase detection with the BM Purple
substrate (Roche Diagnostics) was carried out according to Thisse
and Thisse [2008] with the following modiﬁcations: 2ml tubes
were used during the entire procedure, hybridization was carried out
at þ658C, 130 ng of sense or antisense probe was used per reaction
and a dilution ratio of 1:2,000 was used for the anti-DIG antibody
(sheep anti-digoxigenin-AP Fab fragments, Roche Diagnostics). The
stained ﬁsh were analyzed and photographed under a dissecting
microscope. The localization of the staining was assessed by
comparing to the anatomical reference images by Haffter et al.
[1996].
RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR
Expression of the SAP30L, nkx2.5 and ppox genes was assayed by
quantitative real-time PCR (qRT-PCR). Total RNA was extracted
from zebraﬁsh embryos and adult ﬁsh tissues with an RNeasy Mini
Kit (Qiagen), and converted to cDNA using an iScript Select cDNA
Synthesis Kit (Bio-Rad) and random primers according to the
manufacturers’ instructions. The housekeeping gene EF1A (Ensembl
ID: ENSDARG00000020850) [Tang et al., 2007] was used as a
normalization control. The primer sequences are described in the
Supplementary data. qRT-PCR was performed by using an Evagreen
Ssofast supermix kit (Bio-Rad) as instructed by the manufacturer.
An average threshold cycle (Ct) value was calculated from two or
three replicate samples. The mRNA levels (mean SD) are expressed
relative to those of the housekeeping gene, EF1A. The PCR runs were
repeated twice, and no signiﬁcant differences between replicate runs
were observed (data not shown). For the microarray experiments, the
total RNA was extracted from whole embryos collected at 12 or
24 hpf.
ANTISENSE MORPHOLINO EXPERIMENTS
The translational start site of the zebraﬁsh SAP30L mRNA
(Ensembl ID: ENSDARG00000030213) was targeted with two
independent antisense morpholinos: SAP30L-MO1 and SAP30L-
MO2 (Fig. 2a, Supplementary Table I). Their sequences exhibited no
signiﬁcant similarity to other loci in a search of a zebraﬁsh database.
The random control morpholino (RC, see Supplementary Table I) has
no gene targets or observable biological activity in the zebraﬁsh.
The p53-targeting morpholino was also used (Supplementary
Table I). All morpholinos were purchased from Gene-Tools, LLC.
The effective concentrations of morpholinos were experimentally
titrated and are indicated in the ﬁgures or ﬁgure legends.
WESTERN BLOTTING
The efﬁcacy of MO1 and MO2 in blocking the translation of the
SAP30L mRNA was analyzed using a human anti-SAP30L antibody
[Korkeamaki et al., 2008]. MO1-, MO2-, or RC-injected larvae were
collected at 2 dpf (days post-fertilization) directly into 2 Laemmli
buffer (10 larvae/50ml), and lysed by boiling and passing through a
pipette vigorously. The lysates were centrifuged for 5min to remove
the debris, and the soluble fraction was used for further analysis. The
proteins were resolved on 12% SDS–PAGE gels and transferred to
nitrocellulose membranes (Amersham Biosciences). The immuno-
blots were probed with an anti-SAP30L antibody, and the proteins
were detected by enhanced chemiluminescence. In all zebraﬁsh
lysates, the anti-SAP30L-antibody recognized only a single band,
the molecular weight of which is a few kilodaltons lower than in
human control (lysed cells transfected with Myc-His-tagged
SAP30L), as expected due to the presence of the tag and the larger
size of human SAP30L.
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ANALYSIS OF HEART MORPHOLOGY AND FUNCTION
Heart morphology at 5 dpf was assessed visually and categorized as
normal or deformed, examples of which are shown in Supplemen-
tary Figure S3. Heart rates were determined visually in unanaesthe-
tized morphant and control larvae at 5 dpf. Ventricular and atrial
performance was analyzed on 10–20 s time-lapse videos. The
longitudinal fractional shortening was calculated according to the
formula (LDd LDs)/LDd, where LDd is the longitudinal diameter at
diastole and LDs the diameter at systole.
HISTOLOGICAL STAINING
The morphant and control larvae were ﬁxed in a 4% formaldehyde–
PBS solution at þ48C and embedded in 2% agarose. The samples
were dehydrated by incubating them in a series of alcohol solutions
(70%, 96%, and absolute ethanol) for 1–2 h in each solution, and
ﬁnally in xylene for at least 1 h. The samples were then embedded
in parafﬁn and 5mm-thick sections were cut in longitudinal
orientation. The sections were ﬁxed on glass slides and depar-
afﬁnised by incubating them twice in xylene (a´ 4min), twice in
absolute ethanol (a´ 3min), twice in 96% ethanol (a´ 3min), once
in 70% ethanol, and rinsing once with water. Hematoxylin–eosin
staining was performed by incubating the samples in Mayer’s
hematoxylin (2min), running water (2min), water (1.5min), 70%
ethanol (15 s), eosin Y (15 s), 96% ethanol (30 s, twice), absolute
ethanol (1min, twice), and xylene (1–4min). After this the slides
were mounted and pictures were taken under a BX60 microscope
using the Cell^D program (Olympus).
O-DIANISIDINE STAINING
Detection of hemoglobin by o-dianisidine staining was performed as
described previously [Ransom et al., 1996]. Larvae stained at 3 dpf
were scored as normal, reduced, or severely reduced based on their
qualitative level of staining which was assessed visually. In the
normal category, staining was judged to be equivalent to that of wild
type larvae, reduced staining was visibly decreased as compared to
wild type, and in the severely reduced category, the larvae showed
little or no staining.
mRNA RESCUE
The mRNA rescue experiments were performed by injecting
simultaneously SAP30L-MO1 or SAP30L-MO2 and a capped
synthetic mRNA encoding the gene of interest. We used various
doses of mRNA in the injections, and the data were pooled for
analysis. The mRNA was synthesized using a T7 mMESSAGE
mMACHINE Kit (Ambion) according to the manufacturer’s instruc-
tions. Brieﬂy, a plasmid template linearized with HindIII was mixed
thoroughly with components of the kit and incubated at þ378C for
2 h, after which the template DNA was removed by a DNase
treatment. The synthesized mRNA was puriﬁed using a MEGAclear
kit (Ambion) according to the manufacturer’s protocol and further
concentrated by ammonium acetate precipitation. The templates
used in the synthesis reactions had been created by cloning the
desired cDNA into the pcDNA3.1/mycHis()A-vector (Invitrogen)
using EcoRI and HindIII restriction sites. The constructs contained
full-length zebraﬁsh SAP30L (drSAP30L) or full-length zebraﬁsh
nkx2.5 (Nkx2.5), each without a stop codon.
STATISTICAL ANALYSES
Quantitative data are given as mean standard deviation. When
appropriate, differences between groups were compared by using
the two-tailed Student t-test or the x2 test for cross tabulations. A P-
value of less than 0.05 was considered statistically signiﬁcant.
Statistical calculations were performed using PASW Statistics
version 18.
MICROARRAYS
200 ng of total RNA was ampliﬁed and labeled with Cy3 using a Low
Input Quick Amp Labeling kit (Agilent Technologies). The samples
were processed using an RNA Spike In kit (Agilent Technologies).
1.65mg of each Cy3-labeled sample was hybridized to Agilent’s
4 44K Zebraﬁsh V3 Gene ExpressionMicroarray overnight at 658C
in the buffers of Agilent’s Gene Expression Hybridization kit. The
arrays were washed according to the manufacturer’s instructions
and scanned with an Agilent Technologies’ scanner (model
G2565CA), using scan proﬁle AgilentHD_GX_1Color. Numerical
data were extracted with Agilent’s Feature Extraction software,
version 10.7.1., using grid 026437_D_F_20100719 and protocol
GE1_107_Sep09.
MICROARRAY DATA ANALYSIS
The R programming language and environment [R Development
Core Team, 2008] and its Bioconductor module [Gentleman et al.,
2004] were used for analysis of data from the microarrays. The raw
data were normalized with quantile normalization, and the quality
of the data was checked with several quality control methods.
Statistical testing was performed with the Limma package [Smyth,
2005], and stringent ﬁltering thresholds were used for both time
point comparisons (fold change FCj3j and P-value P 0.001).
RESULTS AND DISCUSSION
SAP30L mRNA IS EXPRESSED DURING EMBRYOGENESIS AND IN
ADULT ZEBRAFISH TISSUES
SAP30 and SAP30L have been implicated in the regulation of gene
repression through the Sin3A-corepressor complex [Laherty et al.,
1998; Zhang et al., 1998; Viiri et al., 2006, 2009b]. Their function
in vivo remains unknown and we therefore set out to examine the
function of SAP30L using the zebraﬁsh as a model. Contrary to the
human and mouse genomes, only one member of the SAP30 family
has thus far been identiﬁed in the zebraﬁsh genome, and its derived
protein sequence more closely resembles human SAP30L than
SAP30 (Supplementary Fig. S1; Viiri et al., 2009a).
We studied the expression of the SAP30L gene during zebraﬁsh
embryogenesis in whole embryos by qRT-PCR, and determined the
localization of the expression by WISH at 12, 24, 36, 48, and 72 h
post-fertilization (hpf) (Fig. 1a and b). The results show that SAP30L
mRNA is widely expressed during embryogenesis (Fig. 1a and b). The
expression is strongest in the brain, including forebrain, midbrain,
and hindbrain, at the 24, 36, 48, and 72 hpf time points (Fig. 1a). The
pectoral ﬁn buds (at 36 and 48 hpf) and pectoral ﬁns (72 hpf) also
show strong expression of the mRNA. Next to the pectoral ﬁn buds,
staining is seen also in the region of common cardinal vein (see
dorsal view in Fig. 1a) starting at 36 hpf. Furthermore, the heart area
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shows positive staining, ﬁrst seen in the pericardial cavity (24 hpf)
and later in the heart itself. In addition, moderate expression of
SAP30L mRNA is seen in the trunk (including the area of the
intermediate cell mass, ICM), and some embryos show weak staining
in the blood island at 24 hpf. In adult ﬁsh, strong expression is seen
in the brain and moderate expression in muscle, eye, gonad, and
heart tissues (Fig. 1c).
DESIGN AND VALIDATION OF THE SAP30L-TARGETING
MORPHOLINOS
In zebraﬁsh embryos, morpholino oligonucleotides (MO) can be
used to knock down expression of genes of interest. We designed
two translation-blocking morpholinos (MO1 and MO2) which target
the translation initiation site in the SAP30L mRNA (Fig. 2a). In an
in vitro translation assay, a speciﬁc and dose-dependent inhibition
of translation of SAP30L mRNA was detected with the MO1 but not
with RC control (Supplementary Fig. S2). The ability of morpholinos
to block translation of SAP30L was further investigated by using the
SAP30L antibody and Western blotting. A signiﬁcant reduction
in SAP30L protein levels was detected in MO1- and MO2-treated
zebraﬁsh embryos at 2 dpf, demonstrating the efﬁcacy of these
Fig. 1. Expression of SAP30L mRNA in zebraﬁsh embryos, larvae, and adult tissues. A: WISH analysis of SAP30L mRNA expression during embryogenesis at indicated time
points. Staining with an antisense probe is shown in dorsal (top row) and lateral (middle row) views, and a control sense-strand probe is shown in lateral view (bottom row). The
black asterisk points out the heart next to it, the black arrow indicates the pectoral ﬁn bud/pectoral ﬁn, and the white arrow indicates the region of the common cardinal vein. B:
qRT-PCR analysis of SAP30L mRNA in whole embryos during embryogenesis. SAP30L mRNA levels are normalized to the level at 1 day post-fertilization (dpf). C: qRT-PCR
analysis of SAP30L mRNA in adult tissues. SAP30L mRNA levels (mean SD) are expressed relative to those of the housekeeping gene, EF1A. [Color ﬁgure can be seen in the
online version of this article, available at http://wileyonlinelibrary.com/journal/jcb]
Fig. 2. The morpholinos used to target the SAP30L mRNA. A: Sequence of
the coding strand of the zebraﬁsh SAP30L gene, showing the 50-untranslated
region (normal font) and part of the ﬁrst exon (boldface starting from the ATG-
codon). Complementarity of the sequences of the morpholinos SAP30L-MO1
and SAP30L-MO2 to the coding strand of the gene is illustrated. B: Western
blotting analysis of SAP30L protein levels in 2 dpf larvae injected with
SAP30L-MO1 (MO1), SAP30L-MO2 (MO2), or random control morpholino
(RC). Morpholino concentrations used: 400mM for MO1, 600mM for MO2,
600mM for RC. The numbers under the lanes indicate band intensity relative to
RC. The lysates contain identical numbers of larvae per volume of lysis buffer,
and equal volume of sample was loaded on the gel in each case.
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morpholinos in down-regulating the expression of the SAP30L
protein in vivo (Fig. 2b).
KNOCKDOWN OF SAP30L EVOKES CARDIAC DEFECTS AND
REDUCED HEMOGLOBIN LEVELS
In order to investigate the role of SAP30L in zebraﬁsh development,
we injected morpholinos (MO1 or MO2) into 1- to 4-cell stage
embryos, and observed their development for 5–6 dpf. The SAP30L
morphants showed prominent and progressive pericardial edema.
Importantly, most of the SAP30L morphants exhibited deformed
cardiac morphology (85–89%; Fig. 3a, Supplementary Fig. S3),
with the hearts remaining string-like and visible on a single plane,
in contrast to the three-dimensional complexity of the healthy
hearts in the control larvae (Fig. 3b). Cardiac function was assessed
by determining the heart rates and the contractility of the chambers.
The results demonstrate signiﬁcantly reduced heart rates in
MO1- and MO2-injected morphants (Fig. 3c), with the differences
detectable already at 3 dpf. Similarly, a substantial decrease in
the longitudinal fractional shortening values was seen in both
the atrium and the ventricle, as compared to control hearts
(Fig. 3d). Videos illustrating the diminished cardiac function can be
found in the Supplementary data (SV1-3). The results are compatible
with the WISH and qRT-PCR analyses which showed expression of
SAP30L in the developing and adult heart (Fig. 1a and c), and
suggest that the phenotype results speciﬁcally from the knockdown
of SAP30L.
In some SAP30L morphants, the red blood cells seemed
paler as compared to those in control larvae. In a Sin3B-
knockout mouse, impaired erythroid differentiation has been
reported, with a 43% reduction in the number of circulating red
blood cells and a 37% reduction in hemoglobin levels [David et al.,
2008]. In order to determine hemoglobin levels in the SAP30L
morphants, o-dianisidine staining was performed on 3 dpf embryos
(see examples in Supplementary Fig. S4). As summarized in
Figure 3e, the morphants exhibited reduced staining, indicating
reduced hemoglobin levels in the red blood cells. The observed effect
on erythroid differentiation is consistent with the fact that SAP30L
expression is seen at the area of the common cardinal vein and ICM,
Fig. 3. The phenotype induced by knockdown of SAP30L involves defects in the heart and in hemoglobinization of red blood cells. A: The majority of the SAP30L morphant
larvae have deformed hearts (see close-up images of normal and deformed hearts in Supplementary Fig. S2). B: Histological analysis of cardiac morphology. Hematoxylin–eosin
staining of sections reveals string-like appearance of the heart in the MO1- and MO2-injected larvae, in contrast to the RC-injected controls. V, ventricle; A, atrium; Y, yolk sac.
C: SAP30L morphant larvae exhibit reduced heart rates. Heart rates (beats per minute, bpm) are represented as mean bpm SD. D: Both atrial and ventricular performance in
SAP30L morphant hearts are impaired, as shown by the decreased longitudinal fractional shortening values (represented as mean SD). P¼ 0.002; P< 0.001; P¼ 0.005;
P¼ 0.006, as compared to RC control. The morpholino concentrations used in A–D: 300–750mM for MO1, 500–600mM for MO2, 400–750mM for RC. E: SAP30L
morphants exhibit defects in hemoglobinization of red blood cells (see examples in Supplementary Fig. S4). MO1-, MO2-, or RC-injected larvae are scored as normal, reduced, or
severely reduced based on hemoglobin staining by o-dianisidine. Morpholino-concentrations used: 400mM for MO1, 600mM for MO2, 600mM for RC. [Color ﬁgure can be
seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jcb]
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where developing erythrocytes are present [Davidson and Zon,
2004].
In addition, some morphant larvae were slightly smaller than
control larvae, and showed edema in the head and brain (data not
shown).
The phenotypes obtained with both SAP30L-targeting morpho-
linos were essentially similar, with MO2-morphants showing
slightly delayed onset, which concurs with the less decreased level
of SAP30L protein in these morphants as compared to MO1-
morphants (Fig. 2b). Since morpholinos are known to induce off-
target p53-mediated effects [Robu et al., 2007], we co-injected
both morpholinos with the p53-morpholino. Larvae injected with
SAP30L-MO2 alone or together with the p53-morpholino, did not
differ in phenotype. SAP30L-MO1 morphants exhibited a slightly
alleviated but essentially similar phenotype when co-injected with
the p53-morpholino (data not shown).
One way to demonstrate the speciﬁcity of the observed phenotype
is to rescue it by co-injecting the morpholino with the target mRNA
[Eisen and Smith, 2008]. In our case, this strategy could be exploited
only with MO2, since it targets the SAP30L mRNA upstream of the
start codon. No rescue of the reduced hemoglobin staining but a
tendency towards a less severe cardiac phenotype could be observed
in the rescued morphant larvae (data not shown). The incomplete
rescue may be due to various reasons, such as the short half-life of
the injected mRNA, strict temporal or spatial constraints on the
expression at certain developmental stages, inability of the mRNA
to reach the right tissue, or the ﬁne balance between under- and
over-expression of the protein in the embryos and larvae.
SAP30L IS INVOLVED IN MULTIPLE TRANSCRIPTIONAL PATHWAYS
DURING ZEBRAFISH EMBRYOGENESIS
SAP30L is a part of the Sin3A-HDAC multiprotein corepressor
complex [Viiri et al., 2006]. In order to elucidate the transcriptional
pathways in which SAP30L participates during zebraﬁsh embryo-
genesis, we performed a microarray analysis of embryos in which
expression of SAP30L was knocked down. To avoid any secondary
effects on gene expression, we chose early time points at 12 and
24 hpf. It has been reported previously that most developmentally
regulated genes reach their peak expression by 24 hpf, with a sharp
increase in transcript accumulation at 12 hpf [Mathavan et al.,
2005]. In our analysis, 205 genes were up-regulated and 174 genes
down-regulated at the 12 hpf time point, whereas at 24 hpf, the
respective numbers were 143 and 64 (Fig. 4, Supplementary Fig. S5).
Of the affected genes, 46 were identiﬁed at both time points and
showed similar alterations in expression. Since SAP30L is part of a
transcriptional repressor complex, its knockdown may be expected
to lead to more up-regulation than down-regulation of genes. Our
results bear out this expectation and are in line with the published
microarray data for Sin3, another member of the same repressor
complex. RNAi-mediated knockdown ofDrosophila SIN3 resulted in
induction of 364 genes but only 35 genes were repressed [Pile et al.,
2003]. Similarly, in mouse cells in which Sin3A had been knocked
out, the majority of the differentially expressed genes were up-
regulated [Dannenberg et al., 2005]. The results of knockdown of
Drosophila SIN and the mouse mSin3A were similar in that mainly
genes involved in cytosolic and mitochondrial energy-generating
pathways were affected. Our data on knockdown of SAP30L in
Danio rerio show no marked changes in expression of the genes
reported in the Drosophila SIN and mouse Sin3A data sets. Instead,
expression of several nuclear genes encoding mitochondrial
proteins was affected by knockdown of SAP30L. These include
timm8a, cyb5b, ppox, alas2 and fars2 (Fig. 4, Supplementary
Fig. S5).
SAP30L was originally identiﬁed in our laboratory as a TGF-beta-
inducible transcript in a cell culture system that models differentia-
tion of the intestinal epithelium [Lindfors et al., 2003]. Interestingly,
down-regulation of SAP30L in the zebraﬁsh resulted in strong
induction of Smad2, a mediator in the TGF-beta signaling pathway.
The 150 kDa TGF-beta-1-binding protein was similarly up-regulat-
ed at 12 hpf, whereas the bone morphogenetic factor 5 (BMP5), a
member of the TGF-beta superfamily, was slightly down-regulated.
These results taken together with our previous ﬁndings suggest a
role for SAP30L in TGF-beta signaling events.
In gene ontology analysis, the pathway with the most hits is
associated with regulation of transcription. The same result was
obtained when the analysis was performed on the genes that showed
the largest differences in their expression. Indeed, several
transcription factors show altered expression in our microarray
analysis (Fig. 4, Supplementary Fig. S5). Among them are the Wnt-
family transcription factor Wnt7b, which is involved in the
development of vasculature, lung, and kidney [Shu et al., 2002;
Lobov et al., 2005; Rajagopal et al., 2008; Yu et al., 2009; Lin et al.,
2010], and Wnt2, which has been shown to be associated with
cardiogenesis and several other developmental processes [Alexan-
drovich et al., 2006; Wang et al., 2007; Goss et al., 2009, 2011; Sousa
et al., 2010]. In addition, Wisp3, a protein involved in modulation of
Wnt and BMP signaling [Nakamura et al., 2007], was affected.
NKX2.5 EXPRESSION IS REDUCED IN SAP30L KNOCKDOWN
EMBRYOS
One of the genes down-regulated at 12 hpf in the microarray
analysis of SAP30L morphants, Nkx2.5 (Fig. 4), is a well-known
regulator of heart development [Chen and Fishman, 1996; Targoff
et al., 2008; Reamon-Buettner and Borlak, 2010]. The down-
regulation of the Nkx2.5 gene was conﬁrmed by qRT-PCR, which
showed a threefold decrease in its expression in SAP30L-MO1-
treated embryos, and a sixfold decrease in SAP30L-MO2-treated
embryos (Fig. 5a). Interestingly, co-injection of Nkx2.5 mRNA with
SAP30L-MO1 could partially rescue the deformed cardiac morphol-
ogy in the SAP30L morphants (Fig. 5b). Previous studies in other
model organisms have implicated Nkx2.5 in various cardiac
developmental processes, including progenitor speciﬁcation and
proliferation, heart tube extension and looping, and chamber
morphogenesis [Targoff et al., 2008]. Our results suggest that
transcription of Nkx2.5 is regulated by a SAP30L-containing
repressor complex in zebraﬁsh embryos. As SAP30L is a member of
a large corepressor complex and binds DNA only nonspeciﬁcally, its
observed effect on expression of Nkx2.5 is likely to be indirect.
Interestingly, some members of the Sin3A corepressor complex are
known to regulate expression of genes critical for cardiac
morphogenesis and function in both the zebraﬁsh and mice. These
include HDAC1 [Pillai et al., 2004; Montgomery et al., 2007], HDAC2
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Fig. 4. Microarray analyses of zebraﬁsh embryos (at 12 and 24 hpf) treated with SAP30L-MO1 or random control morpholino (RC). The 104 genes showing the largest
differences in expression, ranked according to both the fold-change value and the P-value are shown for both time points and in all three parallel samples (2, 3, 4). Blue color
denotes down-regulation, red up-regulation, and white no change. [Color ﬁgure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/
journal/jcb]
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[Montgomery et al., 2007], HDAC3 [Farooq et al., 2008], and mSDS
[Amsterdam et al., 2004].
GENES INVOLVED HEMOGLOBIN SYNTHESIS ARE
DOWN-REGULATED BY SAP30L KNOCKDOWN
Consistent with the ﬁnding of diminished hemoglobin staining in
the morphant larvae, we observed a marked reduction in expression
of genes involved in hemoglobin synthesis and erythropoiesis
(ppox, alas2, and ba1l globin-like gene) at 24 hpf (Fig. 4,
Supplementary Fig. S5). The zebraﬁsh ppox, a protoporphyrinogen
oxidase, is expressed in the ICM as early as 22 hpf, similar to other
genes involved in hematopoiesis, including alas2, gata1, and
b-spectrin [Detrich et al., 1995; Brownlie et al., 1998; Liao et al.,
2000]. Down-regulation of ppox was conﬁrmed by qRT-PCR, which
showed a sixfold decrease in its expression in SAP30L-MO1-treated
embryos and a 4.8-fold decrease in SAP30L-MO2-treated embryos
(Fig. 5c). In the future, it remains to be elucidated whether the lower
hemoglobin levels observed after knockdown of SAP30L are due to
impaired erythropoiesis, a block in heme biosynthesis, or some other
mechanism. Our results suggest that one function of SAP30L may be
to silence the expression of a factor that inhibits heme synthesis or
erythropoiesis.
CONCLUSION
SAP30 and SAP30L, members of the well-known Sin3A corepressor
complex, have been previously implicated in repression of gene
expression. However, the function(s) of these proteins in the setting
of a living organism has not been established. Zebraﬁsh was chosen
as a model organism because it has only one of these proteins,
SAP30L, enabling us to study its role without interference of
potentially overlapping functions. Here we have demonstrated that
SAP30L is ubiquitously expressed in the zebraﬁsh and participates
in the regulation of transcription of multiple genes. Morpholino-
mediated knockdown of SAP30L protein results in disruption of
cardiac development and function, and a reduction in hemoglo-
binization of red blood cells. Our results give important in vivo
evidence of the role and function of SAP30L during the zebraﬁsh
embryogenesis.
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